Design, evaluation and application of methodology and software for time-to-event outcomes in pharmacogenetic genome-wide association studies by Syed, H
Design, evaluation and application
of methodology and software for
time-to-event outcomes in
pharmacogenetic genome-wide
association studies
Thesis submitted in accordance with the requirements of the University
of Liverpool for the degree of Doctor in Philosophy by
Hamzah Syed
May 2018
ABSTRACT
Thesis title: Design, evaluation and application of methodology and software for time-
to-event outcomes in pharmacogenetic genome-wide association studies
Author: Hamzah Syed
Introduction and aims: Methodology and software for the analysis of genome-wide
association studies (GWAS) have focused on binary phenotypes and quantitative traits.
However, the impact of single nucleotide polymorphisms (SNPs) on time-to-event
(TTE) outcomes is understudied, particularly for pharmacogenetic GWAS. Statistical
methodology and computational tools to design and analyse GWAS with TTE out-
comes are not well developed, due to the scale and complexity of data, particularly
when analysing rare variants. This thesis aims to develop statistical methodology and a
variety of computational tools to aid the design and analysis of both GWAS of common
and rare variants with TTE outcomes.
Methods: This thesis compares existing methodology such as the Cox proportional
hazards, logistic and Weibull regression models using simulations based on a range
of pharmacogenetic GWAS designs with TTE outcomes. This thesis also presents
new statistical methodologies for the analysis of rare variants using a combination of
gene-based tests of association and TTE regression models.
Results: Examination of the literature provided an overview of the methods and soft-
ware used for analysing GWAS with TTE outcomes. One approach taken due to
lack of software availability was to dichotomise event times at a fixed time-point and
analyse the binary outcome using existing GWAS software. A simulation study was
conducted comparing alternative regression models under pharmacogenetic TTE study
designs. This simulation study demonstrated that dichotomisation of the TTE outcome
would result in a loss of statistical power. Hence, the thesis outlines three user-friendly
computational tools specific to TTE GWAS. The first is SurvivalGWAS_Power, which
performs power calculations and generates sample pharmacogenetic data across a range
of design scenarios, allowing for censoring and interactions. Second, SurvivalGWAS_-
SV, software capable of analysing large-scale imputed GWAS data, offering a variety of
survival analysis models. Third, rareSurvival, a command line application, which im-
plements gene-based burden tests for the analysis of rare variants with TTE outcomes.
SurvivalGWAS_SV and rareSurvival have been evaluated through simulation studies
as well as application to a GWAS investigating the pharmacogenetics of acute coronary
syndrome (PhACS). The single variant and gene discovery analyses of the PhACS
study identified novel loci associated with time to recurrence of a cardiovascular event
including rs56045815 located in the CTNNA2 gene.
Conclusions: This thesis introduces three novel computational tools for GWAS with
TTE outcomes. SurvivalGWAS_SV and rareSurvival are compatible with high-
performance computing clusters and are available on Linux, Windows and Mac OSX
operating systems. SurvivalGWAS_SV and rareSurvival were applied to the PhACS
data, identifying significantly associated SNPs and functional units for further follow-
up. With their particular relevance to pharmacogenetic GWAS, SurvivalGWAS_Power,
SurvivalGWAS_SV and rareSurvival, will help in the design of studies and identifica-
tion of genetic biomarkers of patient response to treatment, with the ultimate goal of
personalising therapeutic interventions.
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CHAPTER 1
INTRODUCTION
In the last decade, genome-wide association studies (GWAS) have become the tra-
ditional approach for the discovery of genetic variations contributing to a multitude
of complex human traits and diseases. GWAS aim to test the association between
genetic markers across the genome with a particular phenotype1 within a population
of (typically) unrelated individuals. Prior to this, candidate gene studies were under-
taken based on functional studies and existing biological/clinical knowledge of the trait.
A candidate gene study aims to thoroughly examine a gene, studying variations that
are both common and rare in a population. However, this approach relies on prior
knowledge, with many studies reporting failure to replicate the causal genes previously
found. GWAS differ from candidate gene studies in some important ways: (i) GWAS
are discovery-driven as opposed to hypothesis-driven; and (ii) a greater number of
variants are investigated through GWAS.
The GWAS era rose to popularity in the mid-2000s, consequently spawning the pub-
lication of the landmark GWAS study of 14,000 cases of seven common diseases and
3,000 shared controls conducted by the Wellcome Trust Case Control Consortium
(2007) (WTCCC). This study was one of the first large-scale GWAS to be undertaken.
Following this, in the last decade, thousands of GWAS have been published with asso-
ciations catalogued in the NHGRI-EBI Catalog (MacArthur et al. 2017). GWAS have
produced an extraordinary amount of discoveries of genomic regions associated with
disease risk and many biological characteristics.
The current chapter provides an introduction to the basic concepts of genetic research,
with a focus on GWAS, from inception to present day and with a brief description of
the use of GWAS within the field of pharmacogenetics. Explanations are given on
1An observable characteristic or trait expressed by the genotype.
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the design of GWAS, quality control procedures and association testing. Methodology
for survival analysis is discussed in the context of genetic association studies, with
particular attention given to defining the different models used throughout this thesis,
including phenotype definitions and the incorporation of genetic modes of inheritance
within regression models. Following this, the role of computational tools is examined,
highlighting the latest software innovations. Finally, this introduction concludes with
an overview of all the chapters, defining the aims and explaining the motivation behind
the research in this thesis.
1.1 Background to Genetics Research in Healthcare
One of the major goals of genetic research is to improve healthcare through the predic-
tion of future disease and personalisation of treatments with therapeutic benefits for an
individual. One of the building blocks for attaining this goal is the discovery of genetic
biomarkers2 (i.e. genetic variants) associated with a disease or treatment response.
Methodology and software for analysis are at the forefront of this discovery process.
1.1.1 The Genome and Single Nucleotide Polymorphisms
Genetics is defined as the study of heredity, specifically, transmission of characteristics
from one generation to the next (Teare 2011). Nuclei of human cells store the genetic
information coded by deoxyribonucleic acid (DNA). The genome is a complete set
of DNA made up of a chain of linked nucleotide bases, adenine (A), thymine (T),
cytosine (C) and guanine (G). Bases are nitrogen-containing biological compounds
and are the building blocks for nucleic acids. There are a total number of 22 pairs
and two sex chromosomes, along with 30,000 genes contained in the human genome.
Genes are specific sequences of bases at particular loci that encode instructions on
how to make proteins3. A locus is a fixed position on a chromosome or region of the
2A biomarker or biological marker is a measurable predictor of a biological state, treatment response or
presence of a disease. In genetics research, this can be a measurable characteristic, SNP or gene.
3Proteins determine the function of a cell.
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genome. This fixed position can represent a gene or any interval of variants. Most loci
are identical between individuals, however, several different types of variations exist
such as copy number variants4 and indels5. The most common types of variations in
the DNA sequence are single nucleotide polymorphisms (SNPs), which occur in at
least 1% of the population and represent a single base change. The ‘value’ of these
variants is called the genotype. These genotypes are the different allelic combinations
that can be present at a SNP. For example, consider a bi-allelic variant, meaning that
there are only two alleles in a specific locus, where A is the major (most frequent)
allele, and C is the minor (least frequent) allele. The genotypes are represented as AA
(major homozygous), AC (heterozygous) and CC (minor homozygous). The focus of
genetic association analysis is centred around SNPs as genetic biomarkers. There are
over 10 million SNPs within the human genome. Many are important as they underlie
differences in our traits, such as eye colour and our susceptibility to disease. However,
there is still much unknown about the function of the majority of SNPs in the genome.
These variants are routinely analysed due to their high density in the genome and the
fact that they are relatively easy to genotype using high throughput technology.
1.2 Genome-Wide Association Studies
The objective of GWAS is to identify SNPs that are associated with a trait, covering
millions of variants across the genome in samples of individuals within a study popula-
tion. The GWAS approach enables the detection of variants with varying sizes of effect
on phenotype amongst a vast amount of variants, utilising a stringent threshold for sta-
tistical significance
(
p < 5 × 10−8) to reduce the number of false positive associations
due to multiple testing. This significance threshold is adapted from the Bonferroni
correction (Bland & Altman 1995) for the number of independent statistical tests per-
formed. However, we expect that SNPs across the genome are correlated. Therefore
the 5 × 10−8 threshold is widely-accepted as genome-wide significance based on ap-
4Copy number variants or CNVs are a section of variants that are duplicated across the DNA sequence.
5Indels are insertions or deletions of a range of base-pairs across the DNA sequence.
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proximately 1 million blocks of linkage disequilibrium (LD) (see Section 1.2.1) across
the genome (Pe’er et al. 2008). A variety of corrections for multiple testing exist with
the debate still continuing on the optimal threshold (Panagiotou et al. 2012, Kanai et al.
2016, Fadista et al. 2016) especially with the increasing availability of whole-genome
sequence data where many more variants are interrogated than in GWAS (see Section
1.2.2).
GWAS analysis techniques typically assume that each variant being investigated is
equally likely to be associated with the outcome of interest in an unbiased way. Doing
this maximises the opportunity for the discovery of variants not known, a priori, to be
biologically relevant to the trait under investigation.
Figure 1.1: Historical data of published GWAS from the NHGRI-EBI Catalog. Data
is from the second quarter of 2008 to the fourth quarter of 2017.
1.2.1 Allele Frequency and Linkage Disequilibrium
Determining the allele frequency of a SNP is key to defining the genetic diversity within
a study population. The major allele frequency, p, is defined as the frequency of the
allele which occurs most commonly within a population. The minor allele frequency
(MAF) is thus 1 − p. Where alleles are independent of one another, the loci are said to
be in Hardy-Weinberg equilibrium (HWE). This theorem is based on the assumption
that in the absence of any evolutionary influences such as selection and assortative
mating the allele and genotype frequencies in a population will remain constant from
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one generation to the next. Under this condition the genotype frequencies are derived
as p2, 2p(1 − p) and (1 − p)2 for the major homozygous, heterozygous and minor
homozygous genotypes respectively. Testing SNPs for deviation from HWE is covered
in Section 1.2.3.
The internationalHapMapProject (Altshuler et al. 2010) showed that SNPs are arranged
in blocks of strong linkage disequilibrium (LD). LD is an important term used when an
allelic correlation is identified between two or more loci within a population, suggesting
that genotypes at one locus are correlated with genotypes at a second locus. LD is
important for the discovery and localisation of genes (gene-mapping) associated with
a trait to reveal new insights. The strength of the relationship between loci can be
quantified using many different metrics. For instance, the Pearson’s correlation of
alleles is defined as r2, which is a value between 0 and 1, where 1 signifies perfect
correlation between alleles at one SNP and a second SNP. Many other measures exist,
and Teare (2011) explains them in detail, providing formulae and descriptions on the
benefits of eachmetric. LD between SNPs across a locus can be visualised and explored
further using the web-based tool LDlink (Machiela & Chanock 2015).
1.2.2 Genotyping
With the advancement of high throughput technologies for genotyping using genome-
wide chip arrays, came a surge in the number of GWAS undertaken for common
variation (see Figure 1.1), typically defined as variants with a MAF of at least 1%.
Knowledge of the LD patterns across the genome has helped in the design of genotyping
products. Often the variants from genotype arrays are supplemented via imputation to
increase coverage6. Imputation seeks to make inferences about the genotype of untyped
individuals for a group of variants based on the known phased haplotypes7 from densely
genotyped individuals. Examples of such high-density reference data for imputation
6Coverage is how much of the human genome can be inferred from the genotype chip array. Coverage
in the context of sequencing is the number of sequence reads that have alignments that overlap a certain
position. The greater the coverage, the fewer the sequencing errors in base calling.
7A haplotype is a group of specific alleles for different SNPs on a single chromosome.
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include initiatives such as the 1000 Genomes Project (Auton et al. 2015). The project
sequenced the whole genomes of more than 2500 individuals from 26 populations,
undertaken to increase the number of individuals and populations represented and to
extend variant coverage to lower MAFs.
The introduction of next-generation sequencing (NGS) capabilities such as whole-
genome and -exome sequencing provide complete coverage of variation in individuals,
even lower frequency variants. This process is more costly than array genotyping
but is becoming increasingly feasible, financially, for population-based association
studies. Whole-exome sequencing only covers the exome, which is the collection of
known exons8 in a genome. Sequencing of just the exome is a cheaper method than
whole-genome as exons represent 1-2% of the total sequence but are prime functional
candidates.
1.2.3 Quality Control
GWAS data undergo dynamic quality control (QC) before analysis. The QC protocol
is a critical step, conducted to remove any problematic samples and SNPs that can
cause bias, increased false positive association rates and decreased power to detect
associations. Like any experimental study involving patients and biological materials,
there will inevitably be some missing genotype information and errors in genotype
calling. QC can be separated into two parts: (i) SNP QC and (ii) sample QC. However,
there is no standard order to follow in which each procedure should be carried out.
SNP QC
SNP QC procedures look to exclude low-quality SNPs based on the proportion of
individuals for which a genotype has been called, deviation from HWE and MAF (An-
derson et al. 2010). SNPs that have a low call rate, defined by a study-specific threshold
are removed. Low call rates occur due to missing genotype calls in SNPs, which is
8Genes contain exons which are part of the protein-coding region in the DNA. Exons only comprise 1%
of the genome and provide the most easily understood, functionally relevant information.
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reflective of the problems with the array design or genotype calling methodology for
that SNP. Assessing the distribution of the call rates by each marker, genome-wide
shows outlying SNPs. A test for deviation from HWE is usually undertaken at each
SNP, using Fisher’s exact test at a study-specific significance threshold. Threshold
changes are dependent on the number of SNPs under investigation. Extreme deviation
from HWE is indicative of poor quality genotype calling at a SNP, for example, if
heterozygous genotypes have been under-called compared to the common homozygous
genotype. MAF is also used as a filter because the SNP quality tends to decrease with
MAF. Low numbers in at least one genotype group also lead to lack of power to detect
association amongst complex traits. The threshold used for filtering SNPs based on
MAF is variable on the sample size of a study.
In order to conduct accurate imputation of samples, the allele calls from the study data
and the reference panel data must be aligned to the same DNA strand (Verma et al.
2014). The differences between strands can arise due to the use of different genotyping
platforms and calling algorithms for different sites of a multi-site study or between case
and control groups. The SNPs that are not on the same strand must be "flipped" to the
reference. Strand checks convert the reference allele to the alternative allele; however,
all unresolved SNPs are usually discarded.
Sample QC
Sample quality control shares some similarities to SNP QC such as the exclusion
based on low call rate, which is indicative of a poor quality DNA sample. Samples
are removed due to the proportion of called genotypes that are heterozygous across
autosomes (i.e. heterozygosity rate), which could represent sample contamination or
inbreeding.
Discrepancies between the reported gender from external data and the genetic sex from
the X chromosome genotype data can occur because of sample mix-up or errors in
external data. The distribution of heterozygosity in males and females are different, as
males will have no heterozygous genotype calls because they only have one copy of the
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X chromosome. A routine initial screening to identify gender discordance is to plot
each individual, separated by gender on an x-axis of the X-chromosome heterozygosity
against the proportion of missing genotypes on the y-axis. Another method to identify
gender discordance is using Wright’s inbreeding coefficient, F, calculated from X-
chromosome data. Software such as PLINK (Purcell et al. 2007) employs this check.
For males, we expect the estimate to be close to F = 1, while for females, we expect
close to F = 0. Allowing for low rates of genotyping errors, the threshold for males
is F < 0.8 and F > 0.2 for females. Gender is sometimes adjusted for in association
analyses; therefore it is essential that any misreported sex is excluded, along with any
other collected phenotypic, clinical or external data for a sample that might be incorrect
due to possible sample mix-up which will introduce bias and reduce power of the
downstream association analyses.
1.2.4 Detecting and Accounting for Genetic Structure
Genetic structure arises due to relatedness between samples and population stratifi-
cation. Population stratification is the presence of a systematic difference in allele
frequencies between sub-populations in a study population, possibly due to different
ancestry. Not accounting for structure can increase the false positive error rate as an
association that is found could be due to the underlying structure of the population and
not a trait associated locus. The simplest approach to assess false positives is using
the distribution of observed test statistics summarised through a quantile-quantile (QQ)
plot (see Figure 4.4). In the presence of population structure, the observed test statistics
would be inflated over the expected under the null hypothesis of no association of
the trait with SNPs genome-wide. Devlin & Roeder (1999) proposed correcting for
population stratification using a method called genomic control, based on the observed
association test statistics calculated under an additive model, (as described in Section
1.3.1) using an Armitage trend test. Deviation of observed test statistics from the null
can be assessed by the genomic control inflation factor. A uniform correlation is then
applied dividing observed test statistics by the inflation factor to adjust for population
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structure.
Related or duplicate samples are a source of genetic structure. LD based pruning is
usually undertaken to remove high LD regions or to avoid capturing too much variance
of LD regions before checking for duplicated/related individuals. LD pruning is the
process of creating a subset of markers that are in approximate linkage equilibrium
with each other. For traditional association analysis (not family-based) samples should
be independent of one another because the statistical methods used assume indepen-
dent samples. Therefore related individuals defined as sharing the same alleles for a
proportion of the genome are identified and discarded using the identity by state (IBS)
matrix. Identical samples would have an IBS of 100%, with related samples sharing a
high IBS. Another metric of relatedness that is often of interest is pˆi, known as identity
by descent (IBD) estimation. This measurement is used to remove pairs of individuals
that share a number of chromosomal regions identical by descent. Large values of pˆi
indicate relatedness between pairs of individuals. One sample from each of the related
pairs is excluded based on a threshold of pˆi. The sample that is retained usually has the
highest sample call rate.
The inclusion of samples that are ethnic outliers or the presence of population strat-
ification are a source of confounding9 due to genetic structure. The principle is that
individuals who are geographically close together are likely to be more correlated in
terms of genotypes than those who are far apart. Association analyses assume individu-
als are from a homogenous population background; otherwise, there can be an increase
in type-I error rate.
Statistical techniques, such as principal components analysis (PCA), are essential in
determining differences between populations and visually representing any genome-
wide genotype differences between samples. PCA identifies ethnic outliers by merging
the observed genotype data with reference genotypes from populations available from
the international HapMap Project (Altshuler et al. 2010) or the 1000 Genomes Project
9Confounders are extraneous variables which confound the effect of the exposure on the outcome and
which satisfy confounding criteria (Greenland et al. 1999).
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(Auton et al. 2015). It is expected that the observed genotype data would cluster with
the reference population data, with any outliers adrift from the clusters.
This technique can also be used to calculate principal components (PCs) that can
be used to adjust for population stratification after the removal of ethnic outliers, by
including them as covariates in the analyses of association (this can be adjusted for in
the same way as the treatment covariate demonstrated in Section 1.3.1). The technique
explained in detail by Price et al. (2006), is applied using eigenvalue decomposition of
the genetic covariance matrix, deriving the PCs for the samples. An example of a PCA
plot for the diversity across Europe is demonstrated by Novembre et al. (2008) (Figure
1.2). The most popular choice of software to undertake QC and the identification of
genetic and population structure are both versions of the PLINK (Purcell et al. 2007,
Chang et al. 2015) software.
1.2.5 Single-SNP Association Testing
In order to analyse the genome, SNPs are determined for all individuals. Each SNP
passing QC is analysed separately for association with the trait of interest. Association
analysis can be conducted using a number of statistical models usually within a regres-
sion framework assuming a particular mode of inheritance. These statistical models
are outlined in further detail in Section 1.3. In most cases, the true genetic model
is unknown and can be either additive, recessive or dominant. An "additive" genetic
model is a very common assumption, whereby the effect of the heterozygous genotype
is intermediate between the major and minor homozygous genotypes. Genotypes are
coded according to the number of minor alleles carried, for example, assume the major
and minor alleles at a SNP are A and T. The genotypes are therefore AA = 0, AT = 1
and TT = 2.
Imputation poses a different coding for genotypes. For each SNP a probability is
derived for each possible genotype for an individual. The uncertainty in the genotype
is modelled by averaging the three expected genotypes across the probabilities via a
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Figure 1.2: Population structure in Europe, defined by two principal components,
from genome-wide SNP data in 1,387 individuals. Each small point (pairs of letters)
correspond to an individual, plotted for the first two principal components, and coloured
according to the country fromwhich theywere ascertained. The large circles correspond
to medians for the first two principal components for individuals from each country.
The projection has been rotated to emphasise the correlation with European geography
(inset). Country abbreviations: AL, Albania; AT, Austria; BA, Bosnia-Herzegovina;
BE, Belgium; BG, Bulgaria; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE,
Germany; DK, Denmark; ES, Spain; FI, Finland; FR, France; GB, United Kingdom;
GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; IT, Italy; KS, Kosovo; LV,
Latvia; MK, Macedonia; NO, Norway; NL, Netherlands; PL, Poland; PT, Portugal;
RO, Romania; RS, Serbia and Montenegro; RU, Russia, Sct, Scotland; SE, Sweden; SI,
Slovenia; SK, Slovakia; TR, Turkey; UA, Ukraine; YG, Yugoslavia. Originated from
Novembre et al. (2008).
"genotype dosage" (see Eq. 1.2).
Within the statistical regression framework for association testing, confounding factors
such as covariates and PCs can be adjusted for. These factors may contribute to the
association between SNPs and the trait of interest.
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1.2.6 Rare Variant Association Testing
NGS technologies have become available in recent years and can sequence a large
number of samples, making much of the human variation accessible, including rare
genetic variants, which are not typically captured by GWAS genotyping arrays (even
after imputation). Two common limits used to distinguish rare genetic variants from
common variants is a MAF less than 5% or 1%. The movement towards NGS data has
allowed us to look more deeply into rare genetic variants and investigate their role in
complex traits.
Pre-2015 many investigations had raised hopes that rare variant association studies
(RVAS) would yield a large number of strong effect variants for the purpose of person-
alised medicine10, consequently resulting in a plethora of new drug targets. However,
the expectations have not been met, whereby most rare variants identified to date have
modest effect sizes (Auer & Lettre 2015). However, with the increased coverage of
the genome using various technological advances such as whole-genome sequencing,
the likelihood of finding statistically relevant associations potentially can increase. To
date, most findings have been from GWAS that target common variants, that rarely
succeed in implicating specific genes (i.e. in non-coding regions) to common diseases,
which limits their importance in applications such as drug development. However, rare
variants could be the primary drivers of common diseases (Cirulli & Goldstein 2010).
It is not possible to analyse rare variants with traditional methods used for GWAS as
they have insufficient power to detect associations with variants withMAF less than 5%.
Currently, the best strategy for analysing rare variants is to combine them within units
of association termed "gene-based" analyses, defined using gene annotations, genomic
coordinates or functional characterisation (see Chapter 6).
10Personalised medicine is a treatment that is tailored to an individual based on characteristics such as
demographics, clinical measurements and genetic factors. This area seeks to end the traditional ‘one
size fits all’ approach to treatment, in the hope of developing better healthcare by maximising benefit
and minimising harmful events.
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1.2.7 Visualisation of Results
Association analysis results are best visualised through a Manhattan plot. These plots
show SNPs represented by a point, plotted according to -log10 p-values (y-axis) against
genomic location (x-axis). The benefit of this plot is that it helps distinguish chromo-
somes and SNPs in the presence of millions of statistical tests (see Figure 4.3). The tall
towers of points clustered together represent SNPs in potentially strong LD with each
other. An in-depth look at a particular location of the Manhattan plot, to investigate the
pattern of association signals can be visualised using LocusZoom (Pruim et al. 2010).
Each SNP is coloured according to the strength of LD with the lead11 SNP, based on
reference panel data, such as from the 1000 Genomes Project. Furthermore, local genes
are defined below the plot (Figure B.1).
As mentioned in Section 1.2.4 even modest levels of confounding can distort the null
distribution and overwhelm a small number of true associations. A QQ-plot is also
mandatory to evaluate whether there is any evidence of genomic inflation, analytical
approach bias or presence of population substructure.
1.2.8 Pharmacogenetics
The field of pharmacogenetics aims to identify genetic variants associated with drug
efficacy and safety. Both pharmacogenetics research and GWAS, together will continue
to help underlie genetic biomarkers and their relationship with drug response and
metabolism12 (see Table 2.1).
Individuals sometimes respond differently to treatments and alternative doses of a drug,
which may reflect genetic differences between them. Therefore pharmacogenetics is
key to understanding adverse drug reactions and efficacy to optimise treatments and
improve patient care (Innocenti 2005). There is a rapidly expanding list of genetic
11The lead SNP (usually identified as the most significant SNP associated with the outcome) is a reference
SNP whereby other SNPs (potentially causal) in the region can be identified through LD.
12This process is typically responsible for converting drugs to compounds that are easily absorbed and
excreted.
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variants that lead to altered drug responses. The GWAS Catalog (MacArthur et al.
2017) as of January 2018 shows a total of 225 SNP associations with a response to a
drug.
Variants common and rare can nowbe assessed for their effects on response to treatment.
Therefore, the number of genetic loci that predict response for efficacy and safety to
specific drugs will continue to increase. This information will permit better-designed
clinical studies, with more predictable outcomes (Kamb et al. 2013).
1.3 Fundamentals of Survival Analysis
The focus of most GWAS has primarily been on binary and quantitative phenotypes
since these are themost commonly encountered outcomeswhen studying complex traits.
However, more population-based cohort studies are being undertaken, which provide
long follow-up in combination with genetic data. Therefore, it is now possible to not
only analyse the risk of developing disease through a case-control outcome but also the
time to particular disease onset or another event. Specifically, in pharmacogenetics,
outcomes are often the time until the occurrence of disease remission or treatment
withdrawal due to an adverse drug reaction. The identification of genetic variants
associated with time to a key event (survival, death, relapse) after a clinical intervention
has the potential to have a major impact on drug and dose choice by improving the
benefit/risk ratio for a range of human diseases with substantial population health
burden.
The most powerful analytical approaches for testing association between genetic vari-
ants and these outcomes are to model the time to the occurrence of the event, adopting
survival analysis methodologies. Methods implementing a Cox proportional hazards
(PH)model are already extensively applied within candidate gene studies or small-scale
genetic association studies.
It is important not only to find associations between genetic variants and the outcome
of interest but also to quantify the impact of the effect on a trait. Exploring the effects
14
on survival of a group of patients depends on the values of many explanatory variables,
which are recorded for each patient throughout a study. In the analysis of survival data,
interest lies on the risk or hazard of an event at any time after the study begins (Collett
2003). Two important functions which determine the distribution of the event times
are the survivor and hazard functions. The survivor function, denoted by S(t), is the
probability of survival to time t, whereas the hazard function, h(t), is the probability
that at any given moment, the event will occur, given that it has not already done so.
Time-to-event (TTE) studies have an added complexity when modelling the event of
interest because it has usually not yet occurred for all individuals at the end of follow-
up or has occurred at an unknown time before follow-up. These individuals with
incomplete survival times are called censored observations. Many different types of
censoring can occur. However, themost common is right censoring, which occurs when
a study ends before all individuals have experienced the event of interest. Censoring
can occur due to a number of reasons such as a patient dropping-out from a study.
Together with censoring, another unique feature of TTE studies is that the observed
event times for a study population are often highly skewed, following a wide range of
non-standard statistical distributions.
1.3.1 Statistical Models
There are many different survival models available for the analysis of TTE data, in-
cluding; non-parametric13, semi-parametric and parametric models. The purpose of
this section will be to define the statistical methodology used throughout the thesis,
covering semi-parametric, parametric and alternative dichotomous approaches. Any
proposed extensions to these methods have been defined in the subsequent chapters.
13Non-parametric tests such as the log-rank test compare the survival of two groups, providing a p-value
of significance, however it does not quantify the difference between the two groups.
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Cox Proportional Hazards Model
The concept of PH is defined as the hazard of an event at a particular time point for
individuals in one group being proportional to the hazard at the same time point for
another group.
h1(t) = φh2(t) (Eq. 1.1)
φ is a constant known as the hazard ratio (HR) of the event occurring at any time for an
individual. For example, in Eq. 1.1 we are assuming that the hazard for an individual
with a heterozygous genotype, h1(t), is proportional to the hazard for an individual with
a homozygous genotype, h2(t), constantly over the study period.
The Cox PH model is the most widely used approach when modelling TTE outcomes.
It is a semi-parametric model where the HR takes a parametric form regarding the
regression coefficients, but the baseline hazard is unspecified (Cox 1975). The model
is defined using a partial likelihood function, rendering it computationally beneficial
with an additional advantage of being able to adjust for covariates. A disadvantage
of this model is that the distribution of survival times is unknown. In cases where
the PH assumption is not valid, other analysis models or extensions to the Cox PH
model should be considered. Furthermore, the Cox PH model is known to have poor
properties when the sample size is small, or when the risk factor is imbalanced, i.e. the
sample size is small in one risk group (Wang et al. 2010).
Consider a study investigating the association of a TTE outcome with genetic variants
in a sample of unrelated individuals. Let ti, denote the TTE for the i’th individual
and their additional covariates by the vector xˆi. Also, let Gi j , denote their genotype
at the j’th SNP of interest. Under an additive genetic model, the genotype of the i’th
individual is coded as [0, 1, 2], defined by the number of minor alleles they carry at the
variant. Imputed genotypes are modelled as an additive effect using the probabilities
pi j1 (heterozygote) and pi j2 (minor homozygote):
Gi j = pi j1 + 2pi j2 (Eq. 1.2)
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Under the assumption of PH, we can express the hazard of the event occurring at some
time t for the i’th individual given their genotype at a j’th SNP, conditional on them
not yet having experienced the event by:
hi(t) = h0(t)eβsGi j+βˆxxˆi (Eq. 1.3)
In this model (Eq. 1.3), h0(t) is the baseline hazard at time t, and the parameters βs and
βˆx correspond to the log-relative hazard for each copy of the minor allele at the SNP,
and a vector of covariate effect(s), respectively. The partial likelihood is given by:
L(t |βs, βˆx,G, xˆ) =
n∏
i
eβsGi j+βˆxxˆici∑
j∈R(ti) e
βsGi j+βˆxxˆi
(Eq. 1.4)
where, ci is an indicator taking the values 1 if the event occurred at time ti, and 0 if
the observation was censored. In this expression, R(ti) denotes the risk set at time ti,
corresponding to individuals who have not yet either experienced the event or been
censored.
The interpretation of the parameter estimates from the Cox PHmodel is the log relative
hazard associated with a one-unit increase in the covariate, which means that when we
see a positive estimate using the Cox PH model it is an increased hazard of the event.
Weibull Regression Model
TheWeibull regression model is a parametric survival model that makes an assumption
about the statistical distribution of the data and has completely specified hazard and
survivor functions. The model is beneficial when the HR is not proportional over time
or the data have an accelerated failure time (AFT) feature, whereby the effect of the
covariate is multiplicative on the time scale and it is said to "accelerate" survival time.
Under these conditions we might expect the power of these approaches to be greater
than the Cox PH model. However, a potential drawback to this is that you need to make
a correct assumption on the underlying distribution and shape of the hazard function,
otherwise the results may be misleading.
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This model is most commonly used in situations where it is of interest to estimate the
mean of the survival distribution, the survivor function and acceleration factor (AF).
The AF evaluates the effect of predictor variables on the survival time. The effect of
variables in the Weibull AFT model is to accelerate or decelerate time by some factor.
An additional benefit specific to the Weibull model is that an estimate for both the HR
and AF can be calculated.
The Weibull regression model for right censored observations can be derived using the
Weibull distribution density and survivor functions. Let ti, denote the TTE for the i’th
individual and their vector of covariates by xˆi. Also let Gi j , denote their genotype at
the j’th SNP of interest coded under an additive dosage model for the minor allele.
Within this framework, f (t) = biata−1e−bita is the density function and S(t) = e−bita
is the survivor function, where a is the shape parameter and bi is the scale parameter.
We parametrise the scale and shape parameters to incorporate the unknown regression
coefficients.
bi =
1
eβ0+βsGi j+βˆxxˆi
(Eq. 1.5)
a =
1
σ
(Eq. 1.6)
The parameters β0, βs and βˆx correspond to the log-relative change in time for the
intercept, each copy of the minor allele at the SNP, and a vector of covariate effect(s),
respectively. The likelihood of the observed time to event data under theWeibull model
is then given by:
L(t |θ) =
n∏
i
{[ f (t |θ)]ci [S(t |θ)]1−ci} (Eq. 1.7)
ci =
1 individual has had event0 individual is censored
To obtain maximum likelihood estimates for the set of model parameters
θ = {β0, βs, βˆx, σ}, wemaximise Eq. 1.7 and use theNewton-Raphson iterativemethod.
To obtain reasonable updates of the model parameters the shape paramter σ is updated
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very gradually in increments of 0.1.
θN+1 = θN − H−1∆
Where, H is the Hessian matrix, ∆ is the first order derivative vector, and θN are
parameter estimates in the N’th iteration. From the maximum-likelihood parameter
estimates, we calculate a z-statistic for each regression co-efficient, given by:
z =
βˆ
SE(βˆ)
p = 2
(
1 −
∫ |z |
−∞
2√
pi
e
y2
2 dy
)
(Eq. 1.8)
The estimates from the Weibull regression model are interpreted as the log-relative
change in TTE (or AF) associated with a one-unit increase in the covariate. This
means that when we see a positive estimate using the Cox PH model (increased hazard
of event) we expect a negative estimate using the Weibull regression model (earlier
occurrence of event). The p-value for each regression parameter is calculated using
Eq. 1.8. Alternative tests to calculating the significance of explanatory variables in a
model or comparing two models exist, such as the Wald test and likelihood ratio test
(LRT). The Wald test statistic is given by:
W = I(θ) [θ − θNull]2 (Eq. 1.9)
I(θ) is the expected Fisher information matrix. θNull is the proposed values (null
model). The assumption is that the difference between θ and θNull will be approximately
normally distributed. The Wald test statistic can be used to calculate the p-value for
each model parameter in the Weibull, Cox PH or another regression model. The single
parameter test statistic is compared to a chi-squared distribution:
W2 =
(βˆ − βNull)2
Var(βˆ) ∼ χ
2
1 (Eq. 1.10)
Where, βNull is usually 0. The LRT is used to compare two statistical models (i.e. the
null and alternative), given by:
2(`(θ) − `(θNull)) (Eq. 1.11)
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The p-value is derived using the difference between model log-likelihoods (Eq. 1.11).
The probability distribution of the test statistic is approximately a χ2 distribution with
degrees of freedom equal to the number of free parameters between the alternative and
null models.
Logistic Regression Model
Alternatively, to modelling the event times, we can dichotomise the outcome of indi-
viduals at the end of the study. Let yi denote the dichotomised outcome of the i’th
individual, given by yi = 1 if the event has occurred, and by yi = 0 if not. Individuals
who are censored before the end of the study are excluded from this analysis since it is
unknown whether the event has occurred or not and thus are treated as missing. Within
a logistic regression framework, we can model the log-odds of the occurrence of the
event by:
logit(yi) = β0 + βsGi j + βˆxxˆi (Eq. 1.12)
In this expression, βs corresponds to the log-odds ratio of the minor allele relative to the
major allele at the SNP, and βˆx represents a vector of covariate effect(s). We can form
a likelihood ratio test of association of the SNP, j, with the outcome by maximising the
unrestricted model Eq. 1.12 and comparing with that under the null model, for which
the allelic log-odds ratio, βs, is zero.
1.4 The Importance of Statistical Genetics Software
In the era of large-scale GWAS of thousands of individuals at millions of SNPs, datasets
can eclipse the size of hundreds of terabytes. Computational tools are key for handling
and processing data efficiently. These tools are mainly developed for Linux operating
systems (O/S) as this is largely the O/S run on high-performance computing (HPC)
servers. There are a variety of programming languages available that are used in
the production of statistical genetics software. Command line genetic data analysis
software such as PLINK (Purcell et al. 2007) and SNPTEST (https://mathgen.stats.ox.
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ac.uk/genetics_software/snptest/snptest.html) are written in C++with a large number of
new software pipelines such as HAIL (Seed et al. 2017) that are developed using Python
and Scala. These languages are rising in popularity because of the syntax readability,
their ability to handle scientific datasets and provide a framework for machine learning.
Software to perform power calculations is usually made to cater for multiple O/S,
utilising a graphical user interface (GUI). The reason for this is that they perform less
computationally intensive tasks and should be made with the specifications for those
without knowledge of the command line to use with ease. Power calculators seek to
determine the sample size and statistical power for a particular study depending on a
number of specified parameters. Many power calculators are web-based, such as the
genetic power calculator (GPC) (Purcell et al. 2003). Software like GPC allows all
users with access to the internet the ability to run the program without the need to
download and install the program on a local computer.
With the introduction of NGS, genetic datasets have undergone many changes. Along-
side the change in sequencing and genotyping platforms, the data volume increases,
and different file types that store the data are produced. Due to this, computational
tools need to evolve with these rapid changes, such as the movement from the genotype
(GEN)[.gen] file format to the variant call format (VCF)[.vcf] for sequence-based geno-
types. Software tools are changing the landscape of genetics research. They are making
all stages of the genetic variant discovery process more convenient to undertake, from
study design through to interpretation of analysis results.
1.5 Thesis Objective and Structure
The core aim of this thesis is to develop and evaluate statistical methodology for GWAS
with TTE outcomes, specifically but not limited to the field of pharmacogenetics. The
methodology is implemented within a set of computational tools consisting of a data
simulator and power calculator, and both single- and rare-variant analysis programs.
Secondary aims are to conduct simulation studies for all developed methodology and
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software with a final application to the Pharmacogenetics of Acute Coronary Syndrome
(PhACS) study, which aims to identify genetic risk factors for the recurrence of cardio-
vascular events after treatment. The motivation behind this research is to draw attention
to the underdevelopment of methodology and software for GWAS of common and rare
variants with TTE outcomes. Correct modelling of these outcomes within GWAS has
important implications in determining associations between genetic biomarkers and
traits or diseases. The chapters in this thesis can be separated into four main top-
ics of interest: literature review, methodology conception, software development and
application to data.
Chapter 2 provides a review of key elements of pharmacogenetic study designs and
methodology. An evaluation is conducted using simulation in R, of the power to detect
an association between SNPs and TTE outcomes across a range of pharmacogenetic
study designs whilst comparing alternative regression approaches. Comparison of
statistical power is made using: (i) a Cox PH model; and (ii) a logistic regression
framework with a dichotomised outcome at the end of the study. The investigation
incorporates detailed simulations and empirical evaluation in a candidate gene study of
anti-epileptic drug response with SNPs mapping to/near the ABCB1 gene (Leschziner
et al. 2006). The purpose of this is to identify scenarios for which the difference in
power between the analytical models is minimised.
Chapter 3 briefly reviews current software for simulating genetic data and performing
power calculations. From this, a detailed description is made of the software Survival-
GWAS_Power which performs power calculation for pharmacogenetic TTE studies
over a range of designs and analytical models. Use of the software is demonstrated
through a basic comparison of Cox PH and Weibull regression models.
Chapter 4 provides a comprehensive review of GWAS with TTE outcomes, methodol-
ogy development and current software for a variety of different outcomes. A detailed
outline of the software SurvivalGWAS_SV is given, describing the implementation of
methodology and processing algorithms, through to examples of use. The example is
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an application using simulated SNP data, undertaken for the purpose of testing software
efficiency and the appropriateness of the statistical methods.
A novel methodological framework for gene-based tests of association, with implemen-
tation within the program rareSurvival, is introduced in Chapter 5. The methodology
conception is explained along with the program’s algorithmic pipeline. The program is
tested using a simulation study based on exome array genotype data from two Swedish
cohorts.
The primary application of the novelmethodology and software is to the PhACS study in
Chapter 6. The PhACS study is a prospective pharmacogenetic cohort of 1470 patients
who had a cardiovascular event followed-up 48 months after hospital discharge. The
data is analysedwith both SurvivalGWAS_SV and rareSurvival, with themain objective
of identifying SNPs and genes associated with time to recurrent cardiovascular event
and all-causemortality. Testing the software under realistic conditions, provided insight
into the efficiency of both computational analysis tools.
Concluding remarks and further research proposals are outlined in Chapter 7. The
proposals cover improvements for each of the three computational tools, development
of novel statistical methods for more complex outcomes and study designs. Notably, the
impact of the research contained within this thesis and the future outlook and direction
of the field is discussed.
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CHAPTER 2
EVALUATION OF METHODOLOGY FOR
PHARMACOGENETIC "TIME-TO-EVENT" STUDIES
2.1 Overview
Methodology for modelling time-to-event (TTE) data has been extensively developed
over the years within medical research, from non-parametric procedures such as the
log-rank test to accelerated failure time models (Section 1.3). In the context of single
variant analysis of genomic data where genetic variants are considered as predictors in
the model to estimate hazard ratios, the same methodology can be applied and has been
done so over many years within pharmacogenetic candidate gene studies (Table 2.1).
However, this has not been the case for genome-wide association studies (GWAS), due
to the number of single nucleotide polymorphisms (SNPs), samples and the genotype
uncertainty from imputation to consider. In this instance, the current methodology is
not the limiting factor, rather the availability of analysis software implemented with
sophisticated data handling algorithms to perform tests of association as quickly and
efficiently as possible. This topic is further discussed in Chapter 3 of this thesis.
The traditional approach to the analysis of TTE data is through survival modelling.
Some of these models explicitly account for the most distinctive feature of nearly all
TTE studies: censoring. There are many different types of censoring, including right,
left, administrative or interval. These can occur collectively or individually for many
reasons, for instance, the study ending before the patient experiences the event of
interest or patient drop-out before the end of the study. The latter is a widespread
occurrence in TTE studies, because the trials often extend over a long period, waiting
for individuals to have the event of interest. In pharmacogenetic studies, the outcome
of interest is usually TTE after treatment intervention, where the event could be death,
disease remission, or the occurrence of an adverse drug reaction.
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The Cox proportional hazards (PH) model is the most popular choice for analysis when
examining TTE data. This notion is documented in many pharmacogenetic studies with
survival phenotypes (Table 2.1). However, there are instances where a study records
TTE outcomes, and follow-up data are collected, but a decision has been made to look
at a dichotomous outcome while removing individuals from analysis who would have
otherwise been censored in a TTE analysis.
2.1.1 Dichotomising Time-to-Event Outcomes
In the past, dichotomisation of the TTE outcome was largely undertaken for genome-
wide analyses, since available software packages are mostly limited to binary and
quantitative traits. One approach to circumvent the problem of lack of TTE software
availability is to consider the occurrence of the event as a dichotomous outcome at
some fixed time point, such as the end of the study. Individuals in which the event has
occurred are considered as "cases", while those in which the event has not occurred
are considered as "controls" (Ji et al. 2013, Speed et al. 2014). Nevertheless, this
approach would be expected to result in a loss of power to detect association with SNPs
compared with direct modelling of the TTE outcome because: (i) the event times are
not directly considered, thereby losing information; and (ii) the binary outcome cannot
allow for censoring before the end of the study, in which case individuals will be treated
as "missing" observations. Even though these individuals are classified as missing data
because the TTE has not been observed, they are valuable as the observation that they
went event free over a period is itself highly informative.
George et al. (2014) provide a few introductory examples on why we use survival
analysis. An example will be if a study has found that the final observed proportion
of events between treatment groups is identical. However, if one group had all events
occur shortly after randomisation, while the other had no events until just before the end
of follow-up, then the two treatments would logically be considered to have different
clinical effects despite the same proportions of events at the end of follow-up.
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A GWAS conducted by Ji et al. (2013) looked at depression disorder, and the treatment
outcomes were collected as a score over an eight-week outpatient clinical trial. They
use the logistic regression model to analyse the outcomes response and remission
as binary. The analysis did not yield any SNPs reaching genome-wide significance(
p < 5 × 10−8) . Nonetheless, they found 14 promising SNPs with one associated with
treatment response. This study had the information available for a TTE analysis to be
conducted with outcomes such as time to response and remission, but these data were
not used in a survival analysis. The article also states that two strategies were used to
analyse the primary outcomes: (i) "the primary analyses included only individuals that
were evaluated at the 8-week visit"; and (ii) "the secondary analyses were performed
with outcomes based on the final visit [...] these analyses included subjects who had
completed the full 8-week study, as well as those who dropped out of the study before
the 8-week assessment". This sentence means that those who dropped out of the
study would be classified as censored observations. However, the logistic regression
model used would not account for the observations in the primary analysis, and in the
secondary analysis, those that dropped out would be non-events. Examples of this
approach can also be found in candidate gene studies such as Charland et al. (2014),
Clarke et al. (2014) and Lohoff et al. (2013).
There is extensive literature describing the relative lack of power of binary analyses of
TTE outcomes, but comparisons have not been made in the context of pharmacogenetic
studies. Although there might be power losses by simplifying the outcome, there may
be substantial savings in computational runtime and resources.
2.1.2 Objectives
This chapter seeks to address the following questions:
1. What are the most commonly used pharmacogenetic study designs?
2. What methodology and software are used for analysis?
3. Under which pharmacogenetic settings is the loss in power smallest from assum-
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ing a dichotomised outcome instead of applying a survival analysis approach?
In this chapter, published pharmacogenetic studies are reviewed to summarise the most
widely used designs and analytical approaches. Simulations have been undertaken
to investigate the circumstances under which dichotomisation of a TTE outcome, has
minimal loss in power compared to traditional survival models.
2.2 More Than Five Years of Pharmacogenetic Studies
The field of pharmacogenetics is becoming increasingly widespread year after year
while moving through the GWAS era. Studies are being published for both candidate
gene studies and GWAS. Together, they complement one another in the pursuit of a
common goal: personalised medicine.
To understand the different types of study designs and analysismethodology usedwithin
pharmacogenetics, an evaluation of a total of 42 studies was carried out. This began
by conducting a search on PubMed (https://www.ncbi.nlm.nih.gov/pmc/) and Google
(http://www.google.co.uk) using a combination of the following keywords; "genome-
wide", "survival", "pharmacogenetics", "pharmacogenomics" and "time to". Further
searches were conducted using the keywords directly within The Pharmacogenomics
Journal (https://www.ncbi.nlm.nih.gov/labs/journals/pharmacogenomics-j/) and Phar-
macogenomics (https://www.futuremedicine.com/journal/pgs) website search bars.
After the literature search, the exclusion criteria involved first sorting the papers by rele-
vance and then filtering the papers based on publication date, to include only published
articles from the last five years1. Figure 2.1 provides a more detailed representation of
the number of articles included at every stage of the review process. The reason for
using the latest articles was to eliminate designs that may not be in use anymore, and
by understanding the current study designs, helps us gather ideas about future designs.
All articles included were between 1 January 2012 to 13 November 2015. Articles
1Initial search date: November 2014; Secondary search date: June 2015; Final search date: November
2015.
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beyond this point are discussed in subsequent chapters. If the search indicated that the
manuscript completely focused on a pharmacogenetic GWAS application with survival
or TTE phenotypes, then these would match exact criteria for inclusion. However,
there are very few of these papers. Therefore papers which focussed on candidate gene
pharmacogenetics with TTE phenotypes were also reviewed. The remaining papers
which covered only pharmacogenetics within a candidate gene or GWAS with a binary
outcome were examined based on their study design section. For example, we included
papers that highlighted an interesting setting that was not present in the other papers,
but which could still be used in TTE studies.
Figure 2.1: Literature review eligibility flowchart for pharmacogenetic studies. Blue
boxes indicate process stages. Red coloured text represent excluded articles, and the
green text indicates the final article inclusion.
Table 2.1 presents a summary of the most notable articles examined in the literature
review. It highlights the key features of each study design and statistical analysis
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protocol. In total 33 studies were chosen for further examination of which 25 used a
candidate gene approach, 8 were a GWAS of common variants, and 20 studies included
a TTE outcome. The following classification criteria were used to assess a study’s
relevance for inclusion:
1. GWAS or candidate gene study?
2. Common or rare variants?
3. Was the data imputed?
4. Number of SNPs.
5. Disease of interest.
6. Treatment/Intervention.
7. Study design.
8. Outcome.
9. Analysis model.
10. Software used.
From these articles, a few essential study design features at the foundation of most
pharmacogenetic studies can be identified. Key characteristics of TTE and pharmaco-
genetic studies include scenarios with: (i) a recruitment period, defined as the length
of time within a study where individuals are recruited, and phenotype information is
collected; (ii) follow-up time; (iii) treatment intervention; (iv) multiple drug doses; and
(v) right censoring.
The length of a study from patient recruitment to the end of follow-up can determine the
number of events and censored observations that occur. For example, if the follow-up
time for each individual in a study is after a short period of time for diseases such as
cancer, where interest lies with progression-free survival, then all patients are alive
without disease progression. This will result in no events across genotype groups. In
such cases, the TTE contains much more clinical information than whether or not the
event occurred.
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Study Type Variants Disease Study Design Phenotype
Method &
Software
Innocenti et
al. (2012)
GWAS 484,523
SNPs after
QC.
Pancreatic
cancer
351 patients treated with test
treatment or placebo. Given on
selected days of a 28-day cycle.
OS.Treatment was
stopped for progressive
disease, adverse events,
or patient withdrawal.
Log-linear two
way multiplicative
CPHM. Additive
genetic model. R
‘survival’ package.
Ray et al.
(2015)
Candidate
gene
6 (ABCB1) Chronic
depression
83 patients given 8-12 week
pharmacotherapy. Anti-
depressant treatment. Multiple
drugs and dosages.
Time to remission.
Individuals who crossed
over to another drug
before remission were
censored.
CPHM. Software
unknown.
Ashare et al.
(2013)
Candidate
gene
APOE 4 Smoking
cessation
917 patients in placebo
controlled trial. Adaptive
treatment regimen with
increases in drug dose.
Time to 7 day failure.
Genotype x age, and
genotype x treatment arm
interactions.
CPHM. STATA
12.0.
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Table 2.1 continued from previous page
Study Type Variants Disease Study Design Phenotype
Method &
Software
Koutras
et al. (2014)
Candidate
gene
VEGF Breast
cancer
Multiple treatments and doses.
Treatments adapted during 12
weeks of follow-up depending
on severity of disease.
OS. PFS. Multivariate
CPHM. SAS 9.3.
Depta et al.
(2015)
Candidate
gene
CYP2C19
genotype
Myocardial
infarction
12 month follow-up. Patients
treated with clopidogrel.
All cause mortality.
Time until cardiac
rehospitalisation.
CPHM. SAS 9.2.
Absenger et
al. (2014)
Candidate
gene
CCND1 Colon
Cancer
264 patients. 2 groups of
different stage cancer patients
treated with chemotherapy.
TTR. Censored at the
time of death or at the
last follow-up if the
patient remained tumor
recurrence-free.
CPHM. SAS 9.2.
Ji et al..
(2013)
GWAS 532 877
SNPs
Major
depressive
disorder
8 week outpatient clinical trial. Treatment response. 8
week remission and
response.
Logistic regression
model. R &
PLINK.
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Table 2.1 continued from previous page
Study Type Variants Disease Study Design Phenotype
Method &
Software
Han et al.
(2014)
GWAS 334,127
SNPs
Lung cancer All patients received 2
treatments, different doses on
various days.
OS. PFS. Patients lost to
follow-up, were censored
on the date of last
contact.
Multivariate
CPHM. PLINK
1.07 & SAS 9.1.3.
Uppugunduri
et al. (2014)
Candidate
gene
4 CYP
genotypes.
Stem cell
transplant
Age dependent treatment dose.
Dosage adjusted at 5’th
administration.
EFS was defined as the
time from the day of
transplant to the
occurrence of any event
of interest.
Multivariate
CPHM. SPSS
19.0.
Fernandez-
Rozadilla et
al. (2013)
GWAS 497,366
SNPs
Colerectal
cancer
Colon cancer patients receive 1
of 2 treatments whereas rectal
cancer patients 1 of 2
treatments or a combination of
both with radiation therapy.
Toxicity response.
Patients receiving other
treatment schedules were
excluded from the study.
Logistic
regression.
PLINK.
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Table 2.1 continued from previous page
Study Type Variants Disease Study Design Phenotype
Method &
Software
Pander et al.
(2015)
GWAS 647,550
SNPs after
QC.
Colerectal
cancer
755 patients received multiple
treatments, doses (adaptable)
and delivery systems on
different days.
PFS. SNP x treatment
interaction.Treatment
stopped at disease
progression, toxicity or
death.
CPHM. R
‘survival’ package.
Sato et al.
(2011)
GWAS 109,365
SNPs
Lung cancer 105 patients received a total of
308 cycles of treatment.
Patients followed up until death
or up to 5 years after treatment.
All patients were followed up
for more than 2.5 years.
OS was calculated from
the date of recruitment to
the date of death or the
last follow-up.
CPHM. SAS 9.13.
Table 2.1: Summary of pharmacogenetic studies of special interest from literature review. This table is in no way a full description of the studies,
but a general summary. Abbreviations: QC, quality control; OS, overall survival; PFS, progression free survival; TTR, time to tumour recurrence;
EFS, event free survival; CPHM, Cox PH model; SNPs, single nucleotide polymorphisms; GWAS, genome-wide association study.
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Cancer studies within pharmacogenetics are of interest because they investigate the
effects of multiple treatment options and doses, and Han et al. (2014) is an excellent
example of this. The study was a GWAS of survival in small-cell lung cancer patients
treated with two chemotherapy options. The primary outcome was overall survival
for 139 patients. After quality control, 334,127 SNPs were retained for analysis.
The analysis was run using a multivariate Cox PH model in SAS. Even though this
is a relatively small number of SNPs and sample size, a statistical analysis run in
SAS can have many limitations. First, imputed genotypes increase the complexity
of the data, thereby needing software to be able to read in the different file types
from programs such as IMPUTE2 (Marchini et al. 2007). For imputed SNPs, the
genotype is no longer an integer (0, 1 or 2), but is now equal to the expected allele
count, previously referred to as dosage (Eq. 1.2). Second, as the number of variants
and sample size increases, software such as SAS are not easily amenable to high-
performance computing (HPC) clusters. Software such as SAS and R have a fast-
growing implementation of packages covering a wide range of different data types, and
as shown in Table 2.1, they are the most popular choices to run the Cox PH model.
For the analysis of GWAS with binary and quantitative traits, SAS and R are rarely
used especially since the introduction of bespoke software such as SNPTEST (https:
//mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) and PLINK (Purcell
et al. 2007, Chang et al. 2015). These tools offer efficient analysis and a "user-friendly"
interface for those not familiar with coding environments. Table 2.1 shows three papers
that have used PLINK for analysis. As explained earlier in Section 1.4, with these and
other software available for binary outcomes, the truth remains that, if you simplify the
survival outcome it can be analysed using a logistic regression model in these software
packages with the benefit of computational runtime but at the cost of reduced power.
2.3 Simulation Study
Simulations were undertaken to compare alternative analytical approaches over a range
of study designs, collated from the literature review in Section 2.2. Themain aim of this
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simulation study was to simulate a variety of realistic pharmacogenetic study designs
while evaluating the power to detect an association between SNPs and TTE outcomes
using alternative regression approaches. The study considers designs with censoring
before the end of the study, treatment effects, SNP-treatment interaction effects, and a
variable recruitment period.
This section compares the power for the analysis of event times: (i) under a Cox PH
model; and (ii) within a logistic regression framework with a dichotomised outcome at
the end of the study. Although initially, it is expected that the Cox PH modelling would
be uniformly most powerful, the goal is to identify scenarios for which the difference in
power isminimised and existing software, such as PLINK, could be utilised at minimum
cost.
2.3.1 Procedure
Four commonly used design scenarios of pharmacogenetic GWAS were considered to
evaluate SNP association with TTE outcomes. The scenarios are described in detail
below in Section 2.3.2, and allowed for a variable end of study time and recruitment
period, censoring before the end of the study, multiple treatment effects, and SNP-
treatment interaction. All simulation scripts and analyses were written and performed
in R 3.2.0 (R Core Team 2013). Data were simulated using statistical distribution
functions, such as ‘rweibull’ and ‘rbinom’, for the different parameters discussed in
Section 2.3.2. The ‘survival’ package (Therneau 2015) in R was used to run the Cox
PH model (‘coxph’ function) and the ‘stats’ package (R Core Team 2013) was used
for the logistic regression model (‘glm’ function). The output from all simulations are
displayed as power plots, effect size and −log10 p-value plots.
2.3.2 Scenarios and Datasets
In all scenarios, a study undertaken for a maximum of 60 days was considered. Fur-
thermore, the impact on the analysis by fixing the end of the study, Z , at 20, 30, 40, 50
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or 60 days was examined. Patients who do not experience the event before the end of
the study were assumed to be censored at that point. However, in some scenarios, it is
imperative to allow for the possibility of censoring before the end of the study due to
the occurrence of an adverse treatment reaction or other reasons for drop-out. In these
Figure 2.2: An example of right censoring for four patients. The blue lines and
outcome (binary or TTE) equal to 1, represents the event has occurred. The black
lines and outcome (binary or TTE) equal to 0, or missing, represents that the patient is
censored. The vertical red line at 60 days signifies the end of the study.
scenarios, patients who are censored before the end of the study were excluded from
the logistic regression analysis at the end of the study (Patient 4 in Figure 2.2) because
it cannot be determined whether the event has occurred or not. Figure 2.2 depicts an
example of how the TTE and binary outcomes are determined for four individuals.
For each scenario, consider a simulated SNP effect, φs, on the log-hazard of the
occurrence of the event in the range of 0 (null model to evaluate false positive error
rates) to 0.4. For each simulation, 1,000 replicates of data for a sample of 1,000 patients
was generated. For each replicate, genotype data was simulated for the i’th patient, Gi,
from a multinomial distribution with minor allele frequency (MAF) of 0.4, under the
assumption of Hardy-Weinberg equilibrium and coded under an additive dosage model
for the minor allele, Gi = (0, 1, 2). Assuming PH, the time to the occurrence of the
event, Ti, was simulated from a Weibull distribution with shape parameter 1 and scale
parameter bi. bi is dependent on the genotype Gi, SNP effect φs, vector of log-hazard
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treatment effects φˆx for the vector of treatments xˆi and other scenario-specific factors
outlined below. The shape parameter of the Weibull distribution controls whether the
rate of events is increasing, decreasing or constant over time, while the scale parameter
determines the dispersion of the distributional values.
Ti = Weibull
(
1, bi = d0(t)eφsGi+φˆxxˆi
)
(Eq. 2.1)
1. No treatment effect and censoring occurs only at the end of the study.
The hazard of the event at time T is given using the scale bi = d0(t)eφsGi , where
two baseline scale parameters d0(t) = 15 and d0(t) = 50 were considered. The
baseline scale parameter controls the length of event times acting like a mean for
the spread of the simulated distributional values. A larger value for the baseline
scale parameter means on average a patient’s survival time is longer. Since there
was no censoring before the end of the study, the observed event time for the i’th
patient was τi = Ti if the event occurred before the end of the study; otherwise τi
= Z (i.e. replaced by the end of study time).
2. Random censoring due to drop-out before the end of the study.
The hazard of the event at time T is given using the scale bi = d0(t)eφsGi , where
a baseline scale parameter of d0(t) = 15 is considered. The censoring time of
the i’th individual, ci, was simulated from an exponential distribution with scale
parameters of 20, 40 and 60. The censoring time was assumed to be independent
of the SNP. The end of study time is fixed at 40 days; therefore an exponential scale
parameter of 20 for censoring times corresponds to approximately 50% censored
observations during the study, a scale of 40 corresponds to approximately 30%
censored observations, and a scale of 60 corresponds to approximately 20%
censored observations. If censoring occurred before the end of the study for
the i’th patient, they were assumed to have dropped out at that time, and their
observed time τi = ci. If the simulated censoring occurred after the end of
the study for the i’th patient, their observed event time was τi = Ti if the event
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occurred before the end of the study; otherwise τi = Z (i.e. replaced by the end
of study time).
3. Recruitment period during first ten days of the study and censoring occurs
only at the end of the study.
The hazard of the event is given using the scale bi = d0(t)eφsGi , where a baseline
scale of d0(t) = 15 is considered. The recruitment time, ri, was simulated from
a Uniform distribution over the first ten days of the study. Since there was no
censoring before the end of the study, the observed event time for the i’th patient
was τi = Ti − ri, if the event occurred before the end of the study; otherwise
τi = Z − ri.
4. Multiple treatments with variable effects on outcome and censoring.
Patients were randomly assigned to one of four treatments (A, B, C or D).
Treatment A increased the hazard of the event at any given time, while treatment
C resulted in increased random censoring due to adverse drug reaction before
the end of the study. The hazard of the event using the scale is given by bi =
d0(t)eφsGi+φˆxxˆi , where the baseline scale, d0(t) = 15, φˆx = (0.2, 0, 0, 0) is the
effect of treatment A, B, C, D, and xˆi is an indicator variable taking the value
1 if the i’th patient is assigned to treatment A, and 0 otherwise. If the patient
is assigned to treatment C, censoring occurs more frequently before the end of
the study, with time, ci, simulated from an exponential distribution with a scale
parameter of 10. All other treatments have a scale parameter of 30 to demonstrate
the effects of censoring between treatment C and all other treatments. Similar
to Scenario 2, if censoring occurred before the end of the study, the patient was
assumed to have dropped out at that time, so that τi = ci. If censoring occurred
after the end of the study, the observed event time for the i’th patient was τi = Ti
if the event occurred before the end of the study; otherwise τi = Z (i.e. replaced
by the end of study time). Under this same design, survival times were simulated
with a significant SNP-treatment interaction effect. The hazard now becomes
bi = d0(t)eφsGi+φˆxxˆi+φγGi xˆi with the interaction effect φγ = 0.2, and xˆi defined as
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above.
In parallel, for every scenario above, the event time was dichotomised at the end of
the study, Z , such that the binary outcome for the i’th patient, yi = 1 if Ti < Z , and
0 otherwise. For scenarios 2 and 4, patients censored before the end of the study are
treated as missing for the binary outcome.
2.3.3 Statistical Analysis
For each scenario, the association between the SNP and the TTEwas tested under a Cox
PH model (Eq. 1.3) and with the binary outcome in a logistic regression framework
(Eq. 1.12). For scenarios 1, 2 and 3, the linear component of the regression model
included an effect of the SNP only. However, in scenario 4, the linear predictor was
extended to include an indicator variable to account for the vector of treatment effects
and an interaction effect. The p-value and effect size estimates (log-hazard ratio for Cox
PH model and log-odds ratio for logistic regression model) are the output of interest.
2.3.4 Results
The power and type-I error rate was evaluated for each test to detect association of the
SNP with the outcome at a 5% significance threshold, approximated by the proportion
of replicates for which p < 0.05 for the SNP effect.
Figure 2.3 presents the power to detect association of the SNP, under scenario 1, with
TTE using a Cox PH model and with the dichotomised outcome at the end of the study
in a logistic regression framework. The two plots present power, for the different end
of study times, for a baseline scale of 15 (left) and 50 (right). For a baseline scale of
15, the majority of individuals will have experienced an event by day 20, and almost
all will have experienced the event by day 60. In this setting, the number of censored
observations at the end of the study is low, and the Cox PH model can directly account
for the times at which the events occurred. On the other hand, the logistic regression
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Figure 2.3: Scenario 1 power plots, where the end of study time is varied, and with fixed
end of study time censoring. Left plot is the scenario with a baseline scale parameter
of 15, and the right plot is for the scenario with a baseline scale parameter of 50. Power
is estimated at a 5% significance threshold. Lines with circular points characterise the
Cox PH model and lines with square points are the logistic regression model. The
colour of the line represents the end of study time: 20 days (black); 30 days (red); 40
days (green); 50 days (blue) and 60 days (cyan).
model loses power as the end of study time increases, because the number of cases and
controls becomes more imbalanced. As a result, the difference in power between the
two models increases with the end of study time. For a baseline scale of 50, far fewer
events occur during the study period. As a consequence, there is less to be gained
through direct modelling of event times, and the logistic regression analysis has almost
identical power to the Cox PHmodel. An end of study at 60 days is the most favourable
cut-off point for the logistic regression model as it has the greatest balance of events
and non-events occurring during the trial.
Figure 2.4 presents a comparison of −log10 p-value and estimated effect sizes from
scenario 1 for a baseline scale of 15, SNP effect of 0.1 and an end of study time of 40.
These parameter settings achieve a power of 50% to detect associations using the Cox
PH model. These results highlight that effect sizes from the two approaches are highly
correlated, but the signal of association is more often stronger under the Cox PH model
than logistic regression model. Figure 2.5 presents the power to detect association of
the SNP, under scenario 2, where censoring can occur before the end of the study. As
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Figure 2.4: Scenario 1 −log10 p-value and effect size plots. Blue lines represent 5%
significance levels (left) and log-hazard or log-odds ratios of 1 (right). Baseline hazard
= 15, MAF = 0.4, SNP effect = 0.1 and End of study = 40. This setting represents a
Cox PH model with a 50% power to detect associations between SNPs and survival
outcome.
censoring increases, the power of both models decreases. However, the reduction is
more dramatic for the logistic regression modelling of dichotomised outcomes because
the number of individuals contributing to this analysis decreases, with a consequent
reduction in power. Figure 2.6 presents a comparison of −log10 p-value and estimated
effect sizes from scenario 2 for a baseline scale of 15, SNP effect of 0.1, an exponential
censoring scale parameter of 60 and an end of study time of 40. These parameter
settings achieve a power of 50% to detect associations using the Cox PH model. These
results highlight that effect sizes from the two approaches are again highly correlated,
and the signal of association is typically weaker under logistic regression modelling of
the dichotomised outcome than the Cox PH model.
Figure 2.7 presents the power to detect association of the SNP and outcome, under
scenario 3, which incorporates a variable recruitment period for individuals at the start
of the study. The results are similar to those observed for scenario 1 with a baseline
scale of 15. As for scenario 1, the difference in power between the two modelling
approaches depends on the proportion of individuals in which the event has occurred,
and is maximised for an end of study time of 60 days because most individuals will have
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Figure 2.5: Scenario 2 power plot, where the end of study time is fixed at 40 days, but
with random censoring during the study period. Power is estimated at a 5% significance
threshold. Lines with circular points characterise the Cox PH model and lines with
square points the logistic regression model. The colour of the line corresponds to the
rate of censoring defined by the scale parameter of the exponential distribution: scale
20 (black); scale 40 (red) and scale 60 (green).
Figure 2.6: Scenario 2 −log10 p-value and effect size plots. Blue lines represent 0.05
significance levels (left and log-hazard or log-odds ratios of 1 (right). Baseline hazard
= 15, MAF = 0.4, SNP effect = 0.1, Censoring scale = 60 and End of study = 40. This
setting represents a Cox PH model with a 50% power to detect associations between
SNPs and survival outcome.
experienced the event by this time, even with a variable recruitment period. An end of
study of 20 days shows the smallest difference in power between the models because
very few events occur with the majority of individuals surviving to the end of the study.
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Figure 2.7: Scenario 3 power plot, with variable recruitment period, but with fixed
end of study time censoring. Power is estimated at a 5% significance threshold. The
recruitment period is between 0 and 10 days. Lines with circular points characterise the
Cox PH model and lines with square points the logistic regression model. The colour
of the line represents the end of study time: 20 days (black); 30 days (red); 40 days
(green); 50 days (blue) and 60 days (cyan).
Figure 2.8 presents a comparison of −log10 p-value and estimated effect sizes from
scenario 3 for a baseline scale of 15, SNP effect of 0.1 and an end of study time of 40.
These parameter settings achieve a power of 50% to detect associations using the Cox
PH model. As with previous scenarios, the effect size estimates obtained from the two
models are highly correlated, but signals of association are generally stronger under the
Cox PH model than the logistic regression model.
Figure 2.9 presents the power of the two modelling approaches for scenario 4, where
TTE is dependent on treatment. The first plot (left) includes a treatment effect of
0.2 on survival times with both analysis models adjusting for the treatment covariate.
The second plot (right) includes both a treatment effect of 0.2 and a SNP-treatment
interaction of 0.2, but incorporates only the treatment covariate in the analysis models
(because an interaction effect is not typically assumed, a priori). It is clear from both
plots that as the end of study time increases, which results in more censoring during
the study period, the power of the logistic regression model is substantially reduced.
Introducing a SNP-treatment interaction increases power for both analytical approaches
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Figure 2.8: Scenario 3 −log10 p-value and effect size plots. Blue lines represent 0.05
significance levels (left) and log-hazard or log-odds ratios of 1 (right). Baseline hazard
= 15, MAF = 0.4, SNP effect = 0.1 and End of study = 40. This setting represents a
Cox PH model with a 50% power to detect associations between SNPs and survival
outcome.
Figure 2.9: Scenario 4 power plots, where the end of study time varied, and there was
random censoring during the study period. Power is estimated at a 5% significance
threshold. Lines with circular points characterise the Cox PH model and lines with
square points the logistic regression model. The colour of the line represents the end
of study time: 20 days (black); 30 days (red); 40 days (green); 50 days (blue) and 60
days (cyan).
because the marginal effect of the SNP is increased, even if the interaction effect itself
is not taken account of in the analysis model.
Figure 2.10 presents a comparison of −log10 p-value and estimated effect sizes from
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scenario 4 for a baseline scale of 15, SNP effect of 0.1, treatment effect of 0.2, interaction
effect of 0.2 and an end of study time of 40. These parameter settings achieve a power
of 50% to detect associations using the Cox PH model. These results highlight that
the effect sizes from the two approaches are correlated, but the signal of association
is more often stronger under the Cox PH model with very few replicates with more
significant associations found towards the logistic regression model.
Figure 2.10: Scenario 4 −log10 p-value and effect size plots. Blue lines represent 0.05
significance levels (left) and log-hazard or log-odds ratios of 1 (right). Baseline hazard
= 15, MAF = 0.4, SNP effect = 0.1, Treatment effect = 0.2, Interaction effect = 0.2 and
End of study = 40. This setting represents a Cox PH model with a 50% power to detect
associations between SNPs and survival outcome.
For all parameter settings, the Cox PH analysis of TTE was always at least as powerful
as the logistic regression model, as expected. Across scenarios, the greatest difference
in power occurred when the end of study time was extended because the number of in-
dividuals experiencing the event was maximised, and there was more information in the
event times themselves. It is also true to say that as the number of censored observations
increases the more missing data there is for the logistic regression approach, resulting
in a loss in power to detect associations. While the power of the Cox PH model stays
relatively constant, that of the logistic regression approach gets substantially weaker
because of the increased imbalance in the number of cases and controls.
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2.4 Application to the SANAD Study
The Standard And New Anti-epileptic Drugs (SANAD) Study was an unblinded ran-
domised controlled trial in hospital-based outpatient clinics across the UK comparing
the effects of various drugs (efficacy) on patients with epilepsy. A sub-study of SANAD
conducted by Leschziner et al. (2006) was initiated to investigate the impact of genetic
variation on response to anti-epileptic drugs. They considered 503 epilepsy patients
receiving one of six anti-epileptic drugs over a follow-up period of between 84 and
2296 days. The study evaluated the evidence of association of 501 SNPs mapping
to/near the ABCB1 gene with time to 12-month remission, time to first seizure, and
time to drug withdrawal due to inadequate seizure control or adverse reactions.
For the purpose of this example, the original dataset was manipulated to illustrate
similar designs to that of the simulation study, incorporating binary outcomes as an end
of study time which is not specified in the original trial. The purpose of this analysis
was not to replicate the initial findings of the study but to compare results of modelling
TTE as survival or dichotomous outcomes. Specifically, testing for association of SNPs
with time to first seizure within the first 12, 24, or 36 months of follow-up using a Cox
PH model, and with a dichotomised outcome, at the same follow-up time points, in
a logistic regression model. The numbers of missing observations due to censoring
before the end of the study, for the logistic regression model at 12, 24 and 36 months,
were 56, 69 and 95, of the 503 patients, respectively. Before analysis, SNPs were
eliminated based on a MAF less than 1% and missing genotype rate greater than 5%.
For a full breakdown of summary statistics refer to Table 2.2.
To calculate the observed time for each patient and the corresponding outcome (survival
and binary) based on the three new end of study times, a combination of the original
outcomes of time to drug withdrawal and time to first seizure was used. Figure
2.11 shows a detailed diagram of how each outcome was developed. Adjustment for
covariates such as treatment was not undertaken in this illustrative analysis.
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Sample size Associated SNPs(p <0.05, MAF >1% & Missing <5%)
Outcome Censored Censored beforeend of study Events Non-events SNPs after QC Total Cox PH GLM Shared
Time to Seizure 12 months 156 56 347 100 116 10 6 5 1
Time to Seizure 24 month 138 69 365 69 116 16 9 8 1
Time to Seizure 36 months 132 95 371 37 116 10 9 1 0
Table 2.2: Summary statistics from SANAD study. Missing refers to the percentage of missing genotype data. Shared refers to the number of
shared associations discovered between the Cox PH and logistic regression models. Abbreviations: SNPs, single nucleotide polymorphisms;
GLM, generalised linear model (logistic regression); PH, proportional hazards; MAF, minor allele frequency; QC, quality control. p is the
value of significance.
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Figure 2.11: Outcome calculation diagram for SANAD study sample dataset. Abbre-
viation: EOS, end of the study.
2.4.1 Results
Figure 2.12: −log10 p-value plots for the outcomes time to seizure at 12 months (left),
time to seizure at 24 months (middle) and time to seizure 36 months (right). Blue lines
represent 0.05 significance levels.
Figure 2.12 depicts the −log10 p-value for association of SNPs with time to first seizure
from the SANAD study. Each point corresponds to a SNP, with the p-value for the SNP
effect from the Cox PH model on the x-axis and the p-value for the SNP effect from
the logistic regression model on the y-axis. The two blue lines indicate a nominal 5%
significance threshold for the association. The top left quadrant indicates significant
SNPs found only by the logistic regression model, the bottom right quadrant shows
significant SNPs found only by the Cox PH model, and the top right quadrant indicates
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significant SNPs found by both models. The key observation from this analysis is that,
as the study period increases, the number of associated SNPs found by the logistic
regression model is reduced. This result supports the findings of the simulation study
because, as the end of study time increases, there are more censored events within
the sample. For the outcomes of time to seizure at 12 and 24 months, there is little
difference between significant SNPs found by the logistic regression or Cox PHmodels.
However, for an end of study time of 36 months, the logistic regression model is able
to detect only one association.
2.5 Discussion
As expected, there was very little to gain by simplifying the TTE outcome to binary and
using sub-optimal methodology. The Cox PHmodel was demonstrated to be uniformly
more powerful than the logistic regression analysis of dichotomised outcomes across
simulation scenarios and generated stronger signals of association in the SANAD study.
However, the difference in power between methods was highly dependent on the rate of
censoring and number of events occurring within the study period. If few events occur
and the majority of individuals survive until the end of the study, then there is little to be
gained by modelling TTE outcomes. In these scenarios, a recommendation would be to
perform an initial evaluation of SNP association signals using computationally efficient
software with dichotomised outcomes identifying SNPs for further evaluation with
more rigorous, and computationally demanding, survival modelling, thereby providing
an effective screening tool. Consequently, this has important implications for the
development of analytical protocols in pharmacogenetic studies.
The power of the logistic regression model is significantly affected by the two types of
censoring: (i) at the end of study because the event has yet to occur; and (ii) during the
study period because of the occurrence of an adverse event or drop-out. If there is a lot
of censoring during the study, these observations are treated as missing in the logistic
regression model and therefore result in a lack of power to detect associations between
49
SNPs and outcome. The rate of censoring at the end of the study (i.e. the number of
events that have occurred) will impact the ratio of cases to controls in the dichotomised
outcome. For a given sample size, imbalanced studies will have less power than those
for which the number of cases and controls is equal.
Nearly all of the TTE articles reviewed applied the Cox PH model without giving
an indication of testing the PH assumption. Gregers et al. (2015) is one of the few
articles that were reviewed that justified the use of a Cox PH model. To assess the
proportionality assumption they used Schoenfeld (Schoenfeld 1982) and Martingale
residuals (Therneau et al. 1990). Model checking is essential and can help identify the
correct choice for analysis. For the majority of studies, survival modelling has been
condensed into using Kaplan-Meier curves and log-rank tests to explain differences
between groups and the Cox PH model to quantify the difference using hazard ratios.
This in itself is a big limitation because other statistical models may be more applicable
to the data.
The SANAD study results were consistent with the findings of our simulation study.
The candidate gene study was followed up with a GWAS several years later (Speed et al.
2014). This study was a multi-centre study of two cohorts of 916 newly treated epilepsy
patients. The clinical outcome of interest for this larger study was 12-month remission.
Patients achieving 12-month remission from seizures were defined as "responders",
and patients failing to achieve 12-month remission were defined as "non-responders".
Patients followed for less than 12 months were excluded from the study. For this study
the association analyses were performed using a logistic regression model in PLINK,
thereby losing all time related patient information. Doing this again emphasises the
need for flexible software for the analysis of TTE data that can efficiently handle the
scale and complexity of genetic data throughout the genome.
A final observation from the literature review was that very few studies undertook
sample size and power calculation before study engagement. Yip et al. (2014) a
candidate gene study determining associations between SNPs and treatment response,
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is one studywhich outlines a statistical power calculation procedure. This is an essential
step that will be investigated further in the next chapter.
51
CHAPTER 3
DATA SIMULATION AND POWER CALCULATION
3.1 Overview
In the previous chapter, a few key observations were made regarding power calculations
and genetic data simulation. The first observation was the absence of sample size
calculation protocols in published papers within pharmacogenetics. This observation
is informative since power calculators are currently available for the design of genetic
association studies of binary phenotypes and quantitative traits, but not for time-to-event
(TTE) outcomes, which are of particular relevance in pharmacogenetics. With the rapid
emergence of pharmacogenetic association studies of single nucleotide polymorphisms
(SNPs) and the complexity of the clinical outcomes they consider, there is a definite need
for software to perform power calculations of TTE data over a range of design scenarios
and analytical methodologies. The second observation was the lack of motivation for
the choice of analysis methodology. Most TTE studies within pharmacogenetics stated
use of the Cox proportional hazards (PH) model without considering alternatives or
testing the PH assumption.
3.1.1 Objectives
The objective of this chapter is to define software to perform power calculations for
genetic association studies of TTE outcomes that consider a range of design scenarios
and analytical approaches. The simulation machinery developed in Chapter 2 has been
utilised in the development of algorithms into the simulation and power calculation
software design.
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3.2 Simulating Realistic Genetic Data
One approach to assess power requires simulation of genotype and outcome data. In
Section 2.3, scenarios were designed based on a review of the literature and simulated
data in the R (R Core Team 2013) statistical environment using generated random
deviates from statistical distributions. However, there is specific software used for
simulating genetic data, such as GPOPSIM (Zhang et al. 2015), a simulation tool
for pedigree, phenotypes, and genomic data or genomeSIM (Dudek et al. 2006) for
the simulation of large-scale genomic data in population-based case-control samples.
HAPGEN2 (Su et al. 2011) is software that uses a simulation-based algorithm based
on a re-sampling method. It simulates realistic SNP data based on known haplotypes
from a reference panel, for instance, the 1000 Genomes Project (Auton et al. 2015) or
HapMap3 (Altshuler et al. 2010). HAPGEN2 generates genotype and phenotype files
for case-control studies ready to be used by analysis software.
Software to perform data simulation for GWASwith TTE studies are non-existent. Sim-
ulations can be undertaken separately for genotype and outcome, however incorporating
genetic effects on event times is difficult to achieve without bespoke software.
3.3 Importance of Power Calculations and Sample Size
Power and sample size calculations are an essential component of study design. They
inform us about the required sample size to detect a desired effect size with sufficient
power at a given level of significance. These calculations can be conducted through
simulating many replicates of data based on the investigators’ input parameters or
previous pilot data. These replicates are then analysed using a statistical test to produce
results on power, false-discovery rate and other metrics.
Low et al. (2014) states that for "underpowered studies, and large heterogeneity of study
designs, collaborative efforts are needed to validate these findings and overcome the
limitations of GWA studies before clinical implementation". This sentence defines how
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necessary power calculations are to all types of studies because without it investigators
would be making assumptions through uninformative speculation.
Tools are readily available for GWAS of binary phenotypes and quantitative traits.
These include the freely available Genetic Power Calculator, developed by Purcell et al.
(2003), which was an innovative web-based platform produced in 2001, for performing
power calculations for the design of linkage and association genetic mapping studies
of complex traits. It offers users options for discrete and quantitative trait power
calculations under both case-control and family-based association. Software such as
CaTS (Skol et al. 2006) followed this, introducing a two-stage GWAS power calculator,
which allows for a discovery and replication phase. CaTS jointly analyses data from
the first stage (the proportion of the available samples genotyped on a large number of
markers), and the second stage (the portion of these markers that are later followed up
by genotyping them on the remaining samples). Most recently, GAS (Johnson 2017),
a user-friendly web application for case-control genetic association power calculation,
is at the forefront of the development of interactive applications that are accessible to
everyone without download. However, as yet, software is not available to determine
adequate sample size for pharmacogenetic GWAS of TTE outcomes. This would be
useful in many situations, for instance, where the impact of alternative treatments, and
potentially their interaction with SNPs is often of relevance in the study design protocol.
Owzar et al. (2012) presents methodology and simulation study results for asymptotic
and empirical power and sample size calculations for SNP association studies with TTE
outcomes. They also provide an R package ‘survSNP’ which facilitate the calculations
in the paper using a Cox score test, implemented using the ‘survival’ package developed
by Therneau (2015). However, the package does not allow users the flexibility to
calculate the power and sample size based on different statistical models and study
designs. A graphical user interface (GUI) based software would also be easier to use
for those with limited R experience.
The lack of data simulation and power calculation tools available for pharmacogenetic
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TTE studies has prompted the development of the tool SurvivalGWAS_Power. The de-
sign of the software draws influence from the review of current software in the previous
section. As a result, the software has a user-friendly interface and attempts to present
the results output in the most informative way possible, through plots and statistical
metrics such as the power based on sample size, effect size and allele frequency.
3.4 SurvivalGWAS_Power
SurvivalGWAS_Power was developed from a Windows form based calculator applica-
tion that performed basic arithmetic in C++. The program was then ported over to C#
which, provided more flexibility in the design of the GUI and offered a vast catalogue
of .NET libraries to utilise. Even though it was initially designed for pharmacogenetic
studies based on the literature review in Chapter 2, the potential for application more
widely to other study designs is available.
3.4.1 Implementation
SurvivalGWAS_Power was built as a Windows application, utilising pre-designed
frameworksMath.NET (https://www.mathdotnet.com/) andAccord.NET (Souza 2014),
for the generation of pharmacogenetic data and statistical analyses, respectively. The
software was compiled on a Windows operating system (O/S) using the integrated
development environment (IDE) Visual Studio 2013 (https://www.visualstudio.com/).
SurvivalGWAS_Power requires specification of genetic parameters, such as the magni-
tude of the SNP effect on the outcome and the effect allele frequency (EAF). The varied
collection of design scenarios includes adding a recruitment period, SNP-treatment
interactions, and different censoring options (for example, withdrawal due to an ad-
verse treatment event). The scenarios were created using the thorough examination of
published pharmacogenetic studies in the literature review of Chapter 2. The power
calculations are performed by simulating multiple datasets based on the user-specified
parameter settings and study design options, specifically testing for SNP associations
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(and SNP-treatment interactions, if required) with the TTE outcome across all simulated
datasets.
3.4.2 User Interface
Asmentioned earlier, the software boasts a GUI, making it understandable and practical
to navigate. The main window consists of two panels, the first for design, analysis and
parameter inputs, and the second for all output (see Figure 3.1). The menu bar has
a "Save Sample Data" option, as well as another choice to store all the datasets from
every simulation run. This option might be useful for those who want to test power for
methods not supported by the program. The data are saved as a text file, in R statistical
software readable format. The interface has been designed to be user-friendly; there are
various help buttons to navigate the user through the program in the form of tooltips, and
an example of a commonly used pharmacogenetic study design is available as a guide.
The inputs are split into two sections: (i) data generation inputs; and (ii) statistical
analysis inputs. The user-defined parameter inputs are submitted in text boxes. For a
full description of inputs and results see Table 3.1.
Figure 3.1: SurvivalGWAS_Power v1.5 (Date: 30/11/2017) User interface screen-shot
of the simulator and power calculator tab.
Figure 3.1, presents a screen-shot of the front end of SurvivalGWAS_Power. If the user
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clicks on the tab at the top labelled "Sample data, Analysis output & Histograms" they
will see the additional output from all the analyses and data simulations. Figure 3.2 is a
screen-shot of the interface for the results tab. Data nor power has been simulated here,
so all four boxes are empty. Output details are discussed using an example in Section
3.6.
Figure 3.2: SurvivalGWAS_Power v1.5 (Date: 30/11/2017) User interface screen-shot
of results tab.
Figure 3.3: File menu of SurvivalGWAS_Power v1.5 (Date: 30/11/2017). Options are
to either save the sample data or save data from all simulations.
If the user wishes to save the sample data or data from every simulation run, then this
can be done by clicking on the "File" button located on the top menu and then selecting
the appropriate choice from the drop-down menu, as shown in Figure 3.3. The reason
for this feature was to allow users to use the data for a simulation study or use within
other software such as R using methods not supported by the current implementation of
SurvivalGWAS_Power. The "Help" button depicted in Figure 3.4, has four options for
users to learn more about navigating through the software and details about using and
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distributing the software. Figure 3.5 shows a screen-shot of the "About" option from
the "Help" menu, which displays the version and general description of the software.
Figure 3.4: Help menu of SurvivalGWAS_Power v1.5 (Date: 30/11/2017). Options
include launching an About prompt, example, program shortcut keys and the software
license.
Figure 3.5: About prompt of SurvivalGWAS_Power v1.5 (Date: 30/11/2017). About
prompt includes copyright information, logo, version and software description.
Data generation inputs
Number of simulations The number of simulated datasets.
Number of patients The number of patients within each simulated dataset.
Effect allele frequency Each SNP is simulated using a binomial distribution.
Genotype AA=0, AB=1, BB=2. A value of 0.4 means
that ≈16% of the patients in each dataset will have the
genotype BB.
SNP effect size The log-hazard ratio for each copy of the effect allele
relative to the non-effect allele.
Treatment effect size The log-hazard ratio between treatment and a placebo.
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Table 3.1 continued from previous page
SNP-Treatment
interaction
The effect size of the interaction between the SNP and
treatment.
Proportion of patients
on treatment
Placebo = 0, Test Treatment = 1. A value of 0.5 means
both treatments are divided equally between the
numbers of patients in each dataset.
Survival distribution This is the Weibull statistical distribution used to
simulate each individuals event time. The scale
parameter incorporates SNP, treatment and interaction
effect sizes and a baseline scale parameter.
Shape parameter The shape parameter for the Weibull distribution which
is used to simulate survival times for each patient. A
value < 1 indicates that the failure rate decreases over
time. A value = 1 indicates that the failure rate is
constant over time, reduces to an exponential
distribution. A value > 1 indicates that the failure rate
increases with time.
Baseline scale
parameter
Determines time scale of patient’s survival time. A
value of 20 will simulate survival times around 20.
Censoring Censoring time for each patient. Input for scale
parameter of Weibull distribution, with shape parameter
= 1. If censoring time <survival time, then the patient is
censored with their observed time = censoring time.
Recruitment period Patient’s recruitment time will be between 0 and value
entered. Will effect censoring and observed survival
time for each patient.
End of study time The end of study time.
Analysis model inputs
Input variables Check the box/boxes of the model terms to include in
analysis. SNP has to be selected.
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Table 3.1 continued from previous page
Analysis selection Choice of either the Cox PH model or Weibull
regression model.
Significance level Significance threshold for p-value from analysis.
Power output
SNP effect % The number of simulations at which the p-value for the
SNP is significant at the threshold value.
Interaction effect % The number of simulations at which the p-value for the
interaction is significant at the threshold value.
Joint Association % The number of simulations at which the p-value for
thejoint association through LRT is significant at the
threshold value.
Table 3.1: SurvivalGWAS_Power inputs and results definitions.
3.4.3 Data Simulation Settings
The user will first specify the number of simulations to generate, and the sample size
for each of those simulations. For each replicate of data, a SNP genotype (coded as 0,
1 or 2 according to the number of effect alleles) is generated for each individual from
a binomial distribution dependent on the EAF, assuming Hardy-Weinberg equilibrium.
The user is given the option of incorporating an active treatment against a placebo.
Treatment allocation is simulated using a Bernoulli distribution.
TTE for each individual is then simulated on the basis of specified model parameters
from a Weibull distribution given their allocated treatment and genotype, which allows
for the possibility of a deviation from a PH assumption. The user specifies the value
of the shape parameter, a, of the Weibull distribution. A value of a < 1 indicates that
the failure rate decreases over time. A value of a = 1 indicates that the failure rate
is constant over time, resulting in PH. A value of a > 1 indicates that the failure rate
increases with time. The scale parameter of the Weibull distribution is parametrised to
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incorporate SNP, treatment, and SNP-treatment interaction effects in generating TTE
for each individual. Specifically, the scale parameter for the i’th individual is given by,
bi = d0e−φsGi−φx xi−φγGi xi , whereGi is the SNP genotype coded under an additive model
for the minor allele, and xi is the treatment covariate (coded as 0/1 for placebo/active).
The value of the baseline scale parameter d0, is specified by the user. Larger values of
d0 will simulate larger event times; however, this is dependent on the time-scale (days,
months, years) the investigator wants to design the trial around. The parameters φs and
φx are the effect on log-hazard of the effect allele at the SNP, and the treatment effect,
respectively, and φγ is the interaction effect between the SNP and treatment. The user
specifies the values of each of these parameters.
By using the same notation as the study design parameters outlined in Section 2.3,
the simulated observed TTE outcome can be generated for the following possible
scenarios, each of which includes the option of incorporating treatment and SNP-
treatment interaction effects. In all scenarios, the simulated TTE of the i’th individual
is denoted Ti, and the observed event time (after right censoring) is denoted as τi.
1. Scenario 1 - End of study censoring.
This scenario is designed based on a user-specified fixed end of study time, Z. If
the event occurs before the end of the study, the observed event time for the i’th
individual is τi = Ti; otherwise τi = Z .
2. Scenario 2 - Censoring during the study period and at the end of the study.
The censoring time of the i’th individual, ci, is simulated from a Weibull distri-
bution with a user-defined scale parameter and a fixed shape parameter of 1, to
illustrate the censoring is constant over time. Small values of the scale parameter
will generate more censored observations. If censoring occurs before the end of
the study, the individual is assumed to have dropped out at that time, thus τi = ci.
If censoring occurs after the end of the study, yet the event occurred before the
end of the study, then the observed event time for the i’th individual is τi = Ti;
otherwise τi = Z .
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3. Scenario 3 - Recruitment period and end of study censoring.
The recruitment time, ri, is simulated from a discrete uniform distribution be-
tween 0 and a specified end time. There is no censoring before the end of the
study and if the event occurs before the end of the study the observed event time
for the i’th individual is τi = Ti − ri; otherwise τi = Z − ri.
4. Scenario 4 - Censoring during the study period and at the end of the study
with a recruitment period.
The censoring time of the i’th individual, ci, is simulated from a Weibull distri-
bution with a user-defined scale parameter and a fixed shape parameter of 1. If
censoring does not occur before the end of the study, and an event has occurred,
an individual will have observed time τi = Ti − ri, unless censored at the end of
the study, then τi = Z − ri. If censoring does occur during the study period, then
τi = ci − ri.
In a real study, there are aspects of the design the investigator can control such as
the number of patients, inclusion of covariates and statistical methods. However,
some features cannot be controlled such as the SNP effect size and allele frequency.
Nevertheless, providing these options allows users to prepare for a variety of possible
scenarios.
3.4.4 Methodology
As explained in Chapter 1 and from the pharmacogenetic literature review in Chapter 2,
there are a variety of models for analysing TTE data. Therefore, SurvivalGWAS_Power
gives users the option of testing the power using either a Cox PH model or a Weibull
regression model. Providing a choice will allow investigators to explore an alternative
option to the Cox PH model. Users can select between running their choice of analysis
by fitting a model including (i) the SNP alone; (ii) the SNP and treatment; or (iii) the
SNP, treatment and SNP-treatment interaction.
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The framework ’Accord.NET’ has a built-in Cox PH function, which calculates the par-
tial likelihood and obtains parameter estimates and Wald test p-values (see Eq. 1.10).
The Weibull regression model is not supported in this framework, so maximum likeli-
hood estimates of model parameters are obtained using an iterative Newton-Raphson
method after maximising the right censoredWeibull regression likelihood function (see
Eq. 1.7). An issue with the Weibull regression model parameter estimation using the
Newton-Raphson method is that it is sensitive to starting values. This sensitivity can
lead to unreasonable updates for the shape parameter. Thus a simple exponential model
is first run on the data, and the updates of each iteration are very gradual to achieve
more accurate coefficient estimates.
3.4.5 Validation
The user interface implements a validation system to track user errors at an input. As
the user inputs values into the parameter text boxes, the error provider will check that
the entered values are valid, indicating with either a green tick icon on the right of the
box or an exclamation mark as a warning for an incorrect entry. Each textbox also has
a character limit, and users will be unable to enter non-numerical characters. Before
the power calculation begins, the error provider will check that all required information
has been entered for a selected scenario. If not, the program will display a prompt
notifying the user what the problem is. For example, the user cannot select treatment
as an analysis covariate if a treatment effect has not been included in the simulation
model.
3.4.6 Output
The output comprises of a sample dataset, a table of the analysis output for each
simulation run and two histograms of parameter estimates across simulations: (i)
coefficient values for the SNP effect from the regression model; and (ii) −log10 Wald
p – values for the SNP effect. All histograms can be saved by right-clicking the graph
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and selecting "save as image". Power, at the specified significance threshold, α, is
approximated by the proportion of replicates for which p < α for the SNP effect on
the outcome. Power, at the same significance threshold, is also calculated for the
SNP-treatment interaction effect, if this term is included in the analysis model.
The joint association power is the power to detect an association between the SNP
adjusting for treatment and SNP-treatment interaction effects with the TTE outcome.
The joint association is calculated from a likelihood ratio test (LRT) (see Eq. 3.1)
between two models when the interaction check box is selected. The first model
includes the SNP, treatment and interaction terms in the log-likelihood function of
either the Cox PH (Eq. 1.4) or Weibull regression models (Eq. 1.7) whereas the null
model includes the treatment covariate only. This is a 2 degree of freedom χ2 test.
Figure 3.6 illustrates the simplicity of using SurvivalGWAS_Power through a work-
flow diagram. All .NET libraries are pre-compiled within the software. The user can
interrupt the power calculation process by clicking the "cancel" button at any time.
2(`(βG, βx, βγ) − `(βx)) (Eq. 3.1)
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Figure 3.6: Flowchart of SurvivalGWAS_Power v1.5, from data generation to output.
3.4.7 Installation Guide
The software can be downloaded from the University of Liverpool, Statistical Genet-
ics and Pharmacogenomics Research Group software page: https://www.liverpool.ac.
uk/translational-medicine/research/statistical-genetics/survival-gwas/. As well as the
download, there is a full description of the software. The user must click on the
download SurvivalGWAS_Power link and follow the instructions on the screen. Once
installed the program should be located in C:/Program Files (x86)/University of Liv-
erpool/SurvivalGWAS_Power. To create a desktop shortcut or pin the application to
the taskbar, the user should right-click on the .exe file and select the appropriate option
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listed. To open the program, double-click on the .exe file.
3.5 Performance Results
Figure 3.7 presents run times of SurvivalGWAS_Power under two different analyses
as a function of the number of simulations: (i) SNP effect only; and (ii) SNP effect,
treatment effect and SNP-treatment interaction. Results are presented for the Cox PH
and Weibull regression models, for a sample size of 1000 individuals under design
scenario 2, outlined in Section 3.4.3.
Figure 3.7: Performance of SurvivalGWAS_Power v1.5 assessed by comparing alter-
native regression models. A sample size of 1000 used for each simulation. All lines
represent the terms adjusted for in each statistical model.
Figure 3.7 shows us that under these conditions the Weibull regression model is no-
ticeably faster at processing data than the Cox PH model. However, the speed of the
analyses is not informative about the suitability of the models and should not be taken
into consideration when designing a study. What it does highlight is that overall the
software maintains efficiency, even with the adjustment for treatment and interaction
terms.
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3.6 Example
SurvivalGWAS_Power has been developed to simulate a large number of datasets to
enable efficient estimation of power based on specified model parameters and design
scenarios. This section presents the results of example power calculations for a scenario
to demonstrate the utility of the software. The example specifically compares two
statistical models, while adjustments are made with and without model covariates.
For these examples, it is of interest to investigate the power to detect associations of
a pharmacogenetic TTE study. The outcome of interest is known to have a steady
increase in risk over the first few months after diagnoses with a very high event rate
occurring shortly after. This hazard function is monotonically increasing over a short
period. A Weibull distribution with shape parameter 2 and scale 18 is used to simulate
this. The patients are being treated with either an active treatment or a placebo, and
this would be given to them at the date of recruitment which will be from 0 to 12
months. Follow-up will be assessed every three months with the end of the trial at
three years from the start of the study. Approximately 10% right-censored observations
were simulated in each replicate dataset. This censoring criterion is achieved through
a combination of specifying a scale parameter of 50 for the censoring distribution, a
scale of 18 for the patient event times, keeping the majority of times within the interval
from start to the end of study at 36 months.
Figure 3.8 is a histogram that represents the right-censoring approximation under the
study design mentioned above. It shows that the censoring times are constant over
time whereas the survival times are largely occurring before the end of the study. The
overlapping area shows the frequency at which random censoring could occur if the
censoring time is less than the survival time for a given patient. For this study, it was
of interest to investigate the minimum sample size required to achieve a power of at
least 90% for SNPs with a moderate effect of 0.4 and an EAF of 0.1. The treatment and
interaction effect size used throughout will be 0.3 and 0.2, respectively. Two sets of
analysis have been run. First, a SNP only analysis after which adjustment was made for
67
Figure 3.8: Histogram showing randomly simulated Weibull distribution estimates of
survival and censoring times.
treatment and interaction for the second analysis. The second analysis featured power
calculations for both the SNP effect and the joint association (Eq. 3.1). For all scenarios,
assessment has been undertaken for the power to detect association using the Cox PH
and Weibull regression models at genome-wide significance threshold
(
5 × 10−8) . For
each scenario, 1000 simulations were performed by SurvivalGWAS_Power.
This example is not a complete representation of a study design protocol, but a demon-
stration of the use of the software. Investigators could use the tool for a more detailed
comparison of methods and calculate sample size under different contributing factors.
Different EAF thresholds, different percentage of censored observations, and varying
effect sizes could be explored and how individually and collectively they will affect
the power. These are all aspects to consider in a complete power calculation protocol.
Figure 3.9 presents the input parameter tab of the software. The starting sample size is
set at 400 for all calculations before adjusting and determining the desired sample size
for a power of at least 90%. The example demonstrates the use of the Cox PH model
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Figure 3.9: SurvivalGWAS_Power Example 1 input parameters. The example depicts
a scenario with a sample size of 400, random right censoring and a recruitment period.
Only a SNP effect is analysed within a Cox PH model.
considering only the SNP main effect. However the SNP, and treatment main effects,
and a SNP-treatment interaction effect is taken into consideration in simulating event
times. The analysis model is used to test the SNP association, i.e. the null hypothesis
H0 : φG = 0 against the alternative HA : φG , 0, for which power is estimated to be
90% at a genome-wide significance threshold of p < 5 × 10−8.
Figure 3.10: SurvivalGWAS_Power Example 1 power analysis output from Cox PH
model. (Top left) Simulated sample dataset, (Top right) Parameter estimates of the
SNP effect from each simulation run, (Bottom left) Histogram of SNP coefficient beta
effects (log(HR)) across simulations & (Bottom right) Histogram of −log10 p–values
for the SNP effect across simulations.
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Figure 3.10 shows the additional output from the analysis setup shown in Figure 3.9.
The top left table displays one of the simulated datasets. Each row represents an
individual patient. The dataset is a good way of checking that the censoring indicator
and event times have been calculated correctly for the input parameters. The bottom
left histogram shows the distribution of estimated SNP effect values (log(hazard ratio))
across simulations, which in this example are centred around 0.9, and not the true effect
size of 0.8. This bias occurs as the data are simulated with a SNP-treatment interaction
effect, that the analysis model does not take into account. The reason for the true
log(HR) to be 0.8 and not the input parameter of 0.4 is that the shape of 2 used for
simulating the event times increases the hazard multiplicative by 2.
The top right table shows the Cox PH analysis output from each simulation run,
focussing only on the SNP effect. The bottom right histogram shows the −log10
p-value for the SNP effect across simulations. Power, at the specified significance
threshold, α < 5× 10−8, is approximated by the proportion of the 1000 simulations for
which the p-value, p < 5 × 10−8 for the SNP effect on the outcome.
Figure 3.11: SurvivalGWAS_Power Example 2 input parameters. The example depicts
a scenario with a sample size of 400, random right censoring and a recruitment period.
Only a SNP effect is analysed within a Weibull regression model.
Figure 3.11 shows a power calculation based on the same input parameters shown in
Figure 3.9. However, now assessing evidence of association using aWeibull regression
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model. This model has a power of 92% which is greater than that of the Cox PH
model. Figure 3.12 shows the output tab from theWeibull regression analysis adjusting
Figure 3.12: SurvivalGWAS_Power Example 2 power analysis output from Weibull
regression model. (Top left) Simulated sample dataset, (Top right) Parameter estimates
of the SNP effect from each simulation run, (Bottom left) Histogram of SNP coeffi-
cient beta effects (log(AF)) across simulations & (Bottom right) Histogram of −log10
p–values for the SNP effect across simulations.
for only the SNP effect. The bottom left histogram shows the estimated SNP effect
values (log(change in time)) across simulations. Converting the mean value of −0.45
to a hazard ratio the result is, e0.45×2 = 2.459603, log(2.459603) = 0.9. From this
calculation, these estimates are also biased. To understand the bias generated by the
incorrect models in contrast to fitting the correct model, Figure 3.13 presents the input
parameter tab of the software adjusting for the SNP main effect along with treatment
and an interaction effect. The same simulation model as in the previous example is
used, including censoring during the study period and at the end of the study with a
recruitment period. Event times are simulated with SNP and treatment main effects and
a SNP-treatment interaction effect. From the analysis a Cox PH model is implemented
to test: (i) the null hypothesis H0 : φG = 0 against the alternative HA : φG , 0, for
which power is estimated to be 17% at a significance threshold of p < 5×10−8; and (ii)
the null hypothesis H0 : φγ = 0 against the alternative HA : φγ , 0, for which power is
estimated to be 0% at a significance threshold of p < 5 × 10−8. However, what is most
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Figure 3.13: SurvivalGWAS_Power Example 3 input parameters. The example depicts
a scenario with a sample size of 400, random right censoring and a recruitment period.
A SNP, treatment and interaction effects, are analysed within a Cox PH model.
informative is the joint association test comparing the fit of two models. 92% of all
tests indicate that the model fit with SNP, treatment and interaction terms is statistically
significant at genome-wide significance.
Figure 3.14: SurvivalGWAS_Power Example 3 power analysis output from Cox PH
model. (Top left) Simulated sample dataset, (Top right) Parameter estimates of the SNP,
treatment and interaction effects from each simulation run, (Bottom left) Histogram of
SNP coefficient beta effects (log(HR)) across simulations & (Bottom right) Histogram
of −log10 p–values for the SNP effect across simulations.
Figure 3.14 shows the additional output from the analysis. This output corresponds
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to the setup shown in Figure 3.13. The analysis output table in the top right shows
the SNP, treatment and interaction output. The left histogram shows the distribution
of estimated SNP effect values across simulations, which in this example are centred
around 0.8. Unlike the power calculation based on analysis adjusting for only the SNP
effect, the effect estimates are less biased.
Figure 3.15: SurvivalGWAS_Power Example 4 input parameters. The example depicts
a scenario with a sample size of 400, random right censoring and a recruitment period.
A SNP, treatment and interaction effects, are analysed within a Weibull regression
model.
A Weibull regression model has demonstrated to be the correct choice for analysis,
as the regression-adjusted estimates are essentially unbiased showing a more precise
estimation of the SNP effect size over the 1000 simulations (see Figure 3.16). The
standard errors of the Weibull regression model with and without the inclusion of
covariates are much smaller than the estimates from the Cox PH model. The addition
of the treatment and interaction as covariateswereminimally prognostic of our outcome,
including them in the regression models explained some noise in the data.
The Weibull regression model adjusting for SNP, treatment and SNP-treatment inter-
action effects in the model obtained a power of 24% for the SNP effect compared to the
17% power estimated by the Cox PH model. Overall, an increase in sample size from
400 to 850 for this study is needed to achieve at least 90% power to detect associations
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Figure 3.16: SurvivalGWAS_Power Example 4 power analysis output from Weibull
regression model. (Top left) Simulated sample dataset, (Top right) Parameter estimates
of the SNP, treatment and interaction effects from each simulation run, (Bottom left)
Histogram of SNP coefficient beta effects (log(AF)) across simulations & (Bottom
right) Histogram of −log10 p–values for the SNP effect across simulations.
for the SNP effect at genome-wide significance using both the Weibull regression and
Cox PH models adjusting for SNP, treatment and interaction effects.
As demonstrated by this example, SurvivalGWAS_Power can efficiently estimate the
power of the Cox PH model and Weibull regression model under a variety of pharma-
cogenetic settings. Explicitly, allowing for testing of SNP main effects (i.e. testing
the null hypothesis H0 : φG = 0 against the alternative HA : φG , 0), SNP-treatment
interaction effects (i.e. testing the null hypothesis H0 : φγ = 0 against the alternative
HA : φγ , 0) and LRT of the joint association model.
3.7 Discussion
In response to the lack of power calculation tools and the analytical bottleneck for
identifying genetic factors associated with TTE data, the user-friendly tool, Survival-
GWAS_Power was developed. This program is the first to implement both data genera-
tion and power calculations for GWAS of TTE outcomes. The software is of particular
relevance to pharmacogenetic studies, where the design will likely include alternative
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treatment interventions and SNP-treatment interaction effects. However, the software
is not exclusive to pharmacogenetic designs: for example, the treatment covariate can
be used to represent any binary covariate and the event could be age of disease onset.
This adds flexibility to the software for application to general GWAS of TTE outcomes.
SurvivalGWAS_Power can generate sample pharmacogenetic data with TTE outcomes
over a range of study designs and perform power calculations using different analytical
models. SurvivalGWAS_Power calculates the power to detect association of a SNP
with a TTE outcome at a pre-specified significance threshold. The data can be analysed
using a Cox PH model or Weibull regression model to account for non-proportional
hazards.
To allow for flexibility of analysis using methods that are not currently supported by the
power calculator, individual simulated data sets can also be output from the software.
These datasets allow for users to simulate data and use other programs such as R
for analysis. For example, Uno et al. (2014) have demonstrated that, where the PH
assumption is invalid, the use of the Cox PH model will produce a loss of power to
detect associations. They propose using robust alternative measures for the difference
between survival curves instead of parametric models. The flexibility of our software
enables generation of TTE data under models with non-PH that can be exported for
association testing with methods supported by other software packages.
The project homepage can be found at the University of Liverpool, Statistical Ge-
netics and Pharmacogenetics Research Group website (https://www.liverpool.ac.uk/
translational-medicine/research/statistical-genetics/software/). The software is limited
to Windows O/S users and is licensed under the GNU General Public License, version
3 (GPL-3.0). Therefore academics can edit the software to fit their requirements or use
the code as a reference to help build similar tools.
This chapter explored the area of power and sample size calculation, introducing
different analytical methods and original software. Once a study has been designed, the
next step after the collection of data is the analysis procedure. Chapter 2 had already
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expressed the need for analysis software for GWAS of TTE outcomes. The past, present
and future perspective of this topic is explored in the next chapter.
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CHAPTER 4
SINGLE VARIANT ANALYSIS OF GWAS WITH
TIME-TO-EVENT OUTCOMES
4.1 Overview
Genome-wide association studies (GWAS) have revolutionised our understanding of
the genetic basis of a wide variety of complex human traits and diseases. The focus
of most GWAS has been towards binary phenotypes or quantitative traits, for which
proficient software tools for analysis have been developed, such as SNPTEST (https:
//mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html), PLINK (Purcell et al.
2007) and BOLT-LMM (Loh et al. 2015) (linear mixed models). However, for time-to-
event (TTE) outcomes, very few computational analysis tools are available.
The main challenge, which explains why there currently is a lack of such powerful tools
for survival analysis of GWAS is that the software is required to be computationally
efficient while handling the scale and complexity of genetic data. The design of
algorithms to achieve this requires advanced knowledge of programming pipelines and
thorough examinations of current statistical genetics computational tools. Software
should also offer use of a range of analytical models. This observation arose from
the literature review in Section 2.2 whereby investigators would be inclined to using
the Cox PH model for their study without indicating whether model checking was
undertaken.
4.1.1 Objectives
This chapter seeks to evaluate methodology and software used for GWAS with TTE
outcomes. This review is key to understanding more about the current availability of
computational tools forGWASofTTEoutcomes. This chapter briefly describes popular
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software for binary and quantitative traits, which inevitably helps in the design of a
suitable computational analysis tool which draws on the strengths of other software.
The ultimate aim of this chapter is to develop and test through simulations a novel
computational analysis tool for GWAS with TTE outcomes.
4.2 A Review of Genome-Wide Time-to-Event Studies
In Section 2.2, a comprehensive literature review of pharmacogenetic studies was con-
ducted, covering both genome-wide and candidate gene studies. However, expanding
on the literature review, by analysing papers outside this context, we can gain a broader
understanding of the different types of TTE phenotypes analysed, study designs re-
flecting different censoring options, the underlying genetic models used and imputation
software. As a result, this information provides us with a better understanding of the
specifications for which our analysis software should be built. There are many recent
GWAS published with the focus on survival outcomes. Table 4.1 summarises key
findings from a selection of recent studies.
Taking into account both the information in Tables 2.1 and Table 4.1, it can be observed
that: (i) right censoring is the most common type of censoring; (ii) the additive genetic
model on the log hazard ratio is assumed more often than the recessive and dominant
models; and (iii) the Cox PH model is applied in all studies. The biggest discrepancy
between each study is the choice of imputation software. This disparity is very important
as different imputation programs produce different output file formats, and therefore
association analysis software is required to handle a wide range of genotype file formats.
Computational tools need to read in and transform genotype probability data using
genetic dosage models accounting for genotype uncertainty.
Examining the latest version of each software, IMPUTE2 (Howie et al. 2012) outputs
genotype files in GEN (.gen) format, Beagle 4.1 (Browning & Browning 2016) and
minimac3 (Das et al. 2016) both output variant call format (VCF) files. Each program
uses its own input data format and algorithms to perform the imputation of
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Study Sample
Size
Variants Censoring Phenotype Method Imputation
Software
Analysis
Software
Walter et al.
(2011)
16,995 2.5 million SNPs Right
(i) All-cause mortality.
(ii) Survival free of
major disease or death.
CPHM. Additive
genetic model.
Unknown Unknown
Johnson et al.
(2016)
3256
≈4 million SNPs
in each of 4
cohorts after QC.
Left, Right Overall survival.
Multivariate
CPHM.
IMPUTE2 R 3.1.3
Phipps et al.
(2016)
3494 ≈2.7 million SNPs Right Overall survival.
CRC specific survival.
CPHM. Log
additive genetic
model.
MaCH R 2.15.3
Kapoor et al.
(2014)
1788 4,058,415 SNPs Right Age at onset
CPHM. Log
additive genetic
model.
Beagle 3.3.1
R - ‘Survival’
package
Wu et al.
(2014)
1005 5,038,636 SNPs Right Overall survival
CPHM. Additive
genetic model.
MaCH SAS
He et al.
(2016)
1962 5,918,992 SNPs Right
Time to;
(i) smoking initiation,
(ii) persistent smoking,
(iii) tolerance,
(iv) cessation.
CPHM IMPUTE2
R - ‘coxme’
package.
Table 4.1: Summary of GWAS with TTE outcomes. Abbreviations: CPHM, Cox proportional hazards model; CRC, colorectal cancer; QC,
quality control; SNPs, single nucleotide polymorphisms.
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non-genotyped single nucleotide polymorphisms (SNPs). It is possible to convert be-
tween file types using custom-built software such as PLINK 1.9 (Chang et al. 2015),
GTOOL (http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html), BCFtools (Li
2011) or DosageConvertor (https://genome.sph.umich.edu/wiki/DosageConvertor).
Analysis software should offer compatibility with many of the different file types
produced from imputation. GEN andVCF files are themost frequently used for analysis
before and after imputation. All of the file types that contain genotype information
can be compressed to save space, most commonly gzipped (.gz) or bgzipped (.bgz).
Computational tools that are able to read the compressed files directly save the user
time and computer storage space.
One final observation is that, in all the studies, adjustment was made for multiple
covariates to account for potential confounding variables. Pairing this with the analysis
ofmillions of SNPs and thousands of individuals, the computational burden is increased.
Analytical software needs to be able to perform millions of individual tests, whilst
maintaining computational efficiency.
4.3 Extensions of Time-to-Event Models for GWAS
Statistical methodology for GWAS of TTE outcomes is a rapidly developing area of
research, and there is not as yet a consensus as to themost effectivemethods. Traditional
methodologies within genetic research, indicated earlier in Chapter 2, has been limited
to use of the Cox PH model and log-rank test. Alone these models are unable to deal
with the complexities associated with the modelling of relationships between genetic
biomarkers and TTE outcomes. Outside these traditional analyses, the methodology
has been developed to cater for a wider range of TTE outcomes.
Subirana&González (2013) highlighted the importance of accounting for genotype im-
putation uncertainty within survival models. They compare three approaches through
a simulation study; a naive (directly typed best guess), dosage and latent class (max-
imisation of SNP probabilities in likelihood) approach. The first two are implemented
80
in a Cox PH model and the third within a Weibull regression model. Performance of
both the dosage model and latent class approach are very similar when comparing bias,
mean squared error, power to detect associations and coverage.
Lin et al. (2011) had evaluated the single SNP approach against a kernel machine
SNP-set Cox PH analysis, concluding that the latter is a more robust choice, in that it
suffers a little loss in power when the effect of the SNP is linear but is useful when
the effects of the SNPs are more complex or when epistasis1 is present. This method
is most helpful when multiple SNPs are causal within a region, indicating a greater
application to the multi-SNP analysis of common variants.
Vandin et al. (2015) discussed using standard methods, with the implementation of
the log-rank test for GWAS. There are obvious problems with the use of the log-
rank test such as its failure to handle unbalanced populations2 resulting in many false
positive/negative associations and its inability to adjust for covariates. The paper
continues by providing an alternative algorithm called "ExaLT" which computes a p-
value under an exact permutational distribution. This algorithm, however, is unlikely to
be sufficiently computationally efficient for GWAS. It is also unclear how the proposed
algorithm accounts for continuous confounders.
ExaLT was proven to be beneficial over the standard log-rank test for genomic data,
and therefore should be considered as an option to testing the association between
two groups. Even with this method, the Cox PH model is still considered the optimal
choice for analysis when considering adjustment of covariates and computational ef-
ficiency. The methods described by Subirana & González (2013), Lin et al. (2011),
Vandin et al. (2015) have been considered alongside frequently used survival models
for implementation into software.
1Epistasis is the interaction between multiple genes.
2In a genomics study, the two groups are defined by a SNP, such as comparing carriers and non-carriers
of an allele. The sizes of the groups in many of these studies are unbalanced; one group is usually much
larger than the other.
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4.4 Time-to-Event Analysis Tools in Genetic Research
Many of the recent GWAS published (displayed in Table 4.1) with a focus on survival
outcomes conducted analyses using standard statistical software, such as R or SAS.
These programs are limited as they need a lot of available random access memory
(RAM) and time to load large data files. A standard four core laptop would take weeks
to run an analysis of one million SNPs and over a thousand samples, with the possibility
of the computer running out of memory. To help avoid this issue high-performance
computing (HPC) clusters are used to improve efficiency and provide an increased data
storage capacity, however, R and SAS are not easily amenable to these solutions or
capable of handling large-scale GWAS data.
Programs such as ProbABEL (Aulchenko et al. 2010) were explicitly created to tackle
this problem, though users have flagged many difficulties. ProbABEL is described as a
software package for the analysis of genome-wide imputed SNP data and quantitative,
binary, and TTE outcomes. Nevertheless, it is limited to the use of only the Cox PH
model for TTE data. The output parameter of particular importance in all types of
studies is the p-value, which ProbABEL does not output. The software does output
the coefficient estimates, standard errors and log-likelihood. This implies the user is
required to calculate the p-values themselves, using a Wald or likelihood ratio test
(LRT). However, ProbABEL is currently maintained, and therefore improvements in
future releases may correct many of these problems.
Genipe, created by Lemieux Perreault et al. (2016), is a new pipeline for imputationwith
automatic reporting of output from various statistical analyses. Genipe implements
existing approaches to imputation and then utilises the python package ‘lifelines’ to
generate association summary statistics via the Cox PH model. This tool is useful but
is restricted because it relies on existing software such as PLINK and IMPUTE2, and
is limited to the Cox PH model.
As previously mentioned in Section 1.4, the success of a computational analysis tool
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relies on the choice of programming language and environment. State of the art
software (post-2013) such as SNPTEST, PLINK 1.9, BOLT-LMM (Loh et al. 2015),
EPACTS (https://genome.sph.umich.edu/wiki/EPACTS) are all developed using C++.
Many other GWAS software such as PyLMM (http://genetics.cs.ucla.edu/pylmm/) are
written using Python. Python is considered to be slower than the C based languages, but
ultimately speed is relative to the design of the algorithms and cleanliness of written
code. These languages are chosen due to the convenience of running on the Linux
operating system (O/S) and HPC clusters. In Chapter 3, SurvivalGWAS_Power was
created using C# due to the flexibility it provided for using .NET libraries. C# is
considered faster than Python but slower than C++ when compiling code on Linux
machines. C# is hindered further due to the use of Mono, a third party compiler.
This decrease in performance may change with the introduction of Visual Studio Code
and .NETCore (https://code.visualstudio.com/docs/other/dotnet), which provides users
with a "blazing fast and modular platform for creating server applications that run on
Windows, Linux and Mac".
Due to the inadequacy of current GWAS analysis tools for TTE outcomes, the software
tool SurvivalGWAS_SV has been developed, which has addressed the difficulties that
are faced by other programs and currently employs a single SNP analysis approach
using two commonly used survival analysis models.
4.5 SurvivalGWAS_SV
4.5.1 Implementation
SurvivalGWAS_SV is a freely available program created for the analysis of GWAS of
imputed genotypes with TTE outcomes. It is the second program to be released under
the SurvivalGWAS suite of software, which also includes the complementary power
calculator "SurvivalGWAS_Power" described in detail in Chapter 3. SurvivalGWAS_-
SV is a C# developed program; the executable file (.exe) with all dependencies can be
quickly distributed for any O/S. When used on Linux machines it is necessary to run
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the executable using the compiler Mono (http://www.mono-project.com/download/) or
the untested .NET core.
Key features include: (i) compatibility with the file formats produced by programs such
as IMPUTE2, thereby directly accommodating imputed data without the need for file
conversion; (ii) a range of survival analysis models are available with the foundation in
place for implementing additional methods as required; (iii) options for testing SNP-
covariate interactions, presenting p-values for the entire model and individual covariate
tests of association; and (iv) compatibility with HPC clusters.
SurvivalGWAS_SV has undergone many changes over the last two years. The first
version deployed had a sequential process pipeline, where each SNP was processed one
at a time, analysed and with output generated. Figure 4.1 depicts the multithreaded
analysis process implemented in the most recent version of SurvivalGWAS_SV. Im-
provements to the software over the years have been to cater for the continual change
in data file types, reflecting the addition of VCF files. Updating the software to reflect
the changes within the field should increase the number of users of the software.
The multithreading pattern uses parallel tasks and a concurrent queuing system (reader-
writer lock3) in places to process a sequence of input values. The threads are completely
independent, to avoid shared resources between threads, which can result in overwriting
parameters. Each thread executes a validation and analysis protocol for a given batch,
and the queue for writing to the output file acts as a ‘buffer’ that allows only one
thread to write at a time otherwise threads will be writing on the same line. Whichever
thread finishes first will write to the output file and then move on to the next line of
the input file. A practical example for visualising this multi-threading pipeline would
be to consider multiple assembly lines in a factory. Each item in the assembly line is
taking resources from the same location. Each line produces a fully assembled product.
However, there is only one truck that distributes the products. The product placement
order in the truck depends on whichever assembly line finishes first.
3A reader-writer lock within a program allows a single thread access to a file that multiple threads have
access to. This system is in place to avoid overwriting of file contents.
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Figure 4.1: Flowchart of SurvivalGWAS_SV analysis process.
4.5.2 User Interface
SurvivalGWAS_SV is a console application utilising command line inputs. The soft-
ware is run from a command prompt terminal, compatible with Linux, Windows and
Mac OSX. The program requires little interaction from the user since a script of com-
mands can be submitted to the program, which is useful for the analysis of large data
files. The user can specify "batches" of the data file to analyse in parallel using multiple
compute nodes, where each core can run a different part of the analysis. The program re-
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quiresMono to run the software on Linux andMacOSX. Figure 4.2 shows the execution
of the software through MobaXterm; a windows desktop terminal for the remote server
and SSH client access. The screen-shot shows the printed description of the software
in the terminal after executing the software command; mono survivalgwas-sv.exe.
Figure 4.2: Using SurvivalGWAS_SV throughMobaXterm. Change directory towhere
the SurvivalGWAS_SV executable and libraries are saved. Run executable usingMono.
4.5.3 Inputs
SurvivalGWAS_SV is designed in a very simplistic way. First, the user is required to
specify the two data files that will be read into the program. The first file must be a
genotype file (.gen or .impute) or a VCF text file that contains SNP genotype probabili-
ties (imputed or non-imputed), and the second file should be a sample file (.sample) that
contains all the covariate, survival time and censoring indicator information for each
individual. The software supports VCF files containing the SNP genotype probabilities,
dosages and/or hard genotype calls. In some circumstances, the user would have the
genotype files compressed, either in a .zip or .gz file format, both of which can be read
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into the software directly. Second, the user specifies details about terms to include in
their analysis model, such as covariates and/or interactions, whilst also specifying the
censoring indicator and observed survival time. Third, the user must specify the range
of SNPs to be analysed, to enable efficient parallel computing in batches. Last, the user
must enter the chosen analytical method to use and the name of the file to which the
analysis output will be saved. If the user is analysing covariates within the model, but
does not require summary statistics for the covariates to be included in the output file,
an option is available for only printing the results for the SNP or interaction effects.
This option is helpful when creating graphical summaries, such as Manhattan plots,
using other programs.
GEN file
SNP ID
This entry is usually used to denote the chromosome
number or ‘SNP<number>’.
rs number
This entry is an ID number which uniquely identifies the
genotyped SNP. A rs number is an accession number
used by researchers and databases to refer to specific
SNPs. It stands for ‘Reference SNP cluster ID’.
Base pair position
of the SNP
A value that describes the SNPs position on
the chromosome.
Major allele
The entry will be A, C, T or G, i.e.
corresponding to the four possible nucleotides.
Minor allele The entry will be A, C, T or G.
Table 4.2: GEN file contents. Abbreviations: SNP, single nucleotide polymorphism.
Table 4.2 details the contents of the genotype file. The first column in the file is
the SNP number, the second is the unique SNP identifier number and the third is
the base-pair position of the SNP. Columns four and five are the two alleles. These
alleles represent the major and minor alleles, however, often they are referred to as
the reference (REF) and alternative (ALT) alleles in the GEN and VCF files. The
remaining columns on each row represent the genotype of each individual at the SNP.
Each individual will have three entries, representing their probability of having the
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major homozygous, heterozygous and minor homozygous genotypes respectively. If
there are imputed SNPs in the dataset then the probability for each genotype will be
between 0 and 1, whereas if the data is not imputed then two of the possible genotypes
will be 0 and the other will be a 1, strictly defining this genotype for an individual
as 100% certain. SurvivalGWAS_SV assumes an additive genetic model (mode of
inheritance) and therefore converts these probabilities into dosages for the purpose of
fitting models to test for association. For example, in Script 4.1, each row provides
information on two individuals. At SNP1 the two alleles are A and G therefore the set
of 3 probabilities correspond to the genotypes AA, AG and GG respectively. The first
individual has a probability of 0.9 for the genotype at SNP1 to be AA, 0.1 for AG and 0
for GG. This genotype uncertainty needs to accounted for in the analysis models. The
second individual has a definitive probability of 1 for genotype AA.
1 SNP1 r s 1 1000 A G 0 .9 0 . 1 0 1 0 0
2 SNP2 r s 2 2000 G T 0 0 .65 0 .35 0 0 .99 0 .01
3 SNP3 r s 3 3000 C T 1 0 0 0 1 0
4 SNP4 r s 4 4000 A C 0 .04 0 . 8 0 . 16 1 0 0
5 SNP5 r s 5 5000 A G 0 1 0 0 0 1
Script 4.1: Imputed GEN file contents for five SNPs and two individuals.
1 ## f i l e f o r m a t =VCFv4 . 1
2 ## f i l e d a t e =2016 .12 .14
3 ## sou r c e =Minimac3 , PLINK , VCFtools
4 ## c o n t i g =$<$ID=1$>$
5 ## FORMAT=$<$ID=GT, Number=1 , Type= S t r i n g , D e s c r i p t i o n ="Genotype "$>$
6 ## FORMAT=$<$ID=DS , Number=1 , Type=F lo a t , D e s c r i p t i o n =" E s t ima t e d
A l t e r n a t e A l l e l e Dosage : [ P ( 0 / 1 ) +2∗P ( 1 / 1 ) ] " $>$
7 ## FORMAT=$<$ID=GP , Number=3 , Type=F lo a t , D e s c r i p t i o n =" E s t ima t e d
P o s t e r i o r P r o b a b i l i t i e s f o r Genotypes 0 / 0 , 0 / 1 and 1 / 1 " $>$
8 ## INFO=$<$ID=AF , Number=1 , Type=F lo a t , D e s c r i p t i o n =" E s t ima t e d
A l t e r n a t e A l l e l e Frequency "$>$
9 ## INFO=$<$ID=MAF, Number=1 , Type=F lo a t , D e s c r i p t i o n =" E s t ima t e d Minor
A l l e l e Frequency "$>$
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10 ## INFO=$<$ID=R2 , Number=1 , Type=F lo a t , D e s c r i p t i o n =" E s t ima t e d
Impu t a t i o n Accuracy "$>$
11 # CHROM POS ID REF ALT QUAL FILTER INFO FORMAT
12 1 1000 r s 1 A G . . AF=0 . 1 5 ;MAF=0 . 1 5 ;R2=0.00682 GT:DS :GP
0 / 0 : 0 . 1 0 0 : 0 . 9 0 0 , 0 . 1 0 0 , 0 . 0 0 0 0 / 0 : 0 . 0 0 0 : 1 . 0 0 0 , 0 . 0 0 0 , 0 . 0 0 0
Script 4.2: VCF file contents example for one variant and two individuals.
Sample file
ID_1 This column is a patient identifier for each individual.
ID_2
This column provides an option to give a second patient
identifier for each individual. You may wish to do this to
identify study site, for a multi-site study.
missing
This column details the proportion of missing genotype data
for the individual.
age
This column includes a covariate representing the individual’s
age. This covariate is quantitative.
gender
This column includes a covariate representing the individual’s
gender. The covariate is binary, coded 0 (female) and 1 (male).
bmi
This column includes a covariate representing the individual’s
Body mass index (BMI). This covariate is quantitative.
treatment
This column includes a covariate representing which treatment
the individual has been prescribed. The covariate is binary,
coded 1 (treatment A) and 0 (treatment B).
time_to_event
This column contains the observed survival time for each
patient after right censoring.
status
This column includes the outcome for the individual.
In this case, our outcome is ‘event’ represented by 1 if the event
of has occurred or 0 if the event has not occurred/censored.
Table 4.3: Example contents of a sample file. Not all sample files contain these exact
columns.
With the use of next generation sequencing (NGS) technology, the new standard for
storage of genotypes is with VCF files. The same example as above for SNP1 is
represented in Script 4.2. The first few lines from the top of the sample VCF file
starting with a ##, are meta-information lines, as shown in Script 4.2. These lines are
subsequently followed by the header line then the genotype information for each sample.
The meta-information provides details on the the VCF version number, the source
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program which created the file amongst other information unique to each file. The
FORMAT and INFO rows describe the variables used within the genotype information.
This information includes MAF or if genotype probabilities are included in the file.
The header groups all this information and the genotype information of a variant for
each sample in a single row. A detailed explanation on the latest VCF file versions and
their contents is provided on the Samtools github page (https://github.com/samtools/
hts-specs).
A sample file includes one row per individual and can include as many covariates
as required, each represented by a different column. Covariates can be binary or
quantitative. Some individuals have missing covariate values which should be coded as
"NA", for SurvivalGWAS_SV to distinguish which values are missing and which are
not. These individuals will be excluded from analyses which adjust for that covariate.
Table 4.3 provides a description of the possible columns within a sample file. The
mandatory columns are the "time_to_event" and "status" columns.
4.5.4 Algorithms and Validation
Before the data can be analysed, a number of conversions and quality control measures
must be performed by the software. When the genotype file is read in, one SNP at a
time, either directly typed or imputed, SurvivalGWAS_SV will convert the genotype
probabilities for each individual into a "dosage" under an additive model for the alter-
native allele. This model enables appropriate analysis for imputed SNP data by taking
account of the uncertainty in the imputation process. The dosage model is given by
Eq. 1.2. The implied ordering in the file for genotype probabilities is the reference
homozygote, heterozygote, alternate homozygote. Note that the values are forced to
sum to 1.00 exactly, and only bi-allelic variants are considered.
SurvivalGWAS_SV throws exemptions whenever the user has specified an incorrect
command or states a variable name that cannot be found in the data files. In such
an event, the program will exit the application and will require re-submission of the
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task. The program also handles missing values within the sample file. If an individual
has missing values (in the form of "NA") for survival time, censoring indicator or a
covariate used in the model, then the individual is removed from the analysis with their
corresponding SNP information.
VCF and GEN files are handled differently within SurvivalGWAS_SV because VCF
files contain more information than GEN files. The files differ in a number of important
ways: (i) genotype information within VCF files are given in hard genotype calls,
dosages and/or probabilities; (ii) VCF files contain an estimation of MAF for each
variant; and (iii) sample identification numbers are provided in a VCF file. A lot of this
information needs to be filtered out or skipped over to access the data that is required.
4.5.5 Statistical Methodology
Analysis can be carried out using one of two methods: (i) a Cox PH model; or (ii)
a parametric Weibull regression model. Both methods have their advantages under
different scenarios. More details are discussed in Section 1.3. As discussed in Section
4.3, the contribution of Subirana & González (2013) provided a clear foundation for us
to build upon, influencing the decision to implement the Cox PH andWeibull regression
models, with an additive dosage model, into SurvivalGWAS_SV. Most importantly, the
SNP-covariate interaction effects are modelled using the joint association test outlined
in Eq. 3.1, replacing the treatment covariate with a vector of covariates, xˆi and the SNP-
treatment effect with a SNP-covariate interaction for the users’ covariates of choice.
4.5.6 Usage Commands
1 $ mono su r v i v a l gwa s −sv . exe −gf= − s f = − t h r e a d s = − t = −c= −cov= − i = −
ch r = − l s t a r t = − l s t o p = −method= −p= −o=
Script 4.3: SurvivalGWAS_SV command line example without defined parameters.
In the example shown in Script 4.3, each command is separated by a space and begins
with ‘-’ and ends with ‘=’ before specifying the selected option. Table 4.4 outlines
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the syntax for each command in SurvivalGWAS_SV with their corresponding usage
description. The "-threads=" command is a recent introduction using the ‘semaphore’
class in C#. This command substantially improves the speed of analysis. For example,
a user has availability of a single computing node with 8 cores on a given cluster. The
cluster is interactive, and therefore requires execution of the program on the command
line. If the user wishes to analyse 10,000 SNPs, and they specify "-threads=5", the
software will automatically assign computing resources analysing the 10,000 SNPs in
5 equal batches, across one or more computing cores. However if the user were to
create more threads than is required, this can slow down the analysis, because threads
will start to queue to use resources which are bound by reader-writer locks.
Command Description
-gf= This specifies the genotype file. Typically a .gen, .vcf, .gen.gz.
-sf= This specifies the sample file (.sample).
-threads= Specifies the number of threads. On a multi-core system, multiple,
threads can execute tasks in parallel, with each core executing a
different thread or multiple threads.
-t= This specifies the time to event (column heading name) in the
sample file.
-c= This specifies the censoring indicator/outcome in the sample file.
-cov= This specifies the covariates to adjust for in the model. Each one
separated by a comma (,). e.g. -cov=cov1,cov2,cov3. Note:
Categorical variables need to be converted to binary as software only
assumes continuous or binary covariates.
-i= This specifies the interaction between the SNP and a covariate.
Separate using a comma (,). e.g. –i=SNP,Treatment
-lstart= This specifies the line in the genotype file at which the start position
of analysis will occur. Used to break large files into small batches for
parallel computing.
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Table 4.4 continued from previous page
-lstop= This specifies the line in the genotype file at which the end position
of analysis will occur. Typically the number of lines is equal to the
number of SNPs in the file.
-sp= The start position (in base pairs) on the chromosome. Still need to
specify the number of lines in the file using -lstart & -lstop
commands. This is an optional command.
-ep= The stop position (in base pairs) on the chromosome. This is an
optional command.
-chr= This specifies the chromosome number to be output in the text file.
-p= Enter "onlysnp" if only the results from the SNP analysis are to be
output and "onlyint" if only the results from the SNP-covariate
interaction analysis are to be output. Otherwise, the output will have
separate rows for the SNP and all adjusted covariates.
-m= This specifies the method for analysis. The choice is either "cox" for
the Cox PH model or "weibull" for the parametric Weibull
regression model.
-o= This specifies the name of the file for output to be saved in. e.g.
name.txt
-help Outputs a full list of commands and usage help.
Table 4.4: List of commands available in SurvivalGWAS_SV and their corresponding
usage description.
Assuming all data files and software are in the same folder, the command line in a
Linux terminal for the analysis of 10000 SNPs and two additional covariates using a
Cox PH model is shown in Script 4.4.
1 $ mono su r v i v a l gwa s −sv . exe −gf= d a t a . gen − s f = d a t a . sample − t = ev en t \
_ t ime s −c= c e n s o r i n g −cov= c o v a r i a t e 1 , c o v a r i a t e 2 −ch r =1 − l s t a r t =0 −
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l s t o p =10000 −m=cox −p=on ly snp −o= ou t p u t . t x t
Script 4.4: SurvivalGWAS_SV command line example with dummy input parameters.
The user can specify the exact location of the data files and where the output file will
be saved. e.g. /DIRECTORY/DATA/output.txt. Script 4.5 shows an example of a
shell script (.sh) based on the same parameters displayed in Script 4.4. The purpose of
this shell script is to distribute the analyses between 10 computer cores within a Linux
cluster (Sun-Grid Engine Batch System). These files are usually labelled "example.sh".
1 # ! / b i n / bash
2 #$ −o s t d o u t
3 #$ −e s t d e r r
4
5 DIRECTORY=/ SurvivalGWAS \ _SV # Loca t i o n o f s o f tw a r e and d a t a
6 s t r 1 =0 # S t a r t p o s i t i o n i n geno type f i l e
7 s t r =10000 #Number o f SNPs / l i n e s i n geno type f i l e
8 no_o f_ j ob s =10 #Number o f c o r e s
9 i n c = ‘ exp r \ ( $ s t r − $ s t r 1 \ ) \ / $no_of_ jobs ‘ # I n c r emen t
10
11 #SGE_TASK_ID t a k e s v a l u e s 1 : no_o f_ j ob s
12 n s t a r t = ‘ exp r \ ( $SGE_TASK_ID − 1 \ ) \∗ \ $ inc ’
13 n s t op = ‘ exp r $ n s t a r t + $ i n c − 1 ’
14 mono $DIRECTORY/ su r v i v a l gwa s −sv . exe −gf=$DIRECTORY/ d a t a . gen − s f =
$DIRECTORY/ d a t a . sample
15 − t = e v e n t _ t ime s −c= c e n s o r i n g −cov= c o v a r i a t e 1 , c o v a r i a t e 2 −ch r =1 −
l s t a r t = $ n s t a r t − l s t o p = $ns t op −m=cox −p=on ly snp
16 −o=$DIRECTORY/ ou t p u t $ {SGE_TASK_ID } . t x t
Script 4.5: Shell script for running SurvivalGWAS_SV on a HPC cluster. Comments
are highlighted in green.
1 $ qsub − t 1 :10 example . sh
Script 4.6: Multitple core submission example using the UNIX ’qsub’ command.
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To submit the shell script the command line shown in Script 4.6 should be used. This
command submits the analysis and divides the workload over ten cores. This distri-
bution of data and analyses will produce ten output files which can be concatenated
using the "cat" command in Linux (example provided in Script 4.7). Joining the files
will also add multiple header lines to the file. Therefore it is important to delete the
duplicate header lines before or after concatenation so that errors do not occur when
producing a Manhattan plot in R.
1 $ c a t f i l e 1 f i l e 2 f i l e 3 > j o i n t f i l e . t x t
Script 4.7: Concatenation of multiple files using the UNIX ‘cat’ command.
4.5.7 Output
The format in which the output is displayed is a fundamental feature for the production
of post-GWAS summary statistics and plots using other programs. The output from
the analysis is saved in a text file, the name of which is specified by the user. Each
parameter analysed is recorded in a list under a header row that specifies the values in
each column. Script 4.8, shows the contents of an example output file for five SNPs.
The analysis output displayed is from using the Cox PH model. Table 4.5, contains
a detailed description of all the output file content. The output is different depending
on the statistical model used for analysis. The SNP identifier number, chromosome
number, the base pair position of each SNP, and the p-value are the only four columns
needed to produce a Manhattan plot.
1 InputName r s i d Chr Pos EA NonEA CoefValue HR SE LowerCI UpperCI
Waldpv LRTpv ModLRTpv EAF MAF I n f o s c o r e
2 SNP1 r s1234 10 13380 C G −10.01334 4 .49E−05 42 .63179 0 8 .6952052E+31
0.814341993 0.80691279370237 2.73440577082171E−29 0 .99997639
2 .361E−05 −1
3 SNP2 r s1984 10 16154 C T −276.22756 0 184 .139489 0 5 .919171E+36
0.133594002 0.114161788733577 8.16041572989629E−30 0 .99997555
2 .445E−05 0 .00111351
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4 SNP3 r s4233 10 17544 T C −20.69194 0 32 .044426 0 1 .8063706E+18
0.516986901 0.505106899627898 2.25935260263007E−29 0 .99960455
0 .00039545 0 .00291701
5 SNP4 r s5264 10 17599 T C −0.2082 0 .814684 0 .48563323 0 .3140749
2 .11031612 0.672998575666 0 .674152996 2.58006621541E−29
0 .63879319 0 .36120681 0 .01458189
6 SNP5 r s1229 10 18235 C A −31.0332 0 42 .72901 0 7 .789281203E+22
0.46764205427 0.456629741423332 2.1393434820166E−29 0 .99928541
0 .00071459 0 .00131644
Script 4.8: SurvivalGWAS_SV text file output. Example output for five SNPs analysed
using a Cox PH model.
Output header Description
InputName Variable name (can be the SNP ID, covariate or interaction
name).
rsid The unique SNP identifier for each SNP analysed.
Chr User-specified chromosome number.
Pos Base pair position of the SNP.
EA Reference allele.
NonEA Alternative allele.
CoefValue Effect size estimate. Log-relative hazard (Cox model) or
log-relative change in time (Weibull).
HR Hazard ratio.
AF Acceleration factor (Weibull only).
SE Standard error of coefficient value.
LowerCI Lower 95% confidence interval for HR (Cox model only).
UpperCI Upper 95% confidence interval for HR (Cox model only).
Waldpv Wald test p-value.
LRTpv Likelihood ratio test p-value (Cox model only).
ModLRTpv Model likelihood ratio test.
zscorestat Score test statistic for p-value calculation (Weibull only).
p-value p-value from z-statistic (Weibull only).
96
Table 4.5 continued from previous page
EAF Effect/major allele frequency.
MAF Minor allele frequency.
Infoscore IMPUTE info measure of imputation quality. The info score
metric takes the value 1 if all genotypes are completely certain
and a value of 0 if the genotype probabilities for each sample are
completely uncertain.
Shape The shape parameter estimation of the survival distribution
(Weibull only).
Table 4.5: SurvivalGWAS_SV output file variable headers and corresponding descrip-
tion.
4.5.8 Installation Guide
The software can be downloaded from the University of Liverpool, Statistical Genetics
and Pharmacogenetics Research Group software page: https://www.liverpool.ac.uk/
translational-medicine/research/statistical-genetics/survival-gwas-sv/. As well as the
download, there is a full description of the software, a sample shell script and a fre-
quently asked questions (FAQ) section. To download SurvivalGWAS_SV, navigate to
the webpage URL and follow the instructions provided on the webpage. The down-
loaded folder contains the executable file and all the .NET framework .dll files needed
to run and distribute the software. This software is also bound by the GNU General
Public License, version 3 (GPL-3.0) with no restrictions to use, edit and distribute the
software. The reasoning behind creating software like this is for the sole purpose of
working collectively to advance scientific research in the areas of genetics, mathematics
and bioinformatics.
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4.6 Simulation Study
To demonstrate the utility of SurvivalGWAS_SV, we simulated genotype data using
the software HAPGEN2 (Su et al. 2011), based on European ancestry individuals from
the HapMap3 (Altshuler et al. 2010) reference panel. Approximately 1.5 million SNPs
were simulated across 22 chromosomes for 1000 individuals. One SNP (rs12425539)
on chromosome 12 was selected as the causal variant, to be used to generate TTE data.
This SNP was selected because it represents common variation with a MAF of 0.317.
We generated the TTE data using the power calculator software "SurvivalGWAS_-
Power" (software described in detail in Chapter 3), which simulated the survival time
and censoring indicator for each individual, for this single replicate of genotype data at
the causal SNP.
A treatment covariate (binary) was also simulated for each individual using a binomial
distribution. The active treatment and the placebo were divided evenly (1:1) between
the 1000 individuals. All four datasets were simulated with right censoring occurring
randomly within the sample using an exponential distribution:
1. Events under a PH assumption, with an additive effect of 0.6 in the log-hazard
ratio for each copy of the minor allele. 579 censored observations.
2. Events under a PH assumption, with an additive effect of 0.6 in the log-hazard
ratio for each copy of the minor allele, treatment effect of 0.4 and interaction
effect of 0.5. 670 censored observations.
3. Events under an accelerated failure time (AFT) model, with an additive effect
of 0.8 in the log-hazard ratio for each copy of the minor allele. 758 censored
observations.
4. Events under an AFT model, with an additive effect of 0.8 in the log-hazard ratio
for each copy of the minor allele, treatment effect of 0.4 and interaction effect of
0.5. 534 censored observations.
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The PH data were simulated within SurvivalGWAS_Power, using the description in
Section 3.4.3. Gi becomes the genotype of individual i at SNP rs12425539. xi is the
treatment covariate.
Ti = e2+φsGi+φxxi+φγGixi+Q (Eq. 4.1)
The AFT data were simulated using the model described in Eq. 4.1, where the error
distribution is represented as  = Weibull(shape = 2, scale = 20) and Q = 1/2. For
many distributions like the Weibull, an additional parameterQ is used to scale the error
distribution. The parameters φs and φx are the effect on log-hazard of the effect allele at
the SNP, and the treatment effect, respectively, and φγ is the interaction effect between
the SNP and treatment.
The primary aim of the simulation study was to test whether our causal SNP on chromo-
some 12 can be identified as associated with our outcome using SurvivalGWAS_SV.
Along with testing for associations with just a SNP effect, we investigated whether
there is a SNP-treatment interaction effect present adjusting for treatment and SNP
main effects. The statistical methodology choice was determined by the data, i.e.
datasets (1) and (2) were analysed using the Cox PH model, whereas datasets (3)
and (4) were analysed using the Weibull regression model. Only the SNP term was
included in the analysis models for analysing datasets (1) and (3), while for datasets
(2) and (4), SNP, treatment and interaction terms were included in the analysis mod-
els. After analysis, the number of SNPs was reduced by removing SNPs with a MAF
< 0.01. This MAF threshold was used to eliminate rare variants for which there is
minimal power to detect association and is considered a standard procedure in GWAS
quality control. The secondary aim was to observe the efficiency of the software,
measuring the length of time it took for completion of the analysis from submission
of commands to output using several cores. Figures 4.3 and 4.4 present the results
from the Cox PH model depicted by Manhattan4, and quantile-quantile (QQ) plots
for dataset (1). The Cox PH analysis was able to detect the causal SNP association,
4AManhattan plot named after its resemblance to the Manhattan skyline, is a graphical representation of
−log10 p-values corresponding to chromosome position. It helps visualise and identify associated SNPs
in the presence of millions of individual test results.
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Figure 4.3: Manhattan plot of Cox PH analysis SNP p-values. Red line represents
genome-wide significance threshold 5 × 10−8. The blue line represents suggestive
significance line. Each point represents a SNP. The two shades of blue used for SNPs
is to distinguish between the chromosome boundaries.
Figure 4.4: QQ-plot: Cox PH analysis of each SNP. Observed −log10 p–values are plot
against the expected −log10 p–values.
identifying SNPs to be genome-wide significant in the data simulated using the PH
model. The causal SNP (rs12425539) was the lead associated SNP from the analysis(
βS = −0.579,HR = 0.560, SE(HR) = 0.070, PWald = 1.38 × 10−16
)
. The true value
of the simulated effect was φs = −0.6.
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Figure 4.5: Manhattan plot of Cox PH analysis SNP-treatment interaction p-values.
Red line represents genome-wide significance threshold 5 × 10−8. The blue line repre-
sents suggestive significance line. Each point represents a SNP-treatment interaction.
The two colours (purple and grey) are used to distinguish between the chromosome
boundaries.
Figure 4.6: QQ-plot: Cox PH interaction analysis for each SNP-treatment interaction.
Observed −log10 p–values are plot against the expected −log10 p–values.
Figures 4.5 and 4.6 depict the interaction analysis (2 degrees of freedom joint association
LRT) for dataset (2), simulated using the PH model. The joint association effect
comparing the alternative and null models was found to be genome-wide significant at
SNP rs12425539 and a number of other SNPs at the same locus. Figures 4.7 and 4.8
represent the results from analysing the datasets simulated using the accelerated failure
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time assumption. Figure 4.7 shows us that theWeibull regression analysis identified the
association between the causal SNP and TTE outcome. This result was also observed
for Figures 4.9 and 4.10, which illustrate the output from the joint association interaction
analysis, indicating that the Weibull regression model was able to detect the interaction
effect in dataset (4) at the causal SNP.
This simulation study has demonstrated the use of SurvivalGWAS_SV on a variety of
different TTE datasets. SurvivalGWAS_SV has shown the ability to analyse large-scale
genetic data, allowing for treatment covariate and SNP-treatment interaction effects.
Under all settings, the causal SNPwas identified to be statistically significant at genome-
wide significance
(
p < 5 × 10−8) .
Figure 4.7: Manhattan plot of Weibull regression analysis SNP p-values. Red line
represents genome-wide significance threshold 5 × 10−8. The blue line represents
suggestive significance line. Each point represents a SNP. The two shades of blue used
for SNPs is to distinguish between the chromosome boundaries.
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Figure 4.8: QQ-plot: Weibull-regression analysis of each SNP. Observed −log10
p–values are plot against the expected −log10 p–values.
Figure 4.9: Manhattan plot of Weibull regression analysis SNP-treatment interaction
p-values. Red line represents genome-wide significance threshold 5 × 10−8. The blue
line represents suggestive significance line. Each point represents a SNP-treatment
interaction. The two colours (purple and grey) are used to distinguish between the
chromosome boundaries.
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Figure 4.10: QQ-plot: Weibull-regression interaction analysis of each SNP-treatment
interaction. Observed −log10 p–values are plot against the expected −log10 p–values.
4.6.1 Performance
The entire simulation study analysis was run using eight computer nodes (64 cores).
Each node consisted of an HP Proliant DL170h G6 server, 2 Intel Xeon(R) E5520
2.27GHzquad-coreCPUs, 36GBmemory and 1TBof local storage. Running the single
SNP analysis of ≈1.5 million SNPs across 22 chromosomes for 1000 individuals with
no additional covariates took≈4.5 hours to complete using the Cox PHmodel. Running
the same analysis using the Weibull regression model took ≈3 hours to complete. The
more covariates added to the analysis and the addition of an interaction, the longer the
computational runtime. Each additional covariate took approximately an extra 0.00275
seconds for each SNP analysed.
The Weibull regression analysis runtime varies greatly; this is due to the convergence
criteria of the Newton-Raphson method used for estimation of all parameters. Runtime
is also dependent on missing values within the sample file and whether or not the
genotype file is compressed. Ultimately, cluster specifications and the size of data files
are the most influential factors affecting the speed of the software. As highlighted
above, the only caveat is that Mono is used to compile the code on Linux O/S which
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can reduce the performance. New compilers have become available recently such as
.NET Core run using Visual Studio Code. This new framework could be beneficial for
the future of the software.
4.7 Discussion
SurvivalGWAS_SV is the first analytics software capable of applying a range of sur-
vival analysis methods to genome-wide data, with appropriate handling of imputed
genotypes. SurvivalGWAS_SV is compatible with HPC clusters, thereby allowing an
application to large-scale GWAS datasets efficiently and effectively, without incurring
memory issues. SurvivalGWAS_SV has the potential to enable discovery of genetic
biomarkers of patient response to treatment for a range of complex human diseases and
will offer opportunities for patient stratification according to predicted benefit or risk
of treatment, allowing personalisation of therapeutic intervention.
Despite the great benefit in which GWAS single variant analyses have helped identify
SNP-phenotype associations, much of the genetic heritability5 cannot be explained.
It has been suggested that rare variants, which are typically filtered out of GWAS
analyses, might contribute to this missing heritability. This filtering of rare variants
is undertaken because they would have insufficient power to detect associations using
single variant tests. However, over the last seven years, methodology has been developed
and implemented in software specifically to analyse rare variants collectively within
sets, genes or other functional units. The current state of the methodology will be
explored further in the context of TTE outcomes in the next chapter.
5The proportion of phenotypic variation within a trait occurring due to genetic variation. A value is
usually derived by comparing the trait correlations/relatedness in individuals.
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CHAPTER 5
RARE VARIANT ASSOCIATION STUDIES FOR
TIME-TO-EVENT OUTCOMES
5.1 Overview
Methodology and software for the analysis of common variants within genome-wide
association studies (GWAS) have been comprehensively developed and applied to a
range of different endpoints, including survival data (see Chapter 4). In doing so,
this has led to a vast number of loci identified for a variety of complex traits and
diseases. As of 1 June 2017, the National Human Genome Research Institute’s GWAS
Catalog (MacArthur et al. 2017) reports 9346 single nucleotide polymorphism (SNP)
- trait associations. All 9346 associations are significant at a p-value ≤ 5.0× 10−8 for a
number of different phenotypes that include disease status, physiological measurements
and response to drug. However, GWAS have been designed to identify common variant
associations, which typically have modest effects, and together account for a small
proportion of the genetic variance of the underlying trait (Manolio et al. 2009). It has
been suggested that rare genetic variants may account for the "missing heritability"
of human traits since they are not well covered through traditional GWAS, even after
supplementation by high-density imputation.
An alternative approach to GWAS genotyping of common SNPs is studying poten-
tial genetic factors associated with complex traits through whole-genome and -exome
sequencing. These sequencing solutions offer many advantages such as: i) direct in-
vestigation of low-frequency and rare variants that are not accessible through GWAS
genotyping arrays, even after imputation; ii) through the use of annotation, rare variants
can be aggregated into distinct groups based on similar criteria, e.g. position (gene or
regulatory region), molecular effects, pathways or other biological sets. The groups
are analysed using aggregate tests of association, which offer substantial gains in power
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over single-variant tests.
One of the greatest challenges is designing software for the efficient analysis of rare
variants because of the added complexity of the statistical models that need to be
considered. As established earlier in Chapter 4 in the context of the analysis of common
variants, there is also a lack of software analysing rare variants with time-to-event (TTE)
outcomes.
5.1.1 Objectives
The focus of this chapter is to develop novel statistical methods and computationally
efficient software for rare variant association study (RVAS) analysis of TTE outcomes,
which can address the scale and complexity of sequence data. Specifically, the objec-
tives are to:
1. Briefly review the role of rare genetic variants in common and complex human
diseases.
2. Review the literature comparing and developing gene-based rare variant tests of
association, while considering how to apply these to survival data.
3. Gather evidence on the application of rare variant tests for a range of outcomes
within published studies.
4. Develop novel statistical methods that can be applied to RVASwith complex TTE
outcomes.
5. Construct computationally efficient and freely available software for the imple-
mentation of the proposed methodology.
6. Demonstrate the utility of the proposed software through application to simulated
data based on exome-array study data.
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5.2 Evaluating Gene-based Analysis Methodology
Traditional methodologies for the analysis of GWAS lack power for detecting rare vari-
ant associations (Moutsianas et al. 2015). Instead, multiple rare variants are most often
jointly analysed within "functional units", such as genes, exons or pathways. Aggregate
or "gene-based" analyses are typically performed by assessing the association with rare
variant "burden" or "dispersion" within the functional unit, focussed on the joint effects
of multiple variants. These classes of tests each have their benefits and limitations,
dependent on the underlying genetic architecture of the trait under investigation. Mout-
sianas & Morris (2014) provide a comprehensive overview of available rare variant
tests and a discussion of architectures in which there is an advantage of using one
method over another. In brief, burden tests focus on the effect of the mean number
of minor alleles across variants in a gene. Burden tests are most effective when the
direction of effects of all variants on the outcome in a given gene or functional unit is
the same. On the other hand, dispersion tests focus on the effect of the variance in the
number of minor alleles across variants in a gene and are most effective when variants
have different direction of effects.
The literature, to date, has focused primarily on binary and quantitative traits (Mout-
sianas et al. 2015, Lee et al. 2014, Santorico & Hendricks 2016), and is expanding
rapidly with extensions of existing approaches becoming available over the last few
years (Wu et al. 2015, Ionita-Laza et al. 2013). The reason for this expansion of
methodology is to account for the combination of different characteristics of variants
that influence the power to detect associations. The power of aggregate tests for rare
variants depends on: i) the number of variants per gene; ii) the proportion of variants
(rare and common) in a gene that are causal; iii) the magnitude of effect of each variant;
iv) the direction of effects for variants, i.e. risk or protective1; and v) the region length.
Appropriate approaches for variant aggregation while considering these five factors is
imperative, because only a small fraction of variants within a gene may affect gene
1A variant can act to decrease or increase the trait or disease risk.
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function, and therefore methods for classifying variants as to their effect on function
need to be appropriately designed in the future. It is also essential that when variants
have a different function, they are appropriately weighted for effect size because there
could be one or many that are highly penetrant. If variants affect gene function in
different directions, then inappropriately combining these into a set, may partially
cancel out their effects. Definitions for combining variants within a gene or functional
unit should be established before analysis. Methods for grouping p-values together after
analysis have also been proposed (Lin et al. 2014). Currently, no method is uniformly
most powerful to detect all rare-variant associations, therefore the consensus is to apply
many if not all of the available tests to understand if there is an agreement between
findings.
Chen et al. (2014) have previously introduced methodology behind the implementation
of the general burden test (BT) and sequence kernel association test (SKAT) within a
survival analysis framework. The SKAT is a dispersion test described in detail by Ionita-
Laza et al. (2013) for binary traits. Chen et al. (2014) presented simulations evaluating
the power of BTs and SKATs for TTE outcomes, considering only the Cox proportional
hazards (PH) model, comparing the likelihood ratio test (LRT) with the score statistic.
This paper was important in the development of new methodology for analysing rare
variant associations and TTE outcomes, however coming to the same conclusions
regarding statistical power being dependent on the underlying genetic architecture as
reported for binary and quantitative traits. This paper provides a foundation for further
model development and implementation within a computational analysis tool.
5.3 A Review of Rare Variant Association Studies
RVAS have been an actively researched area over the last few years, in the hope
of uncovering the unaccounted genetic variance of human traits and diseases. Early
studies (Wagner 2013) suffered from a lack of power to detect the effects of rare variants
due to the genotyping chips available. Solutions through imputation from high-density
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reference panels had been proposed and executed (Mägi et al. 2012) with success.
However, the motivation that was once about costly re-sequencing studies has been
overturned due to the substantial decrease in the cost of next-generation sequencing
(NGS) experiments, allowing amore in-depth look at rare variants. This comprehensive
inspection of rare variants is mostly performed using exome sequencing whereas whole
genome sequencing is still considered expensive.
In the field of pharmacogenetics, in particular, there is evidence of a substantial con-
tribution of rare coding variants to drug metabolism and transport (Gordon et al. 2014,
Legge et al. 2017). These variants could have equally large effects on an individual’s
ability to metabolise certain drugs, resulting in response to treatment. de With et al.
(2017) provide an overview of genetic studies conducted for clozapine2, providing
details of studies that have analysed rare-coding variants and their findings. However,
no studies were identified from our literature search for pharmacogenetic TTE studies
analysing rare coding variants. To date, very fewRVAS have been undertaken regarding
TTE outcomes, even in the context of pharmacogenetics. The few that exist inform
us on how rare variants are analysed within TTE settings and the methodology and
software currently employed to carry out the task.
Gaastra et al. (2016) sought to identify rare variants associated with amyotrophic
lateral sclerosis (ALS) survival through a pre-screening of candidate survival genes
found through previous evidence highlighted in the literature. A total of 50 samples
were collected from the UK National DNA bank for motor neurone disease research.
A second set of individuals from the Netherlands (n = 459) for replication of findings
was also analysed. A single gene from three candidates was found to be associated,
which contained a variant associated with longer survival and another with shorter
survival. The statistical analysis was carried out by dichotomising patients into short
and long survival groups and applying the sequence kernel association test (SKAT) (Wu
et al. 2014) comparing the rare variation dispersion in the two groups. This analysis
was conducted in variant association tool (VAT) and the R package ‘SKAT’ (http://
2Clozapine is an anti-psychotic drug used to treat patients with treatment-resistant schizophrenia.
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cran.r-project.org/web/packages/SKAT/). PLINK/SEQ (https://atgu.mgh.harvard.edu/
plinkseq) was then used to identify the individual rare single nucleotide variations
from the gene-based signals. The study produced a lack of evidence to suggest any
associations in the replication set of samples from the Dutch cohort. They concluded
with discussing the possible reasons for the lack of replication. First, the small sample
size (n = 50), limits the statistical power, resulting in false positive associations.
Second, rare variants are more likely to be population specific. The inclusion of
only candidate survival genes (not looking at the entire genome) will have limited the
discovery process. Furthermore, dichotomising the outcome may have reduced the
power to detect true associations if present. As established in Chapter 2 of this thesis,
dichotomising the survival outcome results in a loss of power to detect associations
when compared to a TTE analysis.
Another ALS study (Pang et al. 2017), conducted within the Chinese population, had
investigated the burden of rare variants in known ALS genes influencing survival for
familial and sporadic ALS. A sample size of 8 patients were in the familial ALS group
and a sample size of 46 in the sporadic ALS group. Kaplan-Meier curves were used
to measure the effect of the rare variant burden on the outcomes time to ventilator
and death. Alongside this, the Cox PH model was used to estimate the hazard ratio
(HR) of the rare variant burden on survival. The rare variant association tests were
only performed under a case-control design using RVTESTS (Zhan et al. 2016) and
KGGSeq-integrated SKAT package (Ionita-Laza et al. 2013). The findings of the study
were very promising as the burden of rare variants affected the survival probability
of patients. The study found that patients with two or more rare variants had shorter
survival compared to those with one or none. This study highlights the need for
computational tools which can implement a combination of survival and rare variant
analysis methodology.
Mackelprang et al. (2017) conducted a whole-genome sequencing study to identify
variants associated with increased risk of acquiring HIV-1. The discovery stage used a
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case-control approach to compare variation in genic regions. The method used was a
logistic regression analysis with burden scoring developed byMorris & Zeggini (2010).
The software implementing this method was not stated. In the replication stage of the
analysis, the investigators tested the association between time to seroconversion and
candidate regions from the initial discovery stage. P-values and HRs were estimated
using the Cox model with an aggregate risk scoring based on whether or not an
individual carried a minor allele for any of the rare variants.
As mentioned in the preceding chapters, TTE outcomes are commonly investigated
in cancer studies, and rare-variant association is no different. Winham et al. (2016)
undertook an exome-wide association study to investigate whether rare coding variants
have an association with epithelial ovarian cancer survival. This study was undertaken
because of the lack of associations reported for common genetic variants. The gene-
level analysis was conducted using both the BT and SKAT within a Cox PH model,
which was developed by Chen et al. (2014). The R package ‘seqMeta’ (Voorman
et al. 2017) was used to compute the gene-level meta-analysis, which implements the
R ‘survival’ package (Therneau 2015) functions.
These studies are informative about the role and benefits of rare variant association
analyses with TTE outcomes. The examples discussed in this section all suffer from
very low numbers of individuals in the sample, and adequate sample size is needed
especially for detecting rare variant associations (Wagner 2013). Obtaining these
numbers of subjects may be difficult for some phenotypes, such as treatment responses,
however in pharmacogenetic studies we expect larger effect sizes than complex traits.
The majority of the studies discussed above concluded with stating that more powerful
studies should be undertaken, providing a sense that their findings can be advanced.
The lack of software availability for detecting associations between rare variants and
TTE outcomes led most investigators to using case-control designs with application
through existing software and methodology. However, the impact of dichotomising
the outcome on the statistical power to detect associations was not discussed in any of
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the papers. This reiterates the emphasis throughout this thesis, that there is a need for
bespoke methodology and software for TTE outcomes in genetic association studies.
5.4 Rare Variant Analysis Computational Tools
Software implementing rare variant tests for a variety of binary and quantitative traits,
such asEPACTS (http://genome.sph.umich.edu/wiki/EPACTS), GRANVIL (Mägi et al.
2011) and VAT (Wang, Peng & Leal 2014), are well developed to handle genome- or
exome-wide data from sequencing or array genotyping. However, these computa-
tional tools can only be applied to TTE data after dichotomising the outcome. As
demonstrated in Chapter 2, this will result in a loss of information and power to detect
associations. There are many implementations of rare variant association tests, with
none considered to be optimal. Consequently, programs such as EPACTS and VAT
are considered to be sophisticated programs because they can perform multiple tests,
giving users’ flexibility especially for omnibus3 tests of association or adaptive tests
such as the SKAT-O (Lee et al. 2012), which is a combination of the BT and SKAT.
Due to the demand for analysing more complex phenotypes, other computational tools
exist such as ‘RVFam’ developed by Chen & Yang (2016), a rare variant analysis
software package that has a survival modelling element. This R package is used for
rare variant association analysis of family data. The details of the package are that it is
designed to analyse survival traits using Cox PH with shared frailty in each family by
calling the ’coxph’ function of the ‘survival’ package in R. Although it does not offer
a wider range of analyses, the software is useful for family study data, which is beyond
the scope of this thesis.
To address the need for rare variant analysis of TTE outcomes, we have developed
the rareSurvival analysis tool implemented using C# and run on Linux, Windows or
Mac OSX operating systems (O/S). rareSurvival is capable of handling the scale and
complexity of whole-genome sequence data offering support using analysis via the BT
3Omnibus tests refer to the application of multiple or a combination of many aggregate tests of association.
For example, combining the p-values from both the SKAT and Burden tests (Derkach et al. 2013).
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with optional weighting methods (discussed in Section 5.2) within a Cox PH orWeibull
regression model framework.
5.5 rareSurvival
5.5.1 Implementation
Based on the same algorithmic framework as its companion program, SurvivalGWAS_-
SV, rareSurvival has been developed for the analysis of rare-variants with TTE out-
comes. rareSurvival has been developed using C# and is compatible with Windows
and Linux or Mac O/S through Mono (http://www.mono-project.com/download/).
5.5.2 User Interface
rareSurvival is a console application that can be run from Linux, Windows and Mac
OS X operating system terminals. Users can interactively apply the software on a
command line interface or submit a script of commands to high-performance computing
(HPC) capabilities, allowing more efficient analysis depending on the users’ available
resources. The user can specify batches of the data file to analyse using many computer
cores, where each core can run the analysis process concurrently.
5.5.3 Inputs
Initially, the user is required to specify three data files that will be read into the program.
The first file must be a genotype file which contains the SNP probabilities (imputed
or typed) or a variant call format (VCF) file of sequence-based genotypes (v4.1 and
v4.2 have been tested). The second file should be a sample file (.sample or .txt) which
contains all the covariate and phenotype information for each individual. The final file
to specify is the gene list file which can be in one of two different formats. The gene
list file is a text file which can contain: (i) the gene name, chromosome, base pair start
position and base pair end position, which should be given the file extension .pos (see
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Script 5.1); or (ii) the gene name, chromosome and the rsid of each variant in a row
list separated by a single space, which should be given the extension name .list. The
software can read in genotype files that are compressed, either with a .zip or .gz file
extension. GZIP should be used to compress genotype files into the .gz format. All files
should have content separated by a single space or tab; otherwise, errors will occur.
1 GeneA 1 11873 11909
2 GeneB 1 12851 13469
3 GeneC 1 13671 14425
4 GeneD 1 14362 16765
Script 5.1: Gene list file (.pos) contents for four genes.
In addition, the user needs to specify details about variables to include in their analysis
model such as covariates, while also specifying the censoring indicator and survival
time. Furthermore, they need to specify the range of functional units to be analysed,
based on the number of lines in the gene list file. Since the program will search through
the genotype file for every line in the gene list file, the analysis process can be slow;
however, this can be avoided if the user reads in smaller batches of the input files
separated by chromosomes.
The user must enter the details of the survival analysis method to use and the rare
variant test separately (see Table 5.1). If the data have not already been filtered for
MAF or imputation quality, then a MAF and info-score threshold can be specified. The
default values for filtering out variants based on MAF and info-score are greater than
0.05 and 0.9, respectively. Finally, the name of the output file should be specified for
which the analysis output will be saved. If the user adjusts for covariates within the
analysis model but does not require the covariate results in the output file, then there is
a print option that when specified only outputs the gene analysis results.
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5.5.4 Algorithms and Validation
rareSurvival ensures that the data are processed through a comprehensive validation
procedure. The gene list file is first assessed by the software determining how many
analyses need to be distributed between threads. Once this has been determined the
first line is read in by rareSurvival. After this the genotype file is read in one line at a
time, rareSurvival will convert the genotype probabilities into a SNP coded under an
additive dosage model for the minor allele (see Eq. 1.2). This step is only carried out
for probabilities; if hard genotype calls or dosages are present within a VCF file, then
these are directly read in. The hard genotype calls from VCF files can be in the form
0/0, 0/1, 1/1 or 0 | 0, 0 | 1, 1 | 1.
Two alleles are listed for each variant in the genotype file. The first is assumed to be the
reference allele, the second to be the alternate or non-reference allele. However, due
to imputation, it is not unusual for the ordering to be different. The software identifies
which is the major allele and which is the minor allele by calculating the MAF. In cases
where the hard calls, probabilities or dosages reflect that the major and minor allele
are swapped due to allele frequency calculation then the genotype values are flipped.
For example, a variant has reference allele coded A and alternative coded as T. The
genotypes in the file is represented as [AA, AT, TT], with genotype calls [0, 1, 2].
The alternative allele frequency is calculated to be 0.99. Therefore the alternative and
reference allele are switched to [2, 1, 0] because the reference allele is the minor allele
in this case. This is a trivial process, especially when handling dosage information.
Users are advised to check that data is in the correct format before being read in using
rareSurvival.
Each SNP, in turn, will be matched to the genes base pair position in the gene list
file or the rsid of the variant, if present in the list. If the variant does not match the
specifications in the gene list file, then the programmoves to the next variant. However,
if the variant is to be included, it is then stored in a new data frame of included SNPs.
The program will determine how many SNPs are included once it has scanned the
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entire genotype file or until it has added at least one variant and then identified that the
next variant to be read in is outside of the specified genomic region. All SNPs within
the region will be taken forward to the analysis stage. The group of SNPs within the
gene are analysed, and the software starts the process again reading in the next line
of the gene list file. rareSurvival throws exemptions whenever the user has specified
an incorrect command or states a heading name that cannot be found in the data files,
at which point the program will exit the application, and it will need re-submission
of the task. The program also handles missing values (coded as "NA") within the
sample file. If an individual has missing values for survival time or a covariate used in
the model, then the individual is removed from the analysis with their corresponding
variant information. Figure 5.1 provides a detailed work-flow of rareSurvival from
reading the data to analysis output.
5.5.5 Statistical Methodology
As described in Section 5.2, there is no single gene-based analysis model which has
the greatest statistical power to detect associations amongst all genetic architectures.
This observation prompted an initial implementation of the BT of association and
Madsen-Browning (Madsen & Browning 2009) weighted BT within TTE regression
models. Chen et al. (2014) provided the framework to implement the burden test into
rareSurvival. In contrast to BTs, the SKAT, which was also described by Chen et al.
(2014) was not implemented because it is very computationally demanding and mathe-
matically cumbersome therefore the BT was more of a straightforward implementation.
rareSurvival offers analysis using the Cox PH andWeibull regression models. For each,
a BT with or without Madsen-Browning weights is implemented.
Burden Test within a Cox and Weibull Regression Model
The BT is an aggregated test of association for the genetic burden score. The genetic
burden score is the accumulation of minor alleles at rare variants. There are many
different types of BT, the simplest of which is the sum of all genotype dosages within
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a genomic region with the addition of applying an indicator of whether at least one
rare variant exists within a genomic region. These tests are most powerful when all of
the variants in a region are causal with effects in the same direction. This burden is
introduced into the Cox PH model or Weibull regression model as a predictor in the
same way as a coded SNP genotype in a single variant analysis. Coefficients are then
derived with the corresponding p-value using a Wald test (see Section 1.3) or the LRT.
Under this model, let Bi denote the genetic burden of a given gene or functional unit
for individual i, given by:
Bi =
m∑
j=1
Gi jw j (Eq. 5.1)
In this expression the indicator variable,
w j =

1, if j is included
0, otherwise
Gi j represents the genotype coding of the i’th individual at the j’th rare variant in the
gene. m is the total number of variants within/mapping to a given functional unit. Each
genotype at a variant of interest is coded under an additive dosage model for the j’th
rare variant.
Using Eq. 1.3, we again denote the TTE for the i’th individual by ti, and a vector of
covariates xˆi. Under the assumption of PH, we can express the hazard of the event
occurring at some time t for the i’th individual by:
hi(t) = h0(t)eβGBi+βˆxxˆi (Eq. 5.2)
In this model, the parameters βG and βˆx correspond to the effect on log-hazard of the
burden score, and the vector of covariates, respectively. βG can now be interpreted as
the log-HR per minor allele across variants in the functional unit. The baseline hazard
is represented by h0(t).
Using Eq. 1.7, the likelihood function can be adapted for a more general Weibull
regression model accounting for right censored data analysing the cumulative effects of
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a functional unit. This is carried out by replacing βs (the effect of a single SNP) with
βG and the SNP Gi with the burden score Bi.
Madsen-Browning Weighting within a Cox and Weibull Regression Model
The issue with gene-based tests of association is the imperfect classification of the
effects of variants when most likely a small percentage of variants within a functional
unit are causal. Under the unit-weighting model of the classical BT, all rare variants
included in the aggregation are assumed to have the same magnitude of effect on the
phenotype, as well as the same direction. However, this cannot be the case for all
variants within a functional unit, and simple aggregation methods may incorrectly
combine these into a set. This method can result in partly cancelling out variant effects
that can lead to false-negative associations. Thismakes the task of finding those variants
that are driving the association much more difficult. Typically, variants are excluded
from the analysis on the basis of MAF and annotation. Alternatively, w j can be used
to incorporate weights according to allele frequency.
Different functional variants will have a different magnitude of effect and should be
weighted appropriately in a gene-based test. There aremany different types ofweighting
schemes for a BT, such as, the Madsen-Browning approach that gives greater weight
to variants of lower frequency. They proposed a weight that increases the impact
on the phenotype for lower frequency variants, ensuring that larger effect sizes are
given to variants with very small MAF. This approach is based on the expectation that
rarer variants are more likely to have arisen from recent mutation events, and therefore
selection will have had less opportunity to have removed variants with large detrimental
effects from the population. The weight w j in Eq. 5.1 now becomes: w j = 1√(qj (1−qj )) ,
where q j is the MAF of the j’th variant.
5.5.6 Usage Commands
1 $ mono r a r e s u r v i v a l . exe −gf= − s f = −mf= − t h r e a d s = − t = −c= −cov= − i = −
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ch r = −maf= − i n f o = − l s t a r t = − l s t o p = −method= −rm= −p= −o=
Script 5.2: rareSurvival command line example without defined parameters.
Command Description
-gf= This specifies the genotype file. Typically a .gen, .vcf, .gen.gz.
-sf= This specifies the sample file (.sample).
-mf= This specifies the the gene list file. (.pos or .list).
-threads= Specifies the number of threads. On a multi-core system, multiple,
threads can execute tasks in parallel, with each core executing a
different thread or multiple threads.
-t= This specifies the time to event (column heading name) in the
sample file.
-c= This specifies the censoring indicator/outcome in the sample file.
-cov= This specifies the covariates to adjust for in the model. Each one
separated by a comma (,). e.g. -cov=cov1,cov2,cov3. Note:
Categorical variables need to be converted to binary as software only
assumes continuous or binary covariates.
-lstart= This specifies the line in the gene list file at which the start, position
of analysis will occur. Used to break large files into small batches for
parallel computing.
-lstop= This specifies the line in the gene list file at which the end position,
of analysis. will occur. Typically the number of lines is equal to the
number of genomic regions in the file.
-chr= This specifies the chromosome number to be output in the text file.
-p= Enter "onlygene" if only the results from the gene analysis are to be
output.
-m= This specifies choice of regression model. This is either "cox" for
the Cox PH model or "weibull" for the parametric Weibull
regression model.
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Table 5.1 continued from previous page
-rm= Specifies the choice of rare variant analysis method. This is
"burden" for the BT with unit weighting or "mbweight" for the
Madsen-Browning weighted BT.
-maf= Specifies the MAF threshold for inclusion of variants in the analysis.
-info= Specifies the info-score threshold for inclusion of variants in the
analysis.
-o= This specifies the name of the file for output to be saved in. e.g.
name.txt
-help Outputs a full list of commands and usage help.
Table 5.1: List of commands available in rareSurvival and their corresponding usage
description.
Assuming all data files and software are in the same folder, the command line shown in
Script 5.3 is an example for interactive submission in a Linux terminal. The command
is specifying an analysis of 100 genes on chromosome 6 with one additional covariate
using a BT in a Cox PH model. Filtering based on SNPs with MAF less than equal to
0.01 is also specified.
1 $ mono r a r e s u r v i v a l . exe − t h r e a d s =4 −gf= d a t a . v c f − s f = d a t a . sample −mf=
l i s t . t x t − t = e v e n t _ t ime s −c=outcome −cov= c o v a r i a t e 1 −ch r =6 − l s t a r t
=0 − l s t o p =100 −maf =0 .01 −m=cox −rm=burden −p=on lygene −o= ou t p u t .
t x t
Script 5.3: rareSurvival command line example with dummy input parameters.
As demonstrated in Script 5.2 and 5.3, each command is separated by a space and be-
gins with ‘-’ and ends with ‘=’ before specifying the option, identical to the commands
for SurvivalGWAS_SV (Section 4.5). The user can specify the exact location of the
data files and where the output file will be saved. e.g. /DIRECTORY/DATA/output.txt.
Script 5.4 is an example of a shell script (.sh) to distribute the analyses using rareSur-
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vival, between 10 computer cores within a Linux cluster, using a Sun-Grid engine batch
system.
1 # ! / b i n / bash
2 #$ −o s t d o u t
3 #$ −e s t d e r r
4
5 DIRECTORY=/ r a r e S u r v i v a l # Loc a t i o n o f s o f tw a r e and d a t a
6 s t r 1 =0 # S t a r t p o s i t i o n i n gene l i s t f i l e
7 s t r =100 #Number o f genes / l i n e s i n gene l i s t f i l e
8 no_o f_ j ob s =10 #Number o f c o r e s
9 i n c = ‘ exp r \ ( $ s t r − $ s t r 1 \ ) \ / $no_of_ jobs ‘ # I n c r emen t
10
11 #SGE_TASK_ID t a k e s v a l u e s 1 : no_o f_ j ob s
12 n s t a r t = ‘ exp r \ ( $SGE_TASK_ID − 1 \ ) \∗ $inc ’
13 n s t op = ‘ exp r $ n s t a r t + $ i n c − 1 ’
14 mono $DIRECTORY/ r a r e s u r v i v a l . exe − t h r e a d s =4 −gf=$DIRECTORY/ d a t a . v c f
− s f =$DIRECTORY/ d a t a . sample −mf=$DIRECTORY/ l i s t . t x t − t = e v e n t _ t ime s
−c=outcome −cov= c o v a r i a t e 1 −ch r =6 − l s t a r t =0 − l s t o p =100 −maf =0 .01
− i n f o =0 .8 −m=cox −rm=burden −p=on lygene −o=$DIRECTORY/ ou t p u t $ {
SGE_TASK_ID} . t x t
Script 5.4: Shell script that runs rareSurvival on a HPC cluster. Comments are
highlighted in green.
To submit the script file, there are many different commands dependent on the cluster
manager used. Script 5.5 demonstrates submission using the "qsub" command. The
script and command can be easily changed for alternative cluster workload managers,
such as SLURM, replace "SGE" with "SLURM_ARRAY" in Script 5.4 and submit
using the command line shown in Script 5.6. The concatenation of files should be
carried out using the same command as Script 4.7 in Section 4.5.
1 $ qsub − t 1 :10 example . sh
Script 5.5: Multitple core submission example using ‘qsub’.
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1 $ s b a t c h −− a r r a y =1−10 example . sh
Script 5.6: Multitple core submission example using ‘sbatch’.
5.5.7 Output
The output from the analysis is saved in a text file specified by the user. Details of the
file contents are summarised in Table 5.2. In addition to the standard HR and p-value
output, key output such as the total number of rare variants within a genomic region
provide a value for which the user can filter out single markers. This process is done
because it is of interest to only include the tests of groups with more than one variant.
Often the total MAF of all rare variants in the gene or the mean MAF per variant in the
gene is of interest, as this can also be used as an additional tool for filtering. Script 5.7
is a sample of an output text file showing analysis of four genes.
1 InputName / Gene Chr RareCount To ta lSample MAFSum AvMAF InfoSum AvInfo
CoefValue HR SE LowerCI UpperCI Waldpv LRTpv ModLRTpv
2 GeneA 10 1 1 0 .000236 0 .000236 1 1 −0.31479947 0 .72993523
621.36388324 0 I n f i n i t y 0 .999595770477929 NA 0.548746029322796
3 GeneB 10 1 1 0 .007075 0 .007075 1 1 0 .02452142 1 .02482455 0 .01844898
0 .98843072 1 .06255839 0.183799127698855 NA 0.204347599530058
4 GeneC 10 8 8 0 .000943 0 .000118 1 0 .125 0 .01261971 1 .01269967
0 .00599925 1 .00086215 1 .0246772 0.0354179036648269 NA
0.0500864643631872
5 GeneD 10 2 2 0 .000236 0 .000118 1 0 . 5 −0.01065098 0 .98940554
0 .01685544 0 .95725453 1 .0226364 0.527451151265893 NA
0.506230074265232
Script 5.7: rareSurvival text file output. Example output for four genes analysed using
a BT within a Cox PH model.
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Output header Description
InputName/Gene Variable name (can be the gene name or covariate).
Chr User-specified chromosome number.
RareCount Total number of rare variants in gene.
TotalSample Total number of variants (common and rare) in gene.
MAFSum Sum of rare variant MAFs in gene.
AvMAF Mean of rare variant MAFs in gene.
InfoSum Sum of rare variant info-scores in gene.
AvMAF Mean of rare variant info-scores in gene.
CoefValue Coefficient estimated value.
HR Hazard ratio of accumulation of minor alleles.
AF Acceleration factor (Weibull only).
SE Standard error of coefficient value.
LowerCI Lower 95% confidence interval for HR (Cox model only).
UpperCI Upper 95% confidence interval for HR (Cox model only).
Waldpv Wald test p-value.
LRTpv Likelihood ratio test p-value (Cox model only).
ModLRTpv Model likelihood ratio test.
Shape
The shape parameter estimation of the survival distribution
(Weibull only).
Table 5.2: rareSurvival output file variable headers and corresponding description.
5.5.8 System and Installation Guide
The software can be downloaded from the University of Liverpool, Statistical Genetics
and Pharmacogenomics Research Group software page: https://www.liverpool.ac.uk/
translational-medicine/research/statistical-genetics/raresurvival/. As well as the down-
load, there is a full description of the software, and a sample shell script. rareSurvival
is publicly available and can be obtained by visiting the web-link, and then by following
the instructions on the web page. The downloaded folder contains the executable file
and all the .NET framework .dll files needed to run and distribute the software. This
software is also bound by the GNU General Public License, version 3 (GPL-3.0) with
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no restrictions to use, edit and distribute the software.
5.6 Simulation Study
To demonstrate the features of the software and to provide an evaluation of its efficiency,
we conducted simulations based on Illumina Exome Array genotype data (primarily
coding variants) obtained from 2,120 individuals from two cohorts of elderly Swedish
individuals.
5.6.1 Background
The two cohorts were from the Prospective Investigation of Vasculature in Uppsala
Seniors (PIVUS) (http://www.medsci.uu.se/pivus/) and theUppsala Longitudinal Study
of Adult Men (ULSAM) (http://www.pubcare.uu.se/ulsam/Database). The cohorts
were typed for the Illumina HumanExome-12 v1 Beadchip at the Wellcome Trust
Centre for Human Genetics, University of Oxford. Genotype calling and quality
control were undertaken at the University of Oxford. In short, genotypes were initially
called with the Illumina GenomeStudio GENCALL software (Guo et al. 2014). Poor
quality samples were excluded based on call rate (< 98%), extreme heterozygosity,
outlying numbers of singletons4, sex discordance and ancestry outliers. Poor quality
variants were excluded based on call rate (< 95%), and extreme deviation from Hardy-
Weinberg equilibrium
(
p < 10−4
)
. Missing genotypes were then recalled using zCALL
(Goldstein et al. 2012). For this final called genotype set, poor quality samples and
variants were excluded on the basis of call rate (< 99%).
5.6.2 Simulation models
The phenotype information was simulated using SurvivalGWAS_Power. Two datasets
were simulated, each with a randomly selected gene containing causal variants.
4Singletons are the rarest of rare variants across the genome. A singleton is unique because it is found in
a single individual in a population.
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Dataset 1
The first gene selected as causal was FNDC1 found on chromosome 6, which included
a total of twenty-five rare variants. Fifteen variants were selected at random to be
causal, simulating survival times for each individual using the number of minor alleles
carried by an individual (Eq. 5.1). All variants had an effect size of 0.6 and with the
same direction of effect. In this expression, vi j represents the individual i, genotype at
the j’th causal variant.
Ti = Weibull
(
1, 10e−
(∑15
j=1 0.6vi j
) )
(Eq. 5.1)
Dataset 2
The second gene selected as causal was OR5B17 found on chromosome 11, which has
a total of 4 rare variants. Survival times were simulated based on all 4 causal variants
but with varying effect sizes κ j = [0.1, 0.2, 0.6, 0.15] with the same direction of effects.
Ti = Weibull
(
1, 10e−
(∑4
j=1 κjvi j
) )
(Eq. 5.2)
Both model settings are suited towards analysis using a BT, as expressed in the com-
parative literature (Santorico & Hendricks 2016, Lee et al. 2014). However, there are
subtle differences in both datasets, which suggest that they are not entirely ideal for
the BT. The first setting has just over half the variants in the gene as causal, and in the
second setting the magnitude of effects of the causal variants is different.
Censoring was randomly simulated using an exponential distribution with scale param-
eter 10. If the censoring time is less than the individual’s event time, then the individual
is censored. There were 1008 censored observations in the FNDC1 dataset and 867
censored observations in the OR5B17. Two additional covariates were simulated for
the sole purpose of collecting information regarding analysis completion times. These
were treatment, a binary covariate simulated using a Bernoulli distribution, and age
of individual, a continuous covariate simulated with a Uniform distribution generating
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values between 20 and 50. More information on the variants used to simulate data can
be found in Table 5.3.
The objective of the simulation study was not to make another comparison of methods,
but rather testing the features of the software and computational efficiency. Interest lies
with rare coding variants, so all variants with MAF >5% in the dataset were filtered
out. Variants were assigned to genes and analysed based on base pair position using
the gene list file which links coding variants (defined by a strict annotation) to genes.
Analysis was completed on a total of 73952 SNPs over 12432 genomic regions across
23 chromosomes for 2120 individuals. Hereafter, filtering for genes that contained at
least two rare variants was performed before visualising the output.
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Gene Unique variant
identity number
Ref/alt
allele
Position MAF Function Simulated effect
size
FNDC1
- C/T 159,636,159 0.000235 Unknown 0.6
rs186515442 G/A 159,646,577 0.000235 Missense 0.6
rs200758408 G/A 159,659,662 0.001650 Missense 0.6
rs61746218 C/T 159,667,972 0.002594 Missense 0.6
rs200171920 A/T 159,672,511 0.000235 Missense 0.6
rs180849332 C/T 159,687,181 0.001650 Missense 0.6
- G/A 159,692,377 0.002830 Unknown 0.6
rs200925962 A/G 159,692,428 0.000943 Missense 0.6
rs202080149 A/G 159,644,604 0.000235 Missense 0.6
rs202114028 G/A 159,653,261 0.000235 Missense 0.6
rs199900169 G/A 159,636,039 0.000943 Missense 0.6
rs201387402 A/G 159,644,575 0.000471 Missense 0.6
- A/G 159,653,612 0.0004717 Unknown 0.6
rs7763726 A/G 159,670,100 0.020047 Missense 0.6
rs186422799 G/A 159,653,921 0.006839 Missense 0.6
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Table 5.3 continued from previous page
OR5B17
rs144440324 G/C 58,125,740 0.000235 Missense 0.1
rs55810057 A/G 58,125,774 0.018632 Missense 0.2
rs199650837 A/T 58,126,153 0.000943 Stop-gained 0.6
rs140465731 C/T 58,126,340 0.000471 Missense 0.15
Table 5.3: List of causal variants used in simulation study. Stop-gained: leading to a gain of a stop codon. Missense: leading to an amino acid
change. Abbreviations: MAF, minor allele frequency; Ref, reference; Alt, alternative.
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5.6.3 Results
Dataset 1
Figure 5.2: Mirrored Manhattan plot of dataset 1, comparing alternative rare variant
tests within a Cox PH model. Red line: Genome-wide significance
(
5 × 10−8) , Blue
line: Suggested significance
(
1 × 10−5) , Green line: Bonferroni corrected exome-wide
significance
(
4.0 × 10−6) .
Figure 5.2 presents the results from the analysis of the first simulation study dataset
using both a BT andMadsen-Browning weighted BT in a Cox PHmodel. The mirrored
Manhattan plot shows us that both methods were successful in identifying the FNDC1
gene with the causal variants. The FNDC1 gene is highly associated with the phenotype
using the weighted burden test at a Bonferroni corrected significance level for the total
number of genes (12,432 genes) at 4.0 × 10−6 (represented in Figure 5.2 with a green
line). However, the association signal found by the unweighted burden test was not
significant at the corrected threshold but was close to the suggested significance line.
The p-values presented represent that of the Wald test. Table 5.4 shows a summary of
the top genes found by both rare variant tests, comparing estimation using the Wald
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and LRT. There is close agreement between the p-values of all 4 tests for FNDC1, with
the Wald test p-value from the Weighted BT as the most significantly associated.
Many other genes represented in Table 5.4 are significantly associated with the sim-
ulated TTE outcome. All of the genes have very low total MAF, which is indicative
of a false positive association. The variants within these genes may be similar to the
variants from the FNDC1 gene in terms of the minor allele for each individual at each
variant. Only the gene HTR3D is significantly associated at the Bonferroni corrected
threshold of 4.0×10−6. All associated genes other than FNDC1, have a smaller number
of aggregated rare variants and it is likely that if most of the variants in these genes are
similar to the causal variants within FNDC1 then it is reasonable to assume that the
genes would show strong association with the TTE outcome. Furthermore, the sample
size for this dataset is relatively small. Therefore, the minor allele at a rare variant
may, by chance, appear in an individual with an extreme trait value. The gene-based
analyses, only need a few of these rare variants to generate a highly significant result,
where the chance of such an outcome increases as the sample size decreases.
The accumulation of the simulated effect for dataset 1 was 0.6 across 15 variants.
There were 25 variants in total within FNDC1, with 10 variants with unknown effects
on outcome (i.e. not included in the simulation model). The average known estimate
of the HR for the simulated burden would be e(0.6×15)/25 = 1.433329. The estimated
HR from the BT is 1.31861988. The HR is underestimated because of the inclusion of
non-causal variants in the analysis.
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Gene CHR
Rare
Count
MAF Total WaldPBurden LRTPBurden WaldPMB LRTPMB
ESYT3 3 10 0.000236 0.000171 8.53 × 10−5 0.003013 9.93 × 10−4
HTR3D 3 5 0.000236 8.01 × 10−7 3.42 × 10−6 2.70 × 10−10 1.23 × 10−6
FNDC1 6 25 0.000943 1.22 × 10−5 2.54 × 10−5 2.13 × 10−6 1.64 × 10−5
MTFR1L 1 3 0.000236 4.54 × 10−5 0.001331 2.62 × 10−5 0.001317
SLC44A3 1 2 0.000236 7.96 × 10−5 0.006332 7.96 × 10−5 0.006332
CCDC150 2 3 0.000472 6.23 × 10−5 0.002874 6.23 × 10−5 0.002874
INSIG1 7 3 0.000472 2.65 × 10−5 0.001281 1.46 × 10−4 0.003591
NDUFAF5 20 3 0.000708 2.63 × 10−5 0.000718 4.23 × 10−5 0.001449
ARSH 23 3 0.000236 2.99 × 10−5 0.006049 2.99 × 10−5 0.006052
TTC16 9 3 0.000708 0.003641 0.000935 0.002806 8.09 × 10−5
Table 5.4: Table of significantly associated genes from FNDC1 simulated data. Abbreviations: CHR,
chromosome; LRT, likelihood ratio test; MB, Madsen-Browning.
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Dataset 2
Figure 5.3: Mirrored Manhattan plot of dataset 2, comparing alternative rare variant
tests within a Cox PH model. Red line: Genome-wide significance
(
5 × 10−8) , Blue
line: Suggested significance
(
1 × 10−5) , Green line: Bonferroni corrected exome-wide
significance
(
4.0 × 10−6) .
In contrast to the data simulated using the FNDC1 gene, OR5B17 contained a smaller
set of SNPs with each variant contributing to the underlying association signal. The
results of theOR5B17 gene analysis was found to be inconsistent between the four tests.
OR5B17, shows strong association when analysed using the classical BT, but not at
exome-wide significance. The discrepancy between the p-values for each test could be
due to the variety of low to intermediate effects for the causal variants the TTE outcome
was simulated with.
Similarly to the results from the FNDC1 dataset, Table 5.5 shows a number of signifi-
cantly associated genes for the OR5B17 simulated dataset. As mentioned earlier these
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associations are most likely the result of the small sample size, very low MAF and
similarities between the variants in those genes with the variants in the OR5B17 gene
for which the TTE outcome was simulated.
The accumulation of the simulated effect for dataset 2 was 0.2625 across 4 variants.
There were 4 variants in total for the gene OR5B17 all contributing to the effect on
outcome within the simulation model. The average known estimate of the HR for the
simulated burden would be e0.2625 = 1.300176. The estimated HR from the BT is
1.78928621. The average effect per minor allele for the BT, is inconsistent with the
average simulated effect.
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Gene CHR
Rare
Count
MAF Total WaldPBurden LRTPBurden WaldPMB LRTPMB
RSPH1 21 2 0.000236 1.98 × 10−10 0.000142 1.98 × 10−10 0.000142
HHIPL2 1 8 0.004481 0.000279 3.58 × 10−5 0.007074 0.001859
OR5B17 11 4 0.000472 9.75 × 10−6 4.79 × 10−5 0.025496 0.044330
SLC14A1 18 4 0.000708 6.19 × 10−7 0.000171 1.31 × 10−5 0.000652
ITGA8 10 12 0.000236 0.117635 0.126302 3.63 × 10−5 0.000383
WDR87 19 6 0.015566 0.002192 0.001404 0.001253 0.000225
Table 5.5: Table of significantly associated genes from OR5B17 simulated data. Abbrevitions: CHR,
chromosome; LRT, likelihood ratio test; MB, Madsen-Browning.
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5.6.4 Performance
The entire analysis was run using 5 computer nodes (40 cores). Each node consisted of
a HP Proliant DL170h G6 server, 2 Intel Xeon(R) E5520 2.27GHz quad-core CPUs, 36
GB memory and 1 TB of local storage. Running the complete gene-based analysis of
each dataset using a Cox PH model with a BT and weighted BT under our simulation
study setting with no additional covariates took ≈20 hours to complete (4 sets of
analysis). The more covariates added to the analysis the longer the computational
runtime. Computational runtime is highly dependent on sample size, missing values
within the sample file, size (i.e. the number of variants) and compression status of
the genotype file. The largest contributing factor is ultimately the specifications of the
computing resource available to the user. Only the run times for the FNDC1 simulated
data are presented in Table 5.6 because both datasets have identical sample size and
number of genes. The Madsen-Browning weighted BT effects the runtime minimally.
Approximately a tenth of a second slower to complete the analysis of theFNDC1 dataset
compared to the classical BT.
Number of covariates Runtime
0 324.198 minutes
Treatment (Binary) 378 minutes
Treatment &
Age (Continuous)
445.2 minutes
Table 5.6: Computational runtime of the simulation study analysis using rareSurvival
with and without additional covariates. Number of covariates including adjustment for
each gene. Computational runtime of FNDC1 simulated data analysis using BT within
a Cox PH model.
5.7 Discussion
rareSurvival is a new analysis program for RVAS with TTE outcomes. The utility of
rareSurvival has been demonstrated through analysis of exome-array simulated data
using the novel methodology that combines aggregated tests of association within a
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regression framework for survival outcomes. A caveat, as with most rare variant
association software the analysis process is slow, though it can be increased with the
separation of data into smaller sets, i.e. by chromosome, and linking each separated
genotype file to its corresponding gene list file. rareSurvival is the first analytics
software capable of applying a variety of survival analysis models together with gene-
based tests of association to population-based RVAS data.
rareSurvival will play a key role in the discovery of novel genes associated with
patient response to treatment for a range of complex human traits and diseases. Using
rareSurvival for the combination of sequence-based genetic data with clinical data will
help us better understand the genetic architecture of complex diseases, facilitating the
translation of statistical results into practical solutions to advance disease prediction
and treatment.
RVAS and GWAS should be considered as complementary to one another in the search
for causal variants for a number of complex traits and diseases. Methodology and
software development for RVAS together with the ongoing effort for GWAS will result
in improvedmodelling ofTTEoutcomes. With the advancements towardsNGSdata and
the pursuit of the analysis of more complex outcomes, future versions of rareSurvival
will incorporate multifaceted survival models, together with the latest rare variant
analysis methods, to account for non-PH, competing risks, variable variant effect sizes
and directions. The use of both rareSurvival and SurvivalGWAS_SV are demonstrated
through the analysis of the Pharmacogenetics of Acute Coronary Syndrome study data
in the next chapter.
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CHAPTER 6
PHARMACOGENETICS OF ACUTE CORONARY
SYNDROME
The objective of this chapter was to apply SurvivalGWAS_SV and rareSurvival to the
Pharmacogenetics of Acute Coronary Syndrome (PhACS) study data. The primary
aim was to investigate the genetic basis of recurrence of coronary events and all-cause
mortality following a primary acute coronary event. The secondary aim was to test the
performance of the software through the application to this genome-wide association
study (GWAS) of common and rare variants. Details of the study design, quality
control (QC) procedure, exploratory analysis of covariates, association analyses and
further investigation of significant variants and genes are provided.
6.1 Background
6.1.1 Cardiovascular Disease
Acute Coronary Syndrome (ACS) is classified as a cardiovascular disease (CVD) that
occurs in situationswhere the blood supplied to the heart is abruptly blocked. Both heart
attacks and myocardial infarction (MI) come under the term ACS, which is the leading
cause of mortality worldwide (http://www.who.int/mediacentre/factsheets/fs310/en/),
affecting more than 7 million people in the UK alone, of which an estimated 160,000
deaths occur each year (BHF 2017).
Many therapeutic options exist for the treatment of ACS, ranging from prescription
drugs (such as aspirin, clopidogrel, statins and beta-blockers), through to surgical
intervention, such as percutaneous coronary intervention (PCI) and coronary artery
bypass grafting (CABG). There is significant inter-patient variability in response to
cardiovascular drugs, and factors contributing to this include patient demographics
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(e.g. age, gender) and medical history (e.g. smoking status) (Winham et al. 2015,
Turner et al. 2015, El Desoky et al. 2006). More recently, researchers have searched for
a genetic basis to this variability. Many studies are investigating this issue, which has
generated some statistically significant findings: e.g. SNPs inCYP2C19 forClopidogrel
(Dean 2015) and ADRBI for Beta-blockers (Shin & Johnson 2010). Franchini (2016)
provides an overview of candidate gene studies and GWAS conducted for ACS.
6.1.2 Study Objective
The objective of PhACS was to investigate the association between genetic variants and
treatment response, in terms of mortality, non-fatal myocardial infarction, non-fatal
stroke, bleeding events and cardiac failure after an acute coronary event.
6.1.3 Study Design
PhACS is a UK prospective pharmacogenetic cohort study involving 1,470 patients
who have had an ACS as their main diagnosis at hospital admission. Patients were then
followed up prospectively for up to 48months after dischargewith patient demographics
and relevant clinical factors recorded. Turner et al. (2017) describes the study design
and cohort selection in detail.
6.1.4 Phenotypes
The time-to-event (TTE) outcome was defined as corresponding to the occurrence of
any of the following events after hospital discharge (D/C): MI, stroke or cardiovascular
death. The primary outcome was the time to any one of the following outcomes,
whichever occurred first after baseline D/C to the end of the study: cardiovascular
mortality, non-fatal MI or non-fatal stroke. If none of these events occurred during
follow-up, patients were censored either at death for non-cardiovascular reasons or
end of follow-up, whichever occurred first. The secondary TTE outcome was time to
all-cause mortality after D/C. If mortality did not occur, patients were censored at the
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end of follow-up. Throughout this chapter, time to cardiovascular event will be referred
to as the primary outcome and time to all-cause mortality as the secondary outcome.
6.1.5 Genotype Data
Patients were genotyped using the Illumina Omni Express array. Furthermore, the
design of the array adopted a comprehensive genotyping strategy to maximise the
genome coverage, which involved using data from the HapMap (Altshuler et al. 2010),
1000 Genomes Project (Auton et al. 2015) and previous literature, to genotype all
common functional variants and tagging SNPs, as well as rare variants ensuring that
the diversity of the whole genome is accounted for.
6.1.6 Quality Control Procedure
Before the association analyses, a comprehensive QC procedure was initiated using the
protocol outlined in Section 1.2.3. This procedure was carried out using the software
PLINK (Purcell et al. 2007) and QCTOOL (http://www.well.ox.ac.uk/~gav/qctool_v2/
documentation/alphabetical_options.html). The raw data based on all available samples
were in PLINK binary (BED, BIM, FAM) format before being converted into GEN
format. Genotype imputation was conducted using IMPUTE2 (Howie et al. 2012), and
the 1000 Genomes Project (Auton et al. 2015) data.
6.2 Analysis Plan
The initial step of analysis was to identify possible significantly associated clinical
risk factors for drug response. This selection method was undertaken using a stepwise
Cox proportional hazard (PH) regression framework, implementing both forwards
and backwards selection to identify a model of significant covariates, eliminating
factors from the model which were no longer significant at a Wald p-value significance
threshold of 0.05. This analysis was carried out for both the primary and secondary
TTE outcomes.
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Information on several non-genetic factors collected throughout the study are sum-
marised into four categories; patient demographics, medical history, drugs given to
patients from baseline hospital admission and other treatment (see Table 6.1). These
non-genetic factors are often treated as confounders, though the role of a confounder
should be further investigated via criteria of confounding (Greenland et al. 1999). The
controlling for confounders is done to remove bias of the estimated association between
the genetic factor and the outcome (Greenland et al. 1999, Shmueli 2010). A further
note on the selection of covariates is in Shmueli (2010) who emphasises that the selec-
tion depends on the role of analysis: if it is predictive (or prognostic) vs explanatory
(causal).
Factor Category Covariate Description
Patient
Demographic
Site Two sites: Liverpool & Blackpool.
Age Range from 26 to 94 years old.
Sex Male = 0, Female = 1.
BMI Body mass index.
Medical
History
Hypertension High blood pressure.
Hyperlipidaemia High levels of lipids e.g. cholesterol.
CRF Chronic renal failure.
Diabetes mellitus Type 1 and 2.
Prior MI Prior Myocardial Infarction (up to 5
years before admission).
Past TIA or stroke Prior Transient Ischaemic Attack with
neurological deficit lasting less than 24
hours (up to 5 years before admission).
Smoking status Non-Smoker (0) - Never smoked.
Current smoker (1) - within past 3
months. Previous-smoker (2) - stopped
smoking for more than 3 months.
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Table 6.1 continued from previous page
Troponin1 level Troponin index raised or normal.
Drugs (D/C)
Aspirin On treatment=1, if not = 0.
Clopidogrel On treatment=1, if not = 0.
Beta blocker On treatment=1, if not = 0.
Statin On treatment=1, if not = 0.
ACEI On treatment=1, if not = 0.
Aldosterone
antagonist
On treatment=1, if not = 0.
Other
Treatment
PCI Percutaneous coronary intervention.
CABG Coronary artery bypass grafting.
Beta-blocker (A/D) Beta-blocker taken before admission
into hospital.
ACEI (A/D) Angiotensin-converting enzyme
inhibitor.
Table 6.1: PhACS study clinical factor information. Abbreviations: PCI, percutaneous
coronary intervention; MI, myocardial infarction; TIA, transient ischaemic attack;
ACEI, angiotensin-converting enzyme inhibitor; D/C, after hospital discharge; A/D,
before hospital admission.
Each significant (p < 0.05) factor from the stepwise Cox PH model was graphically
visualised through Kaplan-Meier curves and tested for violation of the PH assumption
through Schoenfeld residuals (Schoenfeld 1982) and diagnostic −log(log(S(t)) vs.
log(t) plots.
The association analysis involves testing for the association of each genetic variant
passing QC with both TTE outcomes separately using a Cox PH model, assuming an
1Troponin is a protein that is released into the bloodstream during a heart attack (https://www.bhf.org.uk/
heart-matters-magazine/medical/ask-the-experts/troponin).
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additive dosage model. Adjustments are made for the significant clinical factors found
using the stepwise regression model and principal components (PCs) to account for
population structure (see Section 1.2.4) in the association analyses. The analyses are
performed using SurvivalGWAS_SV.
Evaluating the evidence for association of each outcome with rare variants within each
gene was conducted using a gene-based burden test (BT) within a Cox PH framework
implemented in rareSurvival. Again, these analyses have been adjusted for non-genetic
factors and PCs identified as significant. The gene-based analyses focussed on assessing
rare variants using the gene classifications/annotations attained from the UCSC genome
browser gene classification list (Kent et al. 2002). Each row in the list contains a
transcript, which is a set of exons and a gene can contain multiple transcripts. The
significance is based on a Bonferroni corrected threshold for the number of transcripts
analysed. The threshold is 0.05/70663 = 7.07 × 10−7.
For both single-variant and gene-based approaches, all analyses include all patients
with complete phenotype and significant covariate information. The output of interest
from the analyses is the p-value, which will be used to identify statistically significant
genetic loci through the visualisation of Manhattan plots. All QC procedures and
analyses were undertaken with a server comprising 8 computer nodes (64 cores). Each
node consisted of an HP Proliant DL170h G6 server, 2 Intel Xeon(R) E5520 2.27GHz
quad-core CPUs, 36 GB memory and 1 TB of local storage.
All significant SNPs found using the single-variant approach were further analysed
through Kaplan-Meier curves in R (R Core Team 2013), to distinguish the survival
between patients split by genotype group. Biological information used throughout Sec-
tion 6.3, regarding gene function is provided by GeneCards, the human gene database
(Safran et al. 2010) (http://www.genecards.org/) and UniProt, the central hub database
for functional information on proteins (UniProt 2017). This information was used to
link any of the significantly associated genes found from both the single-variant and
rare-variant analyses to pathways and expression that may affect cardiovascular events
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or mortality.
6.3 Results
6.3.1 SNP QC
500,387 SNPs with high missing genotype rate (> 5%) were removed from a total of
2,252,914 SNPs. A test for HWEwas undertaken at each SNP using Fisher’s exact test.
A further 1,154,473 SNPs were removed due to deviation from HWE at the threshold
p < 0.0001. Before checking for duplicated/related individuals, markers were removed
using linkage disequilibrium (LD) based pruning, removing markers with high LD
regions (LD > 0.2)
6.3.2 Sample QC
72 individuals were removed with low sample call rate (< 95%). Two individuals were
removed due to an event time of 0 days recorded. These two patients were censored
during the time between admission into hospital and discharge from the hospital.
Four individuals were removed due to duplication and two due to the relatedness
between samples. This was calculated using the identity-by-state (IBS) matrix and
identity by descent (IBD) coefficient. Gender checks against collected clinical data
were undertaken, removing seven individuals that failed to match.
Population structure was investigated through principal components analysis (PCA)
for the merged study data and Hapmap3 data populations: (i) Utah residents with
Northern and Western European ancestry (CEU); (ii) Han Chinese in Beijing (CHB);
(iii) Japanese in Tokyo (JPT); and (iv) Yoruba in Ibadan (YRI). 17 ethnic outliers were
identified and excluded. PCA was conducted again without the HapMap3 data. The
R package ‘SNPRelate’ (Zheng et al. 2012) was used to perform the PCA. Figure 6.1
shows the amount of population variation explained by each of the first six PCs. It can
be noted from Figure 6.1 that the first two PCs explain the majority of the population-
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specific variation. The other PCs explain very little of the variance. Therefore only
the first two PCs have been adjusted for in the association analyses. After applying
Figure 6.1: Proportion of variation explained by principal components. Calculated
using the ‘SNPRelate’ package.
sample and SNP quality control, 1367 samples and 598, 054 SNPs remained. The data
were then imputed up to the 1000 Genomes Phase I reference panel for all ancestries
(March 2012 release). Imputation was performed using software packages, SHAPEIT2
(O’Connell et al. 2014) and IMPUTE2.
After imputation QC the data were separated into variants with MAF > 0.01 (low to
common frequency variants) and MAF < 0.01 (rare variants). A MAF of < 0.01
was chosen because imputation using the 1000 Genomes reference panel produces a
high proportion of low-frequency variants. Both sets were filtered for variants with
an imputation accuracy (info-score) > 0.4. A total of 8,788,380 SNPs remained for
the single-variant analysis and 5,253,064 SNPs over 70663 functional units (defined
as gene boundaries using the UCSC genome browser) remained for the rare-variant
analysis.
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6.3.3 Exploratory Analysis of Clinical Covariates
Demographics and clinical risk factors were tested for association with the primary
and secondary outcomes using a Cox PH framework. The proportion of right-censored
observations for the primary outcome was 86.24% (188 patient events and 1179 patient
non-events). Median event free survival was 1658 days.
HR 95% LCI 95% UCI PWald
Age 1.042 1.027 1.056 9.02 × 10−9
Prior MI 1.921 1.417 2.603 2.57 × 10−5
ACEI A/D 1.579 1.172 2.128 0.00268
Aldosterone antagonist 2.047 1.255 3.339 0.00408
CRF 1.544 1.034 2.307 0.03387
Table 6.2: PhACS: Primary outcome stepwise regressionmodel output. Abbreviations:
HR, hazard ratio; LCI, lower confidence interval for hazard ratio; UCI, upper confidence
interval for hazard ratio; PWald , the p-value calculated using theWald test; CRF, chronic
renal failure;MI,myocardial infaction; ACEI, angiotensin-converting enzyme inhibitor;
A/D, before admission.
Several risk factors were identified to be significantly associated with the primary
outcome as displayed in Table 6.2. Older patients are more likely to have an occurrence
of a cardiovascular event (HR = 1.042, 95% CI = 1.027-1.056). Patients with medical
history such as previous heart attack and chronic renal failure have an increased hazard
of a recurrent cardiovascular event than thosewithout this medical history (PriorMI:HR
= 1.921, 95% CI = 1.417-2.603; CRF:HR = 1.544, 95% CI = 1.034-2.307). Use of
ACE inhibitors prior to admission was associated with an increased hazard of an event
compared with patients not taking the drug (HR = 1.579, 95% CI = 1.172-2.128). Even
though this is a treatment for high blood pressure, they are often prescribed because
the individual has previously had a heart attack. Therefore it is not unusual to see that
individuals have an increased hazard of a cardiovascular event occurring when taking
ACEI because they have had a priorMI which is also highly associated with the primary
outcome. Patients using Aldosterone antagonist after hospital discharge are twice as
likely to have an event (HR = 2.047, 95%CI = 1.255-3.339). A patient using a particular
drug pre-admission or after hospital discharge may indicate the health condition of an
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individual and will ultimately affect the patient’s survival outcome. The secondary
HR 95% LCI 95% UCI PWald
Age 1.079 1.059 1.099 3.33 × 10−16
Prior MI 1.564 1.095 2.236 0.01404
PCI 0.533 0.316 0.899 0.01845
CRF 1.698 1.099 2.623 0.01706
Hyperlipidaemia 1.654 1.134 2.423 0.00905
Statin 0.457 0.264 0.791 0.00512
Aspirin 0.565 0.346 0.923 0.02258
Table 6.3: PhACS: Secondary outcome stepwise regression model output. Abbrevi-
ations: HR, hazard ratio; LCI, lower confidence interval for hazard ratio; UCI, upper
confidence interval for hazard ratio; PWald , the p-value calculated using the Wald test;
CRF, chronic renal failure; MI, myocardial infarction; PCI, percutaneous coronary
intervention.
outcome has a proportion of 90.4% censored observation (131 patient events compared
to 1236 patient non-events). Many of the same clinical factors associated with the
primary outcome are significantly associated with all-cause mortality (see Table 6.3),
such as CRF, older age and previous history of heart attack. Patients that have had
CRF or prior MI are at an increased hazard of mortality (Prior MI: HR = 1.564, 95%
CI = 1.095-2.236; CRF: HR = 1.698, 95% CI = 1.099-2.623). Older patients are more
likely to have an event that causes mortality (HR = 1.079, 95% CI = 1.059-1.099).
PCI is associated with a reduced hazard of mortality, where half as many patients
experience the event compared to those that have not had surgical intervention (HR
= 0.533, 95% CI = 0.316-0.899). Patients with hyperlipidemia have 1.6 times the
likelihood of mortality (HR = 1.654, 95% CI = 1.134-2.423). Patients who take statins
or aspirin after discharge have a reduced hazard of mortality than those not taking these
drugs (Statins: HR = 0.457, 95% CI = 0.264-0.791; Aspirin: HR = 0.565, 95% CI =
0.346-0.923).
6.3.4 Diagnostic Plots of Clinical Covariates
The Kaplan-Meier curve for prior MI shown in Figure 6.2 suggests event-free (cardio-
vascular event) survival amongst patients with no previous MI is significantly better
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Figure 6.2: Prior Myocardial Infarction: Kaplan-Meier, diagnostic PH assumption plot
and a summary table of at-risk individuals for the primary outcome.
than those that had a prior MI. The diagnostic plot indicates that the PH assumption
holds, however showing a slight deviation when the sample size within the risk set is
low. This observation cannot be considered a violation of the PH assumption.
Use of ACE inhibitors pre-hospital admission is shown to increase the likelihood of a
cardiovascular event (Figure A.1). The PH assumption holds for the majority of event
times. Individuals taking aldosterone are depicted in Figure A.2 for having a significant
reduction in survival. Median event-free survival is estimated to be at approximately
950 days for those on aldosterone and about 1680 days for those not. However, the
sample size is small. The diagnostic plot is in keeping with the PH assumption.
Figure A.3 compares those with and without CRF. The survival of the two groups is
statistically significant, indicating that those with CRF are more likely to experience a
cardiovascular event. The PH assumption holds for CRF.
Age is a continuous covariate, such that the proportionality assumption is assessed
using Schoenfeld residuals as shown in Figure 6.3. From the top left plot of Figure 6.3,
the residuals for age have distinctively no pattern with time. Consequently, it is not in
violation of the PH assumption. Assessing all the significant binary covariates again
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with the primary outcome, but through Schoenfeld residuals, all show a very minimal
pattern with time, none of which form two distinct lines of residuals, therefore, PH hold
for all non-genetic factors.
Kaplan-Meier plots for the secondary outcome are located in Appendix A, Figure
A.4 shows that those with no history of prior MI have better survival than those
that have had an MI. Figure A.5 tells us that having the PCI treatment intervention
reduces the risk of mortality. Patients with hyperlipidemia have a minimal reduction
in survival up to 800 days as shown in Figure A.6, after this the difference between
the two groups is statistically significant. Figure A.7 suggests that patients with CRF
have reduced survival compared to those without CRF. As Figure A.8 illustrates, the
survival probability of patients taking aspirin after discharge significantly improved as
opposed to those, not on aspirin. The majority of patients have been given aspirin after
discharge. However, all are taking multiple treatments. Patients taking statins show an
improvement in survival (see Figure A.9) over those not on statins, in the same way as
aspirin; however, the difference is less statistically significant. All significant binary
covariates for the secondary outcome, show parallel event times with no crossing
hazards which supports the PH assumption (see Figure A.4 to A.9). Figure A.10
depicts Schoenfeld residual plots for age and all significant binary clinical covariates.
All covariates show a random pattern with time indicating that the PH assumption
holds.
6.3.5 Single Variant Association Analysis
All patients were analysed using a Cox PH model to estimate the association of each
variant with the primary and secondary TTE outcomes. A Cox PH model was fitted to
the number of copies of the minor allele at each SNP, significant covariates and PCs
accounting for right censored data. A Wald test (see Section 1.3) was conducted to
obtain the p-values.
Figure 6.4 summarises the p-values from the Cox PH for all SNPs. The GWAS of the
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Figure 6.3: Schoenfeld residual plot for each significant clinical factor with the primary
outcome.
primary outcome adjusting for significant clinical covariates and the first two principal
components yielded six loci at genome-wide significance
(
5 × 10−8) . Table 6.4 is a
summary of significant SNPs identified from the GWAS analysis. All significant SNPs
have been investigated further individually through Kaplan-Meier plots comparing
event survival by genotype, to distinguish the differences between carriers and non-
carriers in the study cohort. LocusZoom plots were also produced to identify the
LD between the significant SNPs and nearby variants based on European ancestry
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individuals from the 1000 Genomes Project.
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SNP Gene CHR MAF Info HR 95% LCI 95% UCI p-value
rs113348424 Unknown 14 0.013 0.706 8.806 4.283 18.107 3.33 × 10−9
rs148409050 IMMP2L 7 0.011 0.883 6.346 3.397 11.854 6.80 × 10−9
rs144599889 IMMP2L 7 0.011 0.882 6.305 3.382 11.756 6.90 × 10−9
rs56045815 CTNNA2 2 0.030 0.906 3.102 2.082 4.621 2.60 × 10−8
rs71472467 INO80 15 0.012 0.897 4.857 2.779 8.487 2.86 × 10−8
rs34610018 Unknown 15 0.016 0.914 4.327 2.542 7.367 6.82 × 10−8
Table 6.4: Summary of significant SNPs from single-variant primary outcome analysis. Abbreviations:
CHR, chromosome; MAF, minor allele frequency; HR, hazard ratio; Info, info-score of imputation
quality; LCI, lower confidence interval; UCI, upper confidence interval. p- value is calculated using
the Wald test.
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Figure 6.4: Manhattan plot results for the single variant Cox PH analysis of the primary
outcome. Red line represents genome-wide significance threshold 5 × 10−8. Blue line
represents suggestive significance line. Each point represents a SNP.
Themost significantly associatedSNPwith time to cardiovascular eventwas rs113348424(
3.33 × 10−9) found on chromosome 14. The top left plot in Figure C.1 shows
the cardiovascular event-free survival probability separated by genotype for the SNP
rs113348424. From this, we can deduce that patients that carry the minor allele A are
more likely to have a cardiovascular event relative to those that carry the G allele (HR
= 8.806, 95% CI = 4.283-18.107). This SNP does not map to a gene but is located
between the LINC00639 and SSTR1 genes. Figure B.1 shows that it is in very low LD
(r2 < 0.4) with two other SNPs.
The statistically significant SNPs rs148409050 and rs144599889 on chromosome 7
are located in the IMMP2L gene. Figure 6.6 shows that those with the heterozygous
genotype TC at SNP rs148409050, have a significantly higher probability of a recurrent
cardiovascular event occurring earlier than those with a homozygous genotype. A HR
of 6.346 (95% CI = 3.397-11.854, p = 6.80× 10−9), suggests that individuals carrying
one copy of the C allele have an increased hazard of an event compared to individuals
carrying two copies of the T allele. Themedian event-free survival time for patientswith
the heterozygous genotype is approximately 790 days compared to the T homozygous
group which have a median event-free survival of approximately 1650 days. Likewise,
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Figure 6.5: Association of rs148409050 with time to cardiovascular event. LocusZoom
plot of the region associated with the primary outcome on chromosome 7 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs148409050 shown in purple
and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs148409050 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
the top middle plot in Figure C.1, for rs144599889, shows that event-free survival is
significantly reduced for those carrying the C allele in contrast to those that carry the T
allele (HR = 6.305, 95% CI = 3.382-11.756, p = 6.90×10−9). The median survival for
those with the heterozygous genotype is ≈780 days. Figure 6.5 shows that rs148409050
in the intron2 region is highly correlated with its neighbouring SNP rs144599889 (also
shown in Figure B.2). The SNP is also in moderate LD with many other variants within
and near to the IMMP2L gene. IMMP2L is a protein-coding gene. This gene encodes a
protein involved in processing the signal, peptide sequences used to directmitochondrial
proteins to the mitochondria (https://ghr.nlm.nih.gov/gene/IMMP2L#normalfunction).
Mitochondria are organelles found in almost all cells. They essentially provide energy to
the cell by converting oxygen and nutrients into adenosine triphosphate. Mitochondrial
proteins are one of the necessary proteins for the catalytic activity of the mitochondrial
2An intron is the non-coding sequence in the gene. They can interrupt exons.
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inner membrane peptidase complex.
The bottom left plot showing rs56045815 in Figure C.1 illustrates that the carriers of
the C minor allele have a shorter survival time than those that have both copies of the
G allele (HR = 3.102, 95% CI = 2.082-4.621, p = 2.60 × 10−8). The SNP rs56045815
is shown to be in moderate to high LD with another SNP just below genome-wide
significance (see Figure B.3). rs56045815 (intron) is located in the protein-coding
gene CTNNA2. Diseases associated with CTNNA2 include mixed germ cell cancer.
Among its related pathways are arrhythmogenic right ventricular cardiomyopathy and
Sertoli-Sertoli cell junction dynamics (http://www.genecards.org/cgi-bin/carddisp.pl?
gene=CTNNA2). With its association with right ventricular cardiomyopathy, CTNNA2
may play a vital role in the likelihood of having a cardiovascular event. Right ventricular
cardiomyopathy can weaken the walls of the ventricle by thinning and stretching the
chambers, increasing the risk of sudden cardiac death.
The bottom middle plot in Figure C.1 shows that patients with one copy of the C
allele at SNP rs71472467, have an increased hazard of a cardiovascular event than
those with two copies of the A allele (HR = 4.857, 95% CI = 2.779-8.487, p =
2.86 × 10−8). rs71472467 (intron) on chromosome 15 located in the INO80 gene,
encodes a subunit of the chromatin remodelling complex. This protein is proposed to
bind DNA and be recruited by the YY1 transcription factor to activate certain genes
(https://www.ncbi.nlm.nih.gov/gene/54617). Figure B.4 shows that it is in high LD
with a SNP in the OIP5 gene and in moderate LD with the SNP, rs34610018, close to
INO80, that is genome-wide significant for the primary outcome (see Figure B.5). The
plot for rs34610018 shown in the top right corner of Figure C.1 shows that patients
carrying one copy of the A allele have a median survival time of ≈1300 days compared
to ≈1650 days in the group of individuals that carry two copies of the G allele. (HR =
4.327, 95% CI = 2.542-7.367, p = 6.82 × 10−8).
In summary, Figures 6.6 and C.1 all show that individuals with the heterozygous
genotype for each significant SNP are at an increased risk of a cardiovascular event.
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There is a large disparity between the sample size in each of the genotype groups.
SNPs with a larger MAF would have a more balanced sample size within the groups
contributing to increased power for detection.
Figure 6.7 shows multiple loci associated with time to all-cause mortality. A total of
ten SNPs were found to be genome-wide significant
(
5 × 10−8) . The Cox PH model
output for each of the SNPs is summarised in Table 6.5. The top left plot in Figure C.2
displays the survival curves for the SNP rs141689913. Patients who carry one copy
of the allele A have significantly reduced survival compared to those that carry two
copies of the T allele (HR = 6.424, 95% CI = 3.407-12.109, p = 8.94 × 10−9). The
LocusZoom plot of SNP rs141689913 in Figure B.6 shows that the SNP is in low LD
with five other neighbouring SNPs.
Figure 6.6: Kaplan-Meier plot by rs148409050 genotypes. T is the major allele and C
is the minor allele. Time scale is in days. Median survival time is indicated with the
black dotted line.
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SNP Gene CHR MAF Info HR 95% LCI 95% UCI p-value
rs141689913 Unknown 7 0.015 0.663 6.424 3.407 12.109 8.94 × 10−9
rs199571837 Unknown 14 0.035 0.739 4.593 2.703 7.803 1.73 × 10−8
rs191847613 Unknown 14 0.029 0.805 4.568 2.674 7.806 2.72 × 10−8
rs12402659 Unknown 1 0.028 0.926 4.463 2.633 7.564 2.76 × 10−8
rs190226855 Unknown 12 0.021 0.895 4.606 2.680 7.914 3.21 × 10−8
rs148484124 URGCP - MRPS24 7 0.017 0.902 4.869 2.750 8.622 5.60 × 10−8
rs2695973 Unknown 5 0.028 0.964 0.212 0.121 0.371 5.76 × 10−8
rs76428855 MRPS25 3 0.012 0.439 15.598 5.761 42.234 6.47 × 10−8
rs141058803 Unknown 7 0.018 0.909 4.835 2.725 8.579 7.16 × 10−8
rs141503732 SSPO 7 0.011 0.543 11.718 4.757 28.862 8.75 × 10−8
Table 6.5: Summary of significant SNPs from single-variant secondary outcome analysis. Summary of significant
SNPs from single-variant primary outcome analysis. Abbreviations: CHR, chromosome; MAF, minor allele
frequency; HR, hazard ratio; Info, info-score of imputation quality; LCI, lower confidence interval; UCI, upper
confidence interval. p- value is calculated using the Wald test.
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Figure 6.7: Manhattan plot results for the single variant Cox PH analysis of the
secondary outcome. Red line represents genome-wide significance threshold 5× 10−8.
Blue line represents suggestive significance line. Each point represents a SNP.
Figure 6.8: Association of rs148484124 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 7 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs148484124 shown in purple
and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs148484124 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
According to the top middle and top right plots in Figure C.2, the SNPs rs199571837
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(HR = 4.593, 95% CI = 2.703-7.803, p = 1.73 × 10−8) and rs191847613 (HR = 4.568,
95% CI = 2.674-7.806, p = 2.72 × 10−8) on chromosome 14 show that patients with
one copy of the G allele have an increased hazard of mortality than those that carry both
copies of the T allele. Figure B.7 and B.8 show the LocusZoom plots for rs199571837
and rs191847613, respectively. Both these SNPs map close to the EML1 gene, with the
plot of the locus indicating an extended haplotype of SNPs following the association
of the lead SNP (rs199571837).
The Kaplan-Meier plot for SNP rs12402659 (middle left plot in Figure C.2) reports that
patients carrying one copy of the T allele have a reduced survival probability than those
carrying no copy of the T allele (HR = 4.463, 95% CI = 2.633-7.564, p = 2.76× 10−8).
Figure B.9 shows two SNPs in moderately high (0.6 < r2 < 0.8) LD to the SNP
rs12402659. One is located in the MARK1 gene that is known to be associated with
Alzheimer’s disease (http://www.genecards.org/cgi-bin/carddisp.pl?gene=MARK1).
The central plot in Figure C.2 shows that carriers of the T allele at SNP rs190226855
have reduced survival compared to those that have no copies of the T allele
(HR = 4.606, 95% CI = 2.680-7.914, p = 3.21 × 10−8). The regional plot for the SNP
rs190226855, represented in Figure B.10 does not reveal any SNPs in high LD with the
lead SNP.
The most interesting SNP from this discovery analysis was rs148484124 on chromo-
some 7 (Figure 6.8) because it is highly correlated with many neighbouring SNPs,
including rs141058803 (Figure B.12) which is also associated at the genome-wide
threshold with the secondary TTE outcome. There is also an abundance of differ-
ent genes occupying this locus. rs148484124 is located in the URGCP - MRPS24
gene. This locus represents naturally occurring read-through transcription between
the neighbouring URGCP (up-regulator of cell proliferation) and MRPS24 (mito-
chondrial ribosomal protein S24) genes (http://www.genecards.org/cgi-bin/carddisp.
pl?gene=URGCP-MRPS24). TwoSNPs in highLDwith rs148484124 and rs141058803
are located in the COA1 gene. Other SNPs are found in the BLVRA, UBE2D4 and
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POLR2J4 genes. However, none have any known association with the cardiovascular
system. The Kaplan-Meier plots for both the SNPs rs148484124 (Figure 6.9) and
rs141058803 (Bottom middle plot in Figure C.2) indicate patients with both copies of
the major allele A have greater survival probability than those that only have one copy.
The locus plot (Figure B.11) for rs2695973 located on chromosome 5 shows some
SNPs in moderate to low LD with the lead SNP, however, it does not map to a known
gene. The middle right Kaplan-Meier plot in Figure C.2 for SNP rs2695973 shows a
reduced probability of survival for the heterozygous genotype group.
SNP rs76428855 shown in the bottom left of Figure C.2 shows that median survival
for patients with one copy of the C allele is ≈560 days (HR = 15.598, 95% CI = 5.761-
42.234, p = 6.47 × 10−8). rs76428855 (intron) was found to be located in the protein-
coding gene, MRPS25. Among its related pathways are Mitochondrial translation and
organelle biogenesis and maintenance. MRPS25 helps in protein synthesis within the
mitochondrion (http://www.genecards.org/cgi-bin/carddisp.pl?gene=MRPS25). The
LocusZoom plot (see Figure B.12) shows that the SNP is not correlated with any other
variant.
The last significant SNP to map to a gene was rs141503732. The Kaplan-Meier plot
(Figure C.2) indicates that patients with the heterozygous genotype are more likely to
have a mortality causing event than those with the major homozygous genotype (HR =
11.718, 95% CI = 4.757-28.862, p = 8.75 × 10−8). This SNP is located in the SSPO
(SCO-Spondin) gene, which is a protein-coding gene. Among its related pathways are
HIV life cycle and O-linked glycosylation (http://www.genecards.org/cgi-bin/carddisp.
pl?gene=SSPO). In summary, all the associated SNPs have a low MAF and would
benefit from a replication study with larger sample size. The URGCP - MRPS24 gene
was the most promising candidate associated with all-cause mortality, containing the
SNP rs148484124, which is correlated with a plethora of other associated SNPs in the
flanking chromosome 7 region.
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Figure 6.9: Kaplan-Meier plot by rs148484124 genotypes. A is the major allele and C
is the minor allele. The timescale is in days. Median survival time is indicated with
the black dotted line.
6.3.6 Rare Variant Association Analysis
Results for all 70663 transcripts included in the gene-based analysis of rare variants
with the primary outcome are presented in Figure 6.10. The analysis using the BT with
unit-weighting within a Cox PHmodel produced a total of 10 gene-outcome association
signals found to be significant at a Bonferroni corrected threshold of 7.1× 10−7 for the
number of tests performed.
The top ranking gene that produced the lowest p-value was PRKAG3
(
p = 8.00 × 10−8)
on chromosome 2. The gene contained 16 rare variants which, when collectively
analysed using a BT within a Cox PH model produced a HR of 1.020 (95% CI =
1.013-1.028). This HR suggests that there is a very low increase in the hazard of a
recurrent cardiovascular event for individuals with an increased burden of rare variants.
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Gene CHR BP range Variant Count Total MAF HR 95% LCI 95% UCI p-value
PRKAG3 2 219,687,105-219,696,512 16 0.033 1.020 1.013 1.028 8.00 × 10−8
ARRDC1 9 140,500,095-140,509,811 8 0.025 1.071 1.045 1.097 4.01 × 10−8
LZTS2 10 102,756,964-102,767,585 16 0.041 1.038 1.024 1.052 4.30 × 10−8
ADGRE1 19 6,887,581-6,940,463 136 0.341 1.007 1.005 1.010 2.17 × 10−9
PABPC1L 20 43,538,702-43,567,962 68 0.146 1.008 1.006 1.012 1.30 × 10−8
PHF13 1 6,673,755-6,684,092 11 0.015 1.029 1.017 1.040 6.89 × 10−7
THAP3 1 6,685,209-6,695,645 28 0.064 1.013 1.008 1.018 3.56 × 10−7
DNAJC11 1 6,694,227-6,761,966 115 0.250 1.004 1.003 1.006 4.80 × 10−7
ZNF266 19 9,434,982-9,451,860 50 0.131 1.005 1.003 1.007 2.89 × 10−7
SPINT4 20 44,350,987-44,354,335 14 0.024 1.029 1.018 1.040 3.17 × 10−7
Table 6.6: Summary of significant genes from primary outcome analysis. Variant count includes all types of variants within the
functional unit. Abbreviations: CHR, chromosome; BP, base pair; MAF, minor allele frequency; HR, hazard ratio; LCI, lower
confidence interval; UCI, upper confidence interval. p- value is calculated using the Wald test.
163
Figure 6.10: Manhattan plot results for the rare variant analysis of the primary outcome,
using a BT within a Cox PH model. Red line represents genome-wide significance
threshold 5 × 10−8. The blue line represents suggestive significance line. Each point
represents a gene.
The protein encoded by this gene is a regulatory subunit of the AMP-activated protein
kinase. Genetic variants can be associated with increased glycogen content in skeletal
muscle. The gene is expressed strongly in skeletal muscle, but more weakly in the heart
and pancreas (https://www.ncbi.nlm.nih.gov/gene/53632).
The largest HR was for the protein-coding gene ARRDC1. This HR indicates that there
is a 7.1% increase in hazard per unit increase in the (weighted) count of the 8 rare
variants. ARRDC1 plays a role in the extracellular transport of proteins between cells
through the release in the extracellular space of microvesicles (https://www.uniprot.
org/uniprot/Q8N5I2).
On chromosome 1, three genes found in close proximity to one another are all sig-
nificantly associated with the primary outcome. PHF13, THAP3 and DNAJC11 are
all protein-coding regions. PHF13 modulates chromatin structure and has previously
been associated with ovarian cancer survival time (http://www.genecards.org/cgi-bin/
carddisp.pl?gene=PHF13). THAP3 is highly expressed in the heart, skeletal muscle
and placenta (http://www.uniprot.org/uniprot/Q8WTV1).
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The remaining associated variants were not found to be directly biologically linked
with the cardiovascular system through examination of literature and website searches.
LZTS2 is a protein coding gene that encodes the leucine zipper tumor suppressor family
of proteins, which function in transcription regulation and cell cycle control. It is
implicated in cancer, where it may inhibit cell proliferation and decrease susceptibility
to tumor development (http://www.genecards.org/cgi-bin/carddisp.pl?gene=LZTS2).
ADGRE1 encodes a protein that has a domain resembling seven transmembrane
G protein-coupled hormone receptors at its C-terminus (http://www.genecards.org/
cgi-bin/carddisp.pl?gene=ADGRE1). PABPC1L is a protein coding gene. Diseases
associated with PABPC1L include muscular dystrophy and rigid spine (http://www.
uniprot.org/uniprot/Q4VXU2). ZNF266 is a gene that encodes a protein containing
many tandem zinc-finger motifs. Zinc fingers are protein or nucleic acid-binding
domains, and may be involved in a variety of functions, including regulation of
transcription. ZNF266 is located in a cluster of similar genes encoding zinc fin-
ger proteins on chromosome 19 (http://www.genecards.org/cgi-bin/carddisp.pl?gene=
ZNF266). SPINT4 is a protein coding gene. GO annotations (http://geneontology.org/
page/go-annotations) related to this gene include serine-type endopeptidase inhibitor
activity (http://www.genecards.org/cgi-bin/carddisp.pl?gene=SPINT4).
In summary, according to the hazard ratios estimated in Table 6.6 for all significant
genes, all the HRs above 1 indicate a reduction in median survival time for patients
carrying minor alleles at rare variants, compared to those that do not.
The Manhattan plot for the gene-based analysis of the secondary outcome (see Figure
6.11) shows five genes to be significantly associated at a Bonferroni corrected threshold
of 7.1 × 10−7. The BT within a Cox PH model output is summarised in Table 6.7.
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Gene CHR BP range Variant Count Total MAF HR 95% LCI 95% UCI p-value
ISCA1 9 88,879,463-88,897,490 26 0.061 1.034 1.022 1.047 7.32 × 10−8
LIN52 14 74,181,825-74,227,001 90 0.175 1.007 1.004 1.009 1.76 × 10−8
RPTOR 17 78,518,624-78,831,924 536 1.644 1.001 1.001 1.002 4.07 × 10−7
DENND1C 19 6,467,218-6,481,798 40 0.074 1.014 1.009 1.019 1.49 × 10−7
MRPL39 21 26,957,969-26,979,801 38 0.055 1.005 1.003 1.007 4.08 × 10−7
Table 6.7: Summary of significant genes from secondary outcome analysis. Variant count includes all types of variants within the
functional unit. Abbreviations: CHR, chromosome; BP, base pair; MAF, minor allele frequency; HR, hazard ratio; LCI, lower
confidence interval; UCI, upper confidence interval. p- value is calculated using the Wald test.
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Figure 6.11: Manhattan plot results for the rare variant analysis of the secondary
outcome, using a BT within a Cox PH model. Red line represents genome-wide
significance threshold 5×10−8. Blue line represents suggestive significance line. Each
point represents a gene.
ISCA1 is the most significantly
(
p = 7.32 × 10−8) associated gene with time to all-
cause mortality. It is a mitochondrial protein-coding gene involved in the biogenesis
and assembly of iron-sulfur clusters, which play a role in electron-transfer reactions.
Gene expression has been detected in the cerebellum, kidney and heart (http://www.
genecards.org/cgi-bin/carddisp.pl?gene=ISCA1).
MRPL39 is a protein-coding gene. Among its related pathways are mitochondrial
translation and organelle biogenesis and maintenance. Two isoforms produced by
alternative splicing, whereby Isoform 2 has heart-specific gene expression (http://www.
genecards.org/cgi-bin/carddisp.pl?gene=MRPL39).
A direct link in terms of pathways, expression and literature indicating cardiovascular
disease association could not be identified from the remaining significant protein coding
genes: RPTOR, LIN52 and DENND1C.
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6.4 Discussion
The use of SurvivalGWAS_SV and rareSurvival for the analysis of the PhACS data
successfully demonstrated the ability of the two programs to identify common and rare
variant associations with TTE outcomes. The approximated runtime for the single-
variant analysis of 8,788,380 SNPs of both the primary and secondary outcome using
SurvivalGWAS_SV was a total of 59 hours. The computational runtime for the rare-
variant analysis using rareSurvival was a slower process, amounting to a total of 572
hours which included both the primary and secondary outcome analyses. This was
utilising the cluster specified in Section 6.2.
The analysis from the study yielded interesting results regarding the identification of
novel loci and genes associated with time to recurrent cardiovascular events or mortality
following an acute coronary event. The rare variant analysis using the BT within a Cox
PH model identified candidate genes for further investigation. The programs addressed
a need for the lack of software available to analyse genetic association studies with
TTE outcomes. The PhACS study analysis demonstrated one of the first uses of gene-
based testing of imputed genotype data using the BT within a Cox PH model for TTE
outcomes.
The most interesting gene identified from the analyses of the primary outcome is
CTNNA2, which has related pathways to right ventricular myopathy and contained
SNP rs56045815, which showed a clear difference in event-free survival between
genotype groups. PRKAG3, PHF13, THAP3, DNAJC11 are all expressed in the heart.
Nonetheless, all significant SNPs, including those not mapping directly to a gene, show
significant differences between carrier and non-carriers of genotypes for recurrent
cardiovascular event survival. The most interesting gene identified from the analyses
of the secondary outcome was URGCP-MRPS24, which contains a large number of
strongly associated SNPs in high LD with one another. The genes ISCA1 andMRPL39
are also of interest as both genes are expressed in the heart. These results suggest that
all significant genes may warrant targeted sequencing in larger samples to confirm the
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existence of rare survival influencing variants.
These findings demonstrate the effectiveness of aggregated tests of association in the
identification of genes with time to cardiovascular event and mortality. For all as-
sociations, carrying minor alleles increased the risk of cardiovascular and mortality
events. The statistical power of the association analyses is low because of the small
sample size. Furthermore, caution should be taken when interpreting the significantly
associated SNPs from the single variant analyses because the results are potentially
unreliable due to the low MAFs of variants. Therefore any results would need to be
replicated, and a computationally intensive follow-up test is recommended to distin-
guish true from false positives. Further analyses not reliant on asymptotic methods
should be performed, such as permutation-based methods described by Wang et al.
(2010). Other analyses can be undertaken on the raw PhACS study data and by using
the GWAS results in this thesis. Details of the potential future perspective of PhACS
is detailed in the final chapter.
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CHAPTER 7
DISCUSSION AND CONCLUSION
7.1 Overview
This thesis details research into the evaluation and development of statistical method-
ology and computational tools to analyse genome-wide association studies (GWAS) of
both common and rare genetic variants with time-to-event (TTE) outcomes.
SurvivalGWAS_Power, SurvivalGWAS_SV and rareSurvival will aid in the design of
studies and identification of genetic biomarkers of patient response to treatment, with
the ultimate goal of personalising therapeutic intervention for an array of diseases.
Applying these computational tools to GWAS data has the potential for gene discovery
to guide treatment choices, allowing the benefit/risk ratio to be optimised to achieve
more prolonged survival in patients with diseases.
The preceding chapters have explained in detail many of the different aspects of this
research. This discussion and conclusions chapter summarises the main findings from
all previous chapters, highlighting the impact while calling attention to any limitations
of the research. Recommendations are made to provide researchers with a basis for
building on the current research of this thesis.
7.2 Implications of Research
Identifying genetic variants of treatment response has far-reaching implications in the
field of precision medicine. The potential to personalise medicine for an individual will
mark the end of general-purpose treatments for the entire population. This transition
will increase the efficacy and safety (reduce adverse drug reactions) of treatments. To
achieve this goal, statistical solutions play a key role in the study design and analytic
phases of a study. Specifically, in the context of TTE studies, there is a shortage of
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these computational tools to implement these statistical solutions.
Survival models, most commonly the Cox proportional hazards (PH) model, are being
applied to genetic association studies of TTE outcomes. Even so, many studies opt to
simplify the outcome to a binary response using models, such as logistic regression,
in an attempt to lighten the computational burden of the analysis. Chapter 2 of this
thesis demonstrated a clear advantage of using the Cox PH model of TTE outcomes
over the logistic regression model of a simplified binary outcome through a simulation
study across a wide variety of pharmacogenetic study designs. The comparison of
methodology solidified the assertion that the Cox PH model would have greater power
to detect associations for TTE outcomes than dichotomisation of the outcome. This
research will impact the decision made by analytical teams on models used for the
analysis of TTE outcomes. However even though this was commonly known in other
research areas, the specific application to pharmacogenetics had not been previously
considered.
The simulation studies and literature reviews throughout Chapters 2 to 5 highlighted the
need for computational tools that can perform power calculations and analysis of both
common and rare variants with TTE outcomes. The creation of bespoke software for
this task has great advantages over general use programs such as R because they have
been designed for those with limited computational programming knowledge and the
ability to handle the scale and complexity of genetic data in pharmacogenetic GWAS.
This thesis presents the first software to simulate pharmacogenetic TTE data and per-
forms power calculations based on two analytical models, the Cox proportional hazard
and Weibull regression models (SurvivalGWAS_Power). The graphical user interface
(GUI) provides a user-friendly program for Windows desktop users. SurvivalGWAS_-
Power will aid researchers in the design of pharmacogenetic TTE studies, providing
details on the choice of statistical model and optimal sample size. This software was
followed by two novel analytical tools: one for single variants, SurvivalGWAS_SV
and another for gene-based tests of rare variant association, rareSurvival. Both tools
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offer users simple command line execution of commands and compatibility with high-
performance computing (HPC) clusters, resulting in efficient analyses in a field where
"big data" translates to hundreds of terabytes. Both analytical tools will enable seam-
less analysis of large-scale genetic data in the hope of identifying variants that can
help predict treatment response or prognosis for a number of diseases and traits. This
target was demonstrated in the analysis of the Pharmacogenetics of Acute Coronary
Syndrome (PhACS) study in Chapter 6, which identified some genes and variants that
may have a potential impact on the occurrence of cardiovascular events and mortality.
The analysis performed in Chapter 6 was a demonstration of the application of the
novel methodology and software developed in Chapters 4 and 5 of this thesis to iden-
tify novel relationships between single-variant and gene-based biomarkers for time
to cardiovascular event and all-cause mortality in the PhACS data. In summary, the
single variant analysis of the primary outcome produced 6 SNPs above genome-wide
significance. The most interesting SNP identified was rs56045815, which maps to the
CTNNA2 gene, that is known to impact on arrhythmogenic right ventricular cardiomy-
opathy. The single variant analysis of the secondary outcome identified 10 SNPs at
genome-wide significance. Although biological evidence was not found to associate
these SNPs with all-cause mortality, further investigation is needed. The gene-based
analyses of the primary outcome yielded ten genes significant at 7.1 × 10−7. A locus
containing the genes PHF13, THAP3 and DNAJC11 offers candidates for further ex-
ploration regarding function and pinpointing the causal variants. This statement is also
true for the gene-based analysis of the secondary outcome, which identified six genes,
two of which (ISCA1 and MRPL39) are expressed in the heart. This result suggests
potential candidates for future studies that may lead to targets for improved prediction
of cardiovascular event outcomes.
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7.3 Limitations
The research in this thesis is limited to comparing and contrasting two models, the Cox
PH and Weibull regression models. Even though these are two common approaches,
TTE data can be more complex. This includes different types of censored observation,
multiple causes of an event and repeated measures of an event. The assumption of right
censoring is used throughout this thesis. As is known for TTE data, patients can be left,
interval and right censored as well as truncated, but this cannot currently be accommo-
dated within the software. Figure 7.1 illustrates information collected on four patients
follow-up times. Five different types of TTE outcomes are generated in this example,
which requires different analyses to account for each of them. The software imple-
Figure 7.1: Follow-up times for four patients that experience different censoring,
truncation and events.
menting the Weibull regression model is limited to the adjustment of a maximum of 10
additional non-genetic covariates. This model is further hindered by the convergence
criteria used by the model to estimate coefficients. The Newton-Raphson algorithm
implemented suffers from some inconsistency with estimating model parameters if the
starting values are not close to the "true" value. Alternative convergence algorithms
or extensions to the Newton-Raphson algorithm that account for the uncertainty of the
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shape parameter in the Weibull model should be explored.
The use of C# to develop all three computational tools has been hindered by the lack
of adaptability to Linux operating system computers and clusters, which are most
commonly used within the field. Mono was used to compile the code for Linux and
was the only option for this in 2014. In 2017, Microsoft Windows released Visual
Studio Code and .NET Core which can produce fast running native Linux programs.
Porting the code over from using the .NET framework to the .NET core is a short-term
fix to gain improvement in software efficiency.
The findings of the study of the PhACSdata should be consideredwith the caveat that the
sample size was limited to 1367 patients, and there was no opportunity for replication
of the findings. The rare variant analysis was undertaken with imputed data from the
1000 Genomes Project (Auton et al. 2015), rather than whole-exome or whole-genome
sequencing, which limits the allele frequency to which reliable genotype prediction can
be assured. Larger reference panels, such as the Haplotype Reference Consortium (The
Haplotype Reference Consortium 2016), will enable high-quality imputation to lower
allele frequencies, but sequencing remains the "gold standard".
7.4 Future Perspective
The development of methodology and computational tools for GWAS of common and
rare variants with TTE outcomes has been undertaken in this thesis. There are many
different aspects of this research that can be developed further, which includes novel
methods and computational innovations that will enable more advanced application
into the next generation of genetic data. This section outlines the short and long-term
improvements, which can help develop SurvivalGWAS_Power, SurvivalGWAS_SV
and rareSurvival, as well as the current state of survival analysis methodology.
Survival analysis methodology is evolving quickly within all fields of research, includ-
ing genetics, with the majority of researchers implementing new methods within the
R statistical environment. These methods can be used and adapted for application
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within genetics research. Therefore, future versions of all three programs can employ
more complex analysis techniques and extensions to account for more complex sur-
vival models. The Cox PH model does not adequately account for this complexity,
especially when considering pharmacogenetic outcomes. This is particularly relevant
when testing for associations between genetic variants and treatment failure, where the
event of interest may occur due to multiple reasons such as lack of treatment efficacy or
experiencing an adverse drug reaction. Each reason for drug failure may have distinct
genetic and non-genetic risk factors, and such differences can be accommodated by
considering each distinct outcome in a competing risks model. Competing risks are
analysed using the Fine-Gray model (Fine & Gray 1999), which keeps those individu-
als who have already experienced the non-primary event within the risk set at a given
time. These models provide insight into questions such as, what proportion of patients
experience the event from cause k by time t, or what are the factors affecting the hazard
of the event from cause k?
Other extensions to consider to make all three programs a more complete TTE design
and analysis package would be to add options for parametric models, joint modelling
of TTE and longitudinal data (Sudell et al. 2016) and accounting for recurrent events
that are very common in studies involving epilepsy (Myers & Mefford 2015).
Measuring follow-up after all individuals have been recruited is an important feature
of TTE studies. However, in many cases, an individual has an event immediately after
recruitment or is censored before the follow-up time. These individuals are recorded
as having an event time of zero, and they are typically removed from the analysis or
assigned an event time that is very close to zero. This was observed in the analysis of
PhACS in Chapter 6, where two patients were excluded on this basis. These individuals
can be very informative for survival. Therefore, a solution is needed to handle and
include this information in the analysis.
A final observation from the research in this thesis is that very little work had been
published regarding appropriate adjustment for gene-level interaction effects. Papers
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discussing gene-environment or gene-gene interactions are common for quantitative
traits (Aschard 2016, Ma et al. 2013). Testing for gene-treatment interactions correctly
can have great implications for pharmacogenetics research. GWAS of common and
rare variants in pharmacogenetics still has the potential for drug development with
the application into predictive/personalised medicine. However, the large effect sizes
that most expected (Cirulli & Goldstein 2010) have been modest at best (Auer &
Lettre 2015), and methodology development for interaction effects could help unlock
information about treatment response.
7.4.1 SurvivalGWAS_Power
Chapter 3 discussed the development of power calculation software, covering the foun-
dation of pharmacogenetic study designs and analysis models. The research in this
chapter can be extended by first considering the simulation and testing of more realis-
tic and complex scenarios, such as multiple treatment dose levels and accounting for
flexibility with the treatment or dose administration time. Along with adding more so-
phistication to the treatment covariate, greater flexibility on the inclusion of additional
covariates would be beneficial in the design and analysis of a study.
It is difficult to achieve a complete dataset when undertaking a study. The missing rate
of variables cannot be avoided in both the genotype and phenotype data collected for all
individuals. Adding an option into SurvivalGWAS_Power for increasing or decreasing
the missing rate within data would give users an added benefit in designing realistic
studies.
SurvivalGWAS_Power currently accounts for right censoring only. TTE studies have
a wider variety of censoring and truncation1 options such as left censoring, interval
censoring, left truncation and right truncation. To analyse these options, the likelihoods
of the statistical regression models need to be adapted.
SurvivalGWAS_Power currently simulates a SNP based on an additive genetic model.
1Patients excluded due to inadequate follow-up.
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Providing users with the option of simulating a SNP with different genetic models
(recessive and dominant) is of benefit. In many studies supplementation of SNP
data through imputation is a common practice where genotype data is in the form of
dosages calculated from genotype probabilities. The info-score is a useful metric of
imputation quality, therefore allowing the user to adjust the info-score of a SNP similar
to the control they have over MAF would help in determining the power to detect
associations of the different analytical approaches with a range of imputation quality
SNPs. SurvivalGWAS_Power provides some useful output metrics for users such as the
distribution of estimated hazard ratios amongst replicates. Additional results that will
be informative at the study design stage would be the probability of the disease/event
occurring for each genotype group or allowing the user to specify the proportion of
individuals dependent on genotype that will have the event of interest.
A short-term recommendation for SurvivalGWAS_Power would be to combine the
C# code with R using R.NET. This package is a .NET framework that will enable
calling in methods from libraries and scripts developed in R. A long-term improvement
for SurvivalGWAS_Power, would be to eliminate the need for users to download a
specific version distribution every time there is an update. Instead, the program can
be designed as an interactive web application using R-Shiny (Chang et al. 2017). The
software would be an interactive application with a GUI with the ability to access R
libraries.
Calculating sample size to achieve appropriate power is very disease-specific (Sham
& Purcell 2014). Therefore, a more advanced development of the program could be
to express sample size and power calculation based on pilot data or data from similar
studies to the one the user would like to design. This can be achieved by linking the
application to an internet or MySQL database, which gathers and stores information
from research articles or by direct upload into the program. Generating examples
based on previous literature, provides more information for the user, resulting in more
accurate power calculation to help drive decisions.
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When conducting the simulation study in Chapter 5, it became apparent that there is
software available for simulating rare variant data for binary and quantitative traits (Li
et al. 2012, Chung & Shih 2013). Not only have the programs not been updated in
several years, but they also do not provide options for TTE settings and models. An im-
plementation within SurvivalGWAS_Power for simulating data based on rare-variants
and calculating power for gene-based analysis models would be the first TTE applica-
tion to offer this. Simulation of rare variants could use whole-exome or whole genome
sequence data and population demographic models (Gazave et al. 2013, Excoffier et al.
2013) for a more realistic generation of variant data. Power analysis will be more
accurate with realistic simulated data. The program SEQPower developed by Wang,
Li, Lyn Santos-Cortez, Peng & Leal (2014) should be used as a bedrock to rare variant
power analysis implementation within SurvivalGWAS_Power.
The current release and any extensions to SurvivalGWAS_Power will preemptively
allow investigators the opportunity to cater for a wide variety of challenges faced when
designing pharmacogenetic GWAS.
7.4.2 SurvivalGWAS_SV and rareSurvival
Similar extensions regarding new methodology implementation into SurvivalGWAS_-
Power can be adapted for SurvivalGWAS_SV and rareSurvival. Currently, only the
additive genetic model is assumed, whereas most genetic association software offers a
choice of genetic models. Kim et al. (2013) developed aMaxTest for genomic data with
TTE traits, which identifies the genetic model of each candidate SNP through a gradient
lasso prediction model. This method could be investigated further through implemen-
tation in SurvivalGWAS_SV. Specific to rareSurvival, many different methodologies
could be explored. Developing methodology that incorporates gene-based dispersion
tests of association such as the SKAT or C-alpha statistic (Clarke et al. 2013) within a
Cox PH model.
Short term recommendations for SurvivlGWAS_SV and rareSurvival would be to
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port the code from the .NET framework to .NET Core, which is compatible with
Linux and is substantially faster at running tasks than Mono. An alternative route to
increase efficiency is to build an Apache Spark application in conjunction with Mobius
(https://github.com/Microsoft/Mobius), a C# API. Apache Spark will provide efficient
cluster and single computer management for any .NET framework language.
Both SurvivalGWAS_SV and rareSurvival have a multi-threading system where a
specified number of threads need to be spawned, and these threads run a different part
of the analysis. This implementation can be flawed because a user can specify too many
threads or too few threads, whereby the process is slowed down as the computer cannot
distribute the resources correctly. A pipeline pattern can rectify this problem, taking
the choice away from the user and automatically assigning resources to the task. The
pipeline algorithm processes a sequence of input parameters and executes concurrent
queues of parallel tasks. This means that the programwill be reading the data, analysing
and outputting concurrently without slowing down or waiting for resources to become
available.
Software development has now seen a dramatic change in the field when handling
"big data". Programming languages such as Scala and Python are more commonly
used with Apache Spark (Zaharia et al. 2016) for fast data analysis. Pipelines such
as Hail and SeqSpark (Zhang et al. 2017) are at the forefront of this movement. A
long-term upgrade for SurvivalGWAS_SV and rareSurvival is to develop a data input to
output interpretation pipeline for genetic association studies with TTE outcomes. This
pipeline can be achieved using both Scala and Python, which have the added benefit
of compatibility with R, utilising all the libraries available. The algorithm concept of
both software packages can be kept in place, but re-coded in Python. This platform
would cover not only the main association analysis via single and gene-based tests but
also plot Kaplan-Meier curves for covariates and variants and model checking for the
PH assumption through Schoenfeld residuals. Ideally, conditional analyses after gene-
based analyses would be implemented to localise the causal or multiple causal variant
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associations. An Apache spark pipeline analysis tool will offer automated separation
of data and a one-line command submission to consolidate multiple analyses into one
program.
Rare variant association testing hasmostly been at the gene-level, although some regions
of the genome contain a smaller number of variants making the accumulation of the
variants in these regions more vulnerable to being underpowered (many non-causal
variants included in the pooling), and with a large amount of bias. Firth’s test (Firth
1993) may provide a solution for rare variant tests, especially when the sample size
is small and with a benefit over testing methods that rely on asymptotic assumptions
that produce inflated type-I error rates (Wang 2014). The Firth procedure modifies the
score function for the information matrix after maximisation of the Cox PH model,
producing estimates by penalised maximum likelihood estimation.
After identifying the genomic regions in each of Chapters 4 and 5 simulation study
for which our causal variants were located, the next step would be to pinpoint which
variants within the gene are leading this signal of association. This is a crucial next step,
with a need for further method development similar to Lin (2016) with the application
into rareSurvival. Gene-based tests can hinder this process as these tests do not provide
information at the individual locus and are ill-equipped to identify causal variants
(Jeng et al. 2016). To address this, Jeng et al. (2016) had suggested rare variant
association analysis at the single-locus level, proposing an adaptive false-negative
control procedure.
7.4.3 PhACS
As mentioned in Chapter 6, the PhACS study can be investigated further. First, the
rare-variant analysis identified functional units of significance with our TTE outcomes.
An investigation into the source of these gene-based signals is needed, specifically by
pinpointing whether a single or multiple variants are driving the association by using
conditional analyses, eliminating each variant in turn based on the difference in p-value.
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Some functional units have more than 500 variants to decipher the signal from, such as
RPTOR in Table 6.7, which can prove to be a difficult task.
After the identification of variants through GWAS, a collection of evidence based on
gene function can be undertaken in more detail through a thorough research synthesis
of databases and previous literature. Conducting gene-set enrichment analysis could
be of interest, to identify pathways linked to early treatment response, which may
provide additional insight into relevant underlying biological and molecular processes
for these outcomes. Most importantly, to obtain more knowledge on the effects of
genetic variation on time to cardiovascular events, will require: (i) improved genomic
annotation to establish the impact of genetic variation; (ii) establishment of causal
association through replication based on different groups; and (iii) functional studies
to determine gene function and regulation.
An analysis stratifying by drug use would be informative on the effectiveness of each
treatment, with the possibility of investigating potential treatment interaction effects.
A larger application could be to test SNP-treatment interaction for each cardiovascular
drug under an additive dosage model after adjusting for clinical risk factors, and the
main effects of SNP and treatment. These additional analyses may uncover other
patterns of cardiovascular event-free survival.
A follow-up study with a larger sample size would be beneficial because, on average,
the cumulative MAF of many of the gene regions analysed was less than 0.05, and
the estimated HRs for both the primary and secondary outcome did not deviate from
a value of 1 indicating that the hazard is the same for each group. Another source
that potentially hindered the power to detect associations was that the true genetic
architecture of cardiovascular event survival or mortality was unknown, therefore, the
burden test within a Cox PH model may not have been the most powerful test for this
scenario. This follows on from the earlier point made in this discussion chapter for
using many different gene-based tests such as the SKAT on the data once implemented
in future versions of rareSurvival.
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7.5 Concluding Remarks
The work within this thesis has provided a detailed examination of GWAS with TTE
outcomes. Insight through simulations comparing alternative regression approaches
has solidified evidence of model choice under pharmacogenetic study designs with TTE
outcomes. Novel software has been developed and tested with details provided on the
future perspective of each computational tool. SurvivalGWAS_Power is important as it
is the first genetic data simulator for TTE outcomes, and the first to enable estimation of
power formultiple pharmacogenetic designs and analysismethods. SurvivalGWAS_SV
provides users with an easy to use command line application, offering efficient analysis
of large-scale genomic datasets using HPC clusters. SurvivalGWAS_SV implements
two analytical approaches with an option to analyse SNP-covariate interaction effects.
rareSurvival is the first rare-variant analysis tool for TTE outcomes, employing novel
gene-based tests of association within TTE regression models. The use of the software
in the analysis of the PhACS study data in Chapter 6 is an informative example of
the potential use of the computational analysis tools and how beneficial they are to
the research community. By making the software publicly available, it is envisaged
that they will be applied to the analysis of whole-genome and -exome datasets with
TTE outcomes in pharmacogenetics and other genetic studies to uncover the underlying
mechanisms that affect complex human disease.
This research has implications within the study design phase of pharmacogenetic TTE
studies through to the analysis phase. With the continued development of statistical
methodology and computational tools for GWAS, we will understand more about the
relationship between genetic variants and a multitude of phenotypes. Looking for-
ward, GWAS will continue to expand the catalogue of loci of the genome contributing
to complex human traits. The next phase of understanding the underlying biological
mechanisms that cause disease will be through the collective knowledge of the genome,
transcriptome (RNA), proteome, epigenome, metabolome and the methodological de-
velopment to enable integration of these data resources. This will require co-ordinated
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collaboration between researchers over a wide range of disciplines, including statistics,
genetics, and computational biology. This, in turn, will contribute to the ultimate
goal of many GWAS of complex diseases; the development of novel treatments and
personalised medicine for an individual.
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Appendix A
PHACS: COVARIATE DIAGNOSTIC PLOTS
Figure A.1: ACEI: Kaplan-Meier, diagnostic PH assumption plot and a summary table
of at-risk individuals.
FigureA.2: Aldosterone: Kaplan-Meier, diagnostic PH assumption plot and a summary
table of at-risk individuals.
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Figure A.3: Chronic renal failure: Kaplan-Meier, diagnostic PH assumption plot and a
summary table of at-risk individuals.
Figure A.4: Prior myocardial infarction: Kaplan-Meier, diagnostic PH assumption plot
and a summary table of at-risk individuals.
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Figure A.5: PCI: Kaplan-Meier, diagnostic PH assumption plot and a summary table
of at-risk individuals.
Figure A.6: Hyperlipidemia: Kaplan-Meier, diagnostic PH assumption plot and a
summary table of at-risk individuals.
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Figure A.7: Chronic renal failure: Kaplan-Meier, diagnostic PH assumption plot and a
summary table of at-risk individuals.
Figure A.8: Aspirin after discharge: Kaplan-Meier, diagnostic PH assumption plot and
a summary table of at-risk individuals.
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Figure A.9: Statins after discharge: Kaplan-Meier, diagnostic PH assumption plot and
a summary table of at-risk individuals.
Figure A.10: Schoenfeld residual plot for each significant clinical factor with the
secondary outcome.
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Appendix B
PHACS: LOCUSZOOM PLOTS FOR SIGNIFICANT
SNPS
Figure B.1: Association of rs113348424 with time to a cardiovascular event. Lo-
cusZoom plot of the region associated with the primary outcome on chromosome 1
in PhACS samples. Genes within the region are shown in the lower panel, and the
blue line indicates the recombination rate within the region. Each circle represents the
p-value for a SNP in the discovery sample, with the top SNP rs113348424 shown in
purple and the SNPs in the region coloured depending on their degree of correlation
(r2) with rs113348424 as estimated by LocusZoom from European 1000 Genomes
March 2012 data.
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Figure B.2: Association of rs144599889 with time to a cardiovascular event. Lo-
cusZoom plot of the region associated with the primary outcome on chromosome 7
in PhACS samples. Genes within the region are shown in the lower panel, and the
blue line indicates the recombination rate within the region. Each circle represents the
p-value for a SNP in the discovery sample, with the top SNP rs144599889 shown in
purple and the SNPs in the region coloured depending on their degree of correlation
(r2) with rs144599889 as estimated by LocusZoom from European 1000 Genomes
March 2012 data.
FigureB.3: Association of rs56045815with time to a cardiovascular event. LocusZoom
plot of the region associated with the primary outcome on chromosome 2 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs56045815 shown in purple and
the SNPs in the region coloured depending on their degree of correlation (r2) with
rs56045815 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
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FigureB.4: Association of rs71472467with time to a cardiovascular event. LocusZoom
plot of the region associated with the primary outcome on chromosome 15 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs71472467 shown in purple and
the SNPs in the region coloured depending on their degree of correlation (r2) with
rs71472467 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
FigureB.5: Association of rs34610018with time to a cardiovascular event. LocusZoom
plot of the region associated with the primary outcome on chromosome 15 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs34610018 shown in purple and
the SNPs in the region coloured depending on their degree of correlation (r2) with
rs34610018 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
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Figure B.6: Association of rs141689913 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 7 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs141689913 shown in purple
and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs141689913 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
Figure B.7: Association of rs199571837 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 14 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs199571837 shown in purple
and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs199571837 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
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Figure B.8: Association of rs191847613 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 14 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs191847613 shown in purple
and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs191847613 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
Figure B.9: Association of rs12402659 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 1 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs12402659 shown in purple and
the SNPs in the region coloured depending on their degree of correlation (r2) with
rs12402659 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
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Figure B.10: Association of rs190226855 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 12 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs190226855 shown in purple
and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs190226855 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
Figure B.11: Association of rs2695973 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 5 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs2695973 shown in purple and
the SNPs in the region coloured depending on their degree of correlation (r2) with
rs2695973 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
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Figure B.12: Association of rs76428855 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 3 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs76428855 shown in purple and
the SNPs in the region coloured depending on their degree of correlation (r2) with
rs76428855 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
Figure B.13: Association of rs141058803 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 7 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs141058803 shown in purple
and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs141058803 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
211
Figure B.14: Association of rs141503732 with time to all-cause mortality. LocusZoom
plot of the region associated with the secondary outcome on chromosome 7 in PhACS
samples. Genes within the region are shown in the lower panel, and the blue line
indicates the recombination rate within the region. Each circle represents the p-value
for a SNP in the discovery sample, with the top SNP rs141503732 shown in purple
and the SNPs in the region coloured depending on their degree of correlation (r2) with
rs141503732 as estimated by LocusZoom from European 1000 Genomes March 2012
data.
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Appendix C
PHACS: KAPLAN-MEIER PLOTS FOR SIGNIFICANT
SNPS
Figure C.1: Kaplan-Meier plots of genotypes for all significant SNPs associated with
the primary outcome. Summary table of at-risk individuals. Top left: rs113348424,
Top middle: rs144599889, Top right: rs34610018. Bottom left: rs56045815, Bottom
middle: rs71472467.
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Figure C.2: Kaplan-Meier plots of genotypes for all significant SNPs associated with
the secondary outcome. Summary table of at risk individuals. Top left: rs141689913,
Top middle: rs199571837, Top right: rs191847613, Middle left: rs12402659, Middle
: rs190226855, Middle right: rs2695973, Bottom left: rs76428855, Bottom middle:
rs141058803, Bottom right: rs141503732.
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